

**IMAGE ANALYSIS OF DOMINANT OVARIAN FOLLICLES AND OVARIAN
FOLLICULAR DEVELOPMENT DURING CONTINUOUS AND
CONVENTIONAL ORAL CONTRACEPTIVE DOSING SCHEMES**

A Thesis Submitted to the College of

Graduate Studies and Research

In Partial Fulfillment of the Requirements

For the Degree of Master's of Science

In the Department of Obstetrics, Gynecology and Reproductive Sciences

University of Saskatchewan

Saskatoon

By

REBECCA LYNN BIRTCH

Keywords: ovarian follicles, oral contraceptive, image analysis

© Copyright Rebecca Lynn Birtch, April 2005. All rights reserved.

PERMISSION TO USE

In presenting this thesis in partial fulfilment of the requirements for a Postgraduate degree from the University of Saskatchewan, I agree that the Libraries of this University may make it freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their absence, by the Head of the Department or the Dean of the College in which my thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in my thesis.

Requests for permission to copy or to make other use of material in this thesis in whole or part should be addressed to:

Head of the Department of Obstetrics, Gynecology and Reproductive Sciences

College of Medicine

University of Saskatchewan

Saskatoon, SK

S7N 0W8

ABSTRACT

The objective of this research was to assess ultrasound image attributes of human dominant ovarian follicles in the final stages of development during natural and oral contraceptive (OC) cycles, as well as characterize ovarian follicular and endometrial development during and after continuous versus conventional dosing schemes. We utilized sophisticated computer algorithms to elucidate an association between image attributes and physiologic status of follicles in their final stage of development. We used transvaginal ultrasonography to quantify changes in the numbers and diameters of ovarian follicles and changes in endometrial thickness and pattern during and following discontinuation of two different regimens of OC. Developmental changes in ovarian follicles and corpora lutea were correlated with serum estradiol-17 β and progesterone, respectively to provide a comprehensive approach to examining ovarian and uterine function.

We reported for the first time that follicles which develop during natural and OC cycles have similar image attributes, which provides preliminary evidence that image attributes of human follicles are associated with physiologic status during the growth phase. Further research should be performed to elucidate the exact correlation between image attributes during all stages of follicular development throughout the menstrual cycle, prediction of dysfunctional follicular development (i.e., hemorrhagic anovulatory follicles) and the effects of different OC formulations on follicle development. Once the association between image attributes and various scenarios of follicular development are determined, a computer program could be developed to assess follicular health with a

single ultrasound examination, obviating many ethical constraints that currently prevent large scale progress in ovarian follicular research.

We further documented that continuous OC administration schemes provide greater follicular suppression than conventional dosing schemes. No dominant follicles developed during three consecutive 28 day cycles of continuous OC use, whereas eight dominant follicles developed during the same time period of conventional OC use. We interpreted these findings to mean that continuous OC dosing schemes provide a more effective contraceptive with a decreased risk of “escape” ovulation compared to conventional dosing schemes. Most follicles ovulated in the immediate cycle following discontinuation of OC. We suggest that the delay to fertility following cessation of OC is not due to anovulation but other yet, unknown, biological factors.

ACKNOWLEDGMENTS

“Cast your mind back...” As I look back on the knowledge and experience I have gained during my Master’s degree I can not help but realize that completion of this degree would not have been possible without the continued guidance and support of many extraordinary people. First I would like to thank Dr. Roger Pierson for his patience, generosity and wisdom throughout the course of my graduate work. He has taught me that hard work pays off, but you need to take a few boondoggles along the way if you want to enjoy the journey. An extended thank you goes to both Roger and Kathy Pierson for welcoming me to Saskatchewan and making a difficult transition easy.

I would like to sincerely thank the faculty and staff in the Department of Obstetrics, Gynecology and Reproductive Sciences. I do not think that I will ever meet such a welcoming, warm, supportive group of individuals again in my life. I am grateful for the invaluable knowledge the members of my advisory committee have provided (Drs. Femi Olatunbosun, Gregg Adams and Jaswant Singh). I would like to provide a heart-felt thank you to Dr. Angela Baerwald for taking the time to show me the basics of research. I gratefully thank John Deptuch for his continual computer expertise. Great appreciation is expressed to the research volunteers, without their dedication and participation I would not have been able to complete this degree. Finally, I thankfully acknowledge the Canadian Institutes of Health Research for funding my thesis work.

DEDICATION

*For my husband Evan, my parents Wendy and Rob and my sister Tania.
Thank you for believing in me when I didn't believe in myself.*

TABLE OF CONTENTS

PERMISSION TO USE.....	ii
ABSTRACT	iii
ACKNOWLEDGEMENTS.....	v
DEDICATION.....	vi
TABLE OF CONTENTS.....	vii
LIST OF TABLES.....	ix
LIST OF FIGURES	x
LIST OF ABBREVIATIONS	xi
1. GENERAL INTRODUCTION	1
1.1 Human Ovarian Follicular Dynamics.....	1
1.1.1 Oogenesis and Primordial Follicle Development	2
1.1.2 The Population of Pre-antral Follicles	3
1.1.3 Initiation of Follicular Growth.....	4
1.1.4 Preantral Growth Phase or Basal Follicular Growth	7
1.1.5 Tonic Growth Phase.....	8
1.1.6 Exponential Growth Phase.....	11
1.1.7 Recruitment.....	11
1.1.8 Selection.....	13
1.1.9 Maturation of the Dominant Follicle Destined to Ovulate	14
1.1.10 Ovulation.....	17
1.1.11 Duration of Human Folliculogenesis	21
1.1.12 Summary.....	22
1.2 Ultrasonographic Imaging of the Ovaries and Uterus.....	22
1.2.1 Overview of Ultrasound Imaging	22
1.2.2 Ultrasonographic Characteristics of the Ovary.....	24
1.2.3 Ultrasonographic Characteristics of the Uterus.....	27
1.2.4 Computer Assisted Image Analysis	27
1.2.5 Spot Metering.....	28
1.2.6 Line and Time Series Analysis	29
1.2.7 Region Analysis.....	29
1.3 Ovarian Follicular Development during Oral Contraceptive Use.....	30
1.3.1 The Introduction of Oral Contraceptives.....	30
1.3.2 Characteristics of Oral Contraceptives.....	31
1.3.3 Follicular Development during Oral Contraceptive Use.....	32
1.3.4 Follicular Development during the Hormone Free Interval.....	33
1.3.5 Follicular Development after Prolongation of the Hormone Free Interval.....	35
1.3.6 Follicular Development after Missed Doses	36
1.3.7 Follicular Development during “Sunday Start” Initiation Schemes	37
1.3.8 Follicular Development during Three Different Regimens of Oral Contraceptives.....	37
1.3.9 Inhibiting Menstruation.....	38
1.3.10 Women’s Attitudes Towards Inhibiting Menstruation.....	39
1.3.11 Non-contraceptive Benefits of Oral Contraceptives	40
1.3.12 Return to Fertility following Discontinuation of Oral Contraceptives	42
1.3.13 Summary.....	45

2. GENERAL OBJECTIVES AND HYPOTHESES.....	47
3. ULTRASOUND IMAGE ATTRIBUTES OF HUMAN OVARIAN DOMINANT FOLLICLES DURING NATURAL AND ORAL CONTRACEPTIVE CYCLES.....	48
3.1 Abstract	49
3.2 Introduction.....	50
3.3 Materials and Methods	52
3.4 Results.....	55
3.5 Discussion.....	60
3.6 Acknowledgements.....	63
3.7 References	63
4. OVARIAN FOLLICULAR DYNAMICS DURING AND AFTER CONTINUOUS VERSUS CONVENTIONAL DOSING SCHEMES	66
4.1 Abstract	67
4.2 Introduction.....	67
4.3 Materials and Methods	70
4.4 Results.....	74
4.5 Discussion.....	82
4.6 References	87
5. GENERAL DISCUSSION	92
5.1 Follicular Development during Continuous and Conventional Oral Contraceptive Use.....	93
5.2 Menstrual Regulation during Continuous and Conventional Oral Contraceptive Use.....	98
5.3 Return to Fertility following Discontinuation of Oral Contraceptives.....	101
5.4 Development of Novel Contraception.....	103
5.5 Overall Conclusions	105
5.6 General References.....	106

LIST OF TABLES

Table 1.1	Morphological changes associated with each stage of follicular development.....	6
Table 4.1	Selection of the dominant and subordinate follicles (mean \pm SEM), day to ovulation (mean \pm SEM), estradiol concentrations, and follicle growth rates in natural cycles and in women following discontinuation of conventional and continuous OC regimens.....	81

LIST OF FIGURES

Figure 1.1	Classification of follicles in the human ovary.....	5
Figure 1.2	Complete growth trajectory: conversion of a Class 1 follicle into a Class 8 follicle. Gn, Gonadotropin.....	9
Figure 1.3	Overview of LH-induced pathways in the ovulatory cascade. LH induces synthesis of mediators that promote either degradation of the extracellular matrix (ECM) and/or vascular changes (permeability increase, blood flow increase). These changes lead to a decreased tensile strength and a positive intrafollicular pressure. <i>BK</i> , Bradkinin; <i>GRO</i> , growth regulating oncogene; <i>HI</i> , histamine; <i>IL</i> , interleukin; <i>LT</i> , leukotriene; <i>MCP</i> , monocyte chemotactic protein; <i>MMP</i> , matrix metalloproteinase; <i>NO</i> , nitric oxide; <i>P</i> , progesterone; <i>PA</i> , plasminogen activator; <i>PAF</i> , platelet activating factor; <i>PG</i> , prostaglandin; <i>VEGF</i> , vascular endothelial growth factor.....	19
Figure 3.1	Growth profiles of natural and OC cycle follicles.....	57
Figure 3.2	Ultrasonographic images of a natural cycle and OC cycle follicles. (a) Natural cycle follicle on Day 0, (b) OC cycle follicle on Day 0.....	58
Figure 3.3	Graphical representation of NPV, PH and AUC. Mean \pm SEM (a, b) numerical pixel value (c, d) pixel heterogeneity and (e, f) area under the curve obtained by region analysis (a, c, e) and line analysis (b, d, f) of natural cycle and OC cycle follicles.....	59
Figure 4.1	Follicle numbers for follicles ≤ 4 mm, and >4 mm in diameter during continuous and conventional OC use Cycles 1 to 3.....	75
Figure 4.2	Representative follicular growth profiles during (a) continuous and (b) conventional OC use.....	76
Figure 4.3	Growth profiles and serum estradiol concentrations of follicles which ovulated during compliant OC use.....	77
Figure 4.4	Endometrial thickness during Cycles 1 to 3 during continuous and conventional OC use.....	79

LIST OF ABBREVIATIONS

AUC = area under the curve

BK = bradykinin

BMI = body mass index

cAMP = cyclic adenosine monophosphate

EE = ethinyl estradiol

ECM = extracellular matrix

FSH = follicle stimulating hormone

Gn = gonadotropin

HAF = hemorrhagic anovulatory follicle

HFI = hormone free interval

HI = histamine

MHz = megahertz

IL = interleukin

LH = luteinizing hormone

LNG = levonogestrel

LT = leukotriene

MCP = monocyte chemotactic protein

mg = milligram

mm = millimeter

mm Hg= millimeters of mercury

MMP = matrix metalloproteinase

ng = nanogram

NGM = norgestimate

NO = nitric oxide

NPV = numerical pixel value

OC = oral contraceptive

P = progesterone

PA = plasminogen activator

PAF = platelet activating factor

pg = picogram

PG = prostaglandin

PH = pixel heterogeneity

RAP = Roger Allen Pierson

RLB = Rebecca Lynn Birtch

SEM = standard error of the mean

VEGF = vascular endothelial growth factor

μm = micrometer

μg = microgram

Chapter 1

GENERAL INTRODUCTION

1.1 Human Ovarian Follicular Dynamics

The study of reproductive medicine and biology, arguably, began in 1672 when the Dutch anatomist, Regnier de Graaf (1641-1673), discovered the ovarian follicle and ovulation¹. de Graaf, mistakenly defined the fluid-filled follicle as the oocyte and was corrected in 1827 by Karl Ernst von Baer, when von Baer described the follicle-enclosed “ovulum”, which later became known as the “Graafian Follicle”². The form and function of the ovaries and uterus have been under examination since de Graaf’s documentation of ovarian follicles. However, modern investigations involve novel techniques, such as the biomicroscope; a union between ultrasonography and microscopy. We have come a long way to understanding the intricacies of uterine and ovarian physiologic function and anatomy through these investigations, but we are far from completely understanding the physiologic function and microscopic anatomy of the reproductive organs and how their form and function affect women’s reproductive health.

Introduction of the first Food and Drug Administration approved oral contraceptive (OC), Enovid™, in the early 1960's, heralded a contraceptive revolution for women. Prior to the introduction of Enovid™, women had fewer, less efficacious contraceptive choices. Only three major changes have been made to OC formulations in

the last 40 years; these changes include: (i) a decrease in the concentration of synthetic hormones contained in each pill, (ii) a switch from mestrol to ethinyl estradiol (EE) and (iii) the introduction of new, different progestin formulations. We do not yet fully understand the exact physiologic mechanisms of action associated with the suppression of follicular growth and endometrial development during OC administration.

The research in this thesis focuses on the ultrasound image attributes of dominant ovarian follicles that develop during natural and OC cycles as well as ovarian follicular dynamics and endometrial development during and following discontinuation of continuous and conventional OC dosing schemes. This review examines the current data pertaining to ovarian folliculogenesis during natural cycles and OC administration. Furthermore, the review briefly examines the principles of ultrasound imaging and image analysis techniques.

1.1.1 Oogenesis and Primordial Follicle Development

The formation, development and maturation of an ovum, or oogenesis, occurs completely during fetal life; thus, a female is born with her complete complement of oocytes and is incapable of producing more during her reproductive life-span³. Oogenesis begins during the third week of gestation when primordial germ cells migrate from the yolk sac entoderm to the genital ridge under direction of unknown cellular mechanisms and chemotaxic factors⁴. Arrival of the primordial germ cells at the primordial gonadal structure is associated with the differentiation and maturation of the embryonic ovary and redefinition of the primordial germ cells to oogonia⁴. Interestingly, gonadal development will not occur in the absence of germ cells⁴. Oogonia division continues until the twentieth week of gestation, when approximately 7 million oogonia are present; thereafter, oogonia

enter meiosis in response to factors produced by the rete ovarii^{3,5,6}. Once oogonia enter meiosis, they are redefined as primary oocytes and remain arrested in the diplotene stage of meiotic prophase I (32 μm in diameter) until stimulated to resume meiosis during the ovulatory process of a woman's ovarian cycle^{4,7}.

Follicular development begins during the sixteenth week of gestation when spindle-shaped pre-granulosa cells envelope the primary oocyte in a single layer⁷. An outer layer of collagen, known as the basal lamina, forms around the pre-granulosa cell layer⁷. The entire primitive structure is defined as the primordial follicle. Although some primordial follicles will begin growing immediately, the majority remain in a resting state until they either degenerate, or enter the growing phase⁶. The population of arrested primordial follicles constitutes the ovarian follicular reserve or resting pool of follicles (approximately 2.7×10^5 to 4.7×10^5 follicles at menarche) that provides a woman with her complete follicle complement for her entire reproductive life³.

1.1.2 The Population of Pre-antral Follicles

The population of non-growing follicles is comprised of four types of follicles: (i) primordial follicles (35.0 μm in diameter) are composed of a primary oocyte surrounded by flattened granulosa cells, (ii) intermediary follicles (38.0 μm in diameter) are composed of a primary oocyte surrounded by flattened and cuboidal granulosa cells, (iii) primary follicles (46.0 μm in diameter) are composed of a primary oocyte and a single layer of cuboidal granulosa cells and (iv) secondary follicles (77.0 μm in diameter) are composed of a primary oocyte surrounded by more than one layer of cuboidal granulosa cells^{7,8}. The majority of follicles residing in the non-growing pool are primordial and intermediary follicles¹⁰. True follicular growth does not occur until the germinal vesicle reaches 19 μm

in diameter during the secondary follicle stage of development⁹. Approximately 1000 follicles are lost from the resting pool each month until the age of 35 after which the rate of loss increases such that by menopause 100 to 1000 resting follicles remain within the ovaries¹¹⁻¹⁴. Follicular growth and development from the primordial follicle to ovulation is illustrated in Figure 1.1. Morphologic changes associated with each stage of development are summarized in Table 1.1

1.1.3 Initiation of Follicular Growth

The exact mechanisms and factors responsible for initiation of follicular development are poorly understood; however, the process is considered to be multi-phasic and regulated by biological molecules that act on the oocyte and/or granulosa cells⁶. It is unclear if initiation of follicular growth is due to the release from inhibitory factors or stimulation by activating factors. Available evidence suggests that a balance between inhibiting and activating factors produced by the pre-antral follicles and/or factors present in the ovarian microenvironment are responsible for initiating follicular growth.

A number of factors have been implicated in initiating follicular growth, including; epidermal growth factor, insulin-like growth factor, transforming growth factor, and fibroblast growth factor as well as factors which stimulate cyclic adenosine monophosphate (cAMP) production including vasoactive intestinal peptides, pituitary adenylate cyclase activating peptide and neurotrophins such as nerve growth factor brain-derived neurotrophic factor and neutrophin-4^{6,15}. Conversely, Anti-Müllerian hormone and somatostatin are suggested to inhibit the initiation of follicular growth⁶. The rate at which resting follicles are stimulated to grow is reported to be directly proportional to the number




Figure 1.1: Classification of follicles in the human ovary (From Gougeon, 1996)

Table 1.1: Morphological changes associated with each stage of follicular development
(From Gougeon, 1996)

Stage of Development	Mean Follicle Diameter	Morphological Characteristics
Primordial Follicle	35 μm	<ul style="list-style-type: none"> • Single layer of flattened granulosa cells
Intermediary Follicle	38 μm	<ul style="list-style-type: none"> • Single layer of flattened and cuboidal granulosa cells
Primary Follicle	46 μm	<ul style="list-style-type: none"> • Single layer of cuboidal granulosa cells zona pellucida
Secondary Follicle	77 μm	<ul style="list-style-type: none"> • >1 layer of cuboidal granulosa cells • FSH, estrogen and androgen receptors are expressed in granulosa cells • LH receptors expressed on theca interna • Theca interna and externa begin to differentiate • Differentiation of follicular vascular and lymphatic circulatory systems
Class 1	0.1 - 0.2 mm	<ul style="list-style-type: none"> • No antrum • Two-cell-two gonadotropin hormone synthesis occurs
Class 2	0.2 - 0.4 mm	<ul style="list-style-type: none"> • Cumulus oophorus develops • Antrum development commences • Call Exner bodies form in granulosa cells
Class 3	0.4 - 0.9 mm	<ul style="list-style-type: none"> • Small antrum
Class 4	0.9 - 2.0 mm	<ul style="list-style-type: none"> • Medium antrum
Class 5	2.0 - 5.0 mm	<ul style="list-style-type: none"> • Medium antrum • Recruitment occurs
Class 6	5.0 - 10.0 mm	<ul style="list-style-type: none"> • Medium antrum • Selection occurs • Aromatase activity detected in granulosa cells
Class 7	10 - 16 mm	<ul style="list-style-type: none"> • Large antrum
Class 8	>16 mm	<ul style="list-style-type: none"> • Ovulation

of follicles remaining in the resting pool and appears to be affected by testosterone, age, nutrition, activity of the thymus gland and opioid peptides^{16,17}.

1.1.4 Preantral Growth Phase or Basal Follicular Growth

Follicles begin to enter the preantral growth phase during fetal development and do not stop entering this phase until menopause^{6,7}. The preantral growth phase begins with the progression of a primordial follicle (35.0 μm) into a primary follicle (46.0 μm) through the differentiation of spindle-shaped granulosa cells into cuboidal cells. During this transition a mucopolysaccharide layer is synthesized and secreted by the granulosa cells and/ or primary oocyte to form a zona pellucida around the oocyte¹⁸ (Table 1.1). Gap junctions traverse the zona pellucida between the granulosa cell layer and the oocyte to form a communication system between the cell types⁴. Adherent and gap junctions also develop between adjacent granulosa cells forming a functional syncytium that is essential to maintaining communication within the avascular granulosa cell layer⁶.

Primary follicles are redefined as secondary follicles ($\leq 120 \mu\text{m}$) when at least two layers of granulosa cells surround the primary oocyte and the ovarian stroma cells align parallel next to the basal lamina¹⁰ (Table 1.1). Granulosa cells, of secondary follicles, express follicle stimulating hormone (FSH), estrogen and androgen receptors; however, these receptors are likely not fully functional^{4,19}. The surrounding stromal tissue differentiates into two theca layers, the inner theca interna and the outer theca externa, as the secondary follicle increases in diameter. The theca interna, in secondary follicles, is composed of fibroblast-precursor cells containing luteinizing hormone (LH) receptors and a blood supply that contains one or two arterioles which terminate in a wreath-like fashion of capillaries adjacent to the basal lamina of the granulosa cells^{20,21}. The theca externa, in

secondary follicles, is composed of undifferentiated theca cells^{4,22}. The secondary follicle may continue growing or undergo atresia, with the latter occurring in most cases (>99%)²³.

1.1.5 Tonic Growth Phase

The tonic growth phase is associated with a 15-fold increase in diameter through the conversion of a Class 1 (pre-antral) follicle (0.12-0.20 mm in diameter) into a Class 5 follicle (2.0-5.0 mm in diameter)⁴. Follicular growth and development during this phase are largely due to antral cavity formation, beginning during Class 2, and proliferation of granulosa and theca cells. Antral cavity formation sustains follicular growth and development by providing a unique hormone micro-environment to the follicle and oocyte¹⁶. The antral fluid is composed of protein-bound and free sex steroids, proteins, proteoglycans and electrolytes²⁴. The complete growth trajectory of a follicle from Class 1 to Class 8 is diagrammed in Figure 1.2.

Entry into the tonic growth phase is marked by the transition of a secondary follicle into a Class 1 follicle^{4,25}. The transition into Class 1 occurs when at least one fibroblast-like stromal cell of the theca interna differentiates into an epithelioid cell²⁶. By Class 1 of follicular development, the follicle is capable of producing estrogen via the two-cell two gonadotropin relationship between theca and granulosa cells (Table 1.1). Theca cells are stimulated by LH to produce androgens which cross the basal lamina into granulosa cells, where the androgens are aromatized by enzymes to estrogens and subsequently released into the follicular fluid, the intrafollicular space or the systemic circulation^{4,10}.

It takes approximately 25 days for Class 1 or pre-antral (0.12-0.2 mm in diameter) follicles to develop into Class 2 or early-antral follicles (0.2-0.4 mm in diameter; Figure 1.2).




Figure 1.2: Complete growth trajectory: conversion of a Class 1 follicle into a Class 8 follicle. Gn, Gonadotropin. (From Adashi *et al.*, 1996).

If Class 1 follicular development began during the luteal phase than entry of the follicle into Class 2 would generally occur between days 11 and 14 of the late follicular phase of the following cycle^{4,25}. Gougeon suggested that increased levels of FSH during the late follicular phase are likely responsible for a peak in the population of Class 2 follicles¹⁰. Class 2 is marked by differentiation of granulosa cells and the formation of small antral cavities (0.04 mm in diameter) which eventually coalesce to form a single large antral cavity¹⁰ (Table 1.1). Follicle stimulating hormone is suggested to induce antrum formation^{10,27,28}. Antrum formation subsequently results in the formation of the cumulus oophorus which is a stalk-like projection of granulosa cells surrounding the oocyte that extends into the center of the antral cavity²². Call Exner Bodies develop in tandem with the antrum, however the role of these structures is unknown.

Class 2 follicles proceed to Class 3 (0.4-0.9 mm in diameter) during the end of the luteal phase^{4,25} (Figure 1.2). Transition into Class 3 is marked by an increase in follicle diameter due to an increase in the mitotic index of granulosa cells²⁵. Approximately 15 days later, during the follicular phase of the following cycle, Class 3 follicles convert to Class 4 follicles (0.9-2.0 mm in diameter)^{4,25} (Figure 1.2). Class 4 follicles convert to Class 5 follicles (2.0-5.0 mm in diameter) ten days later during the late luteal phase^{4,25} (Figure 1.2). Transformation from Class 1 to Class 5 takes approximately two cycles in total.

The role of gonadotropins in early follicular development remains controversial²⁹. For example, Hodgen (1989) suggests that follicular development from primordial follicle to primary follicle is gonadotropin independent and subsequent development to a secondary follicle requires gonadotropins, whereas Fauser (1997) and Hillier (1994) suggest follicular growth to Class 2 occurs in the absence of gonadotropins. Continual growth and

development of follicles to Class 5 is observed throughout life, including during conditions when endogenous gonadotropins are significantly decreased such as: pre-puberty, pregnancy, during OC use, and in women without gonadotropin secretion due to hypothalamic-pituitary failure or hypophysectomy, suggesting that follicles <2 mm in diameter require only basal levels of gonadotropins for growth and development^{10,20,21,30-35}. Regardless of when follicles become dependent on gonadotropins, basal levels are required to sustain growth and development to Class 5. Circulating levels of FSH are correlated to follicle quality of Class 5 follicles, therefore, it is suggested that follicles become dependent on cyclic changes when they reach Class 5 and remain dependent on cyclic gonadotropin changes until ovulation during Class 8^{7,10}.

1.1.6 Exponential Growth Phase

During the exponential growth phase the follicle progresses from Class 5 to Class 8 (Figure 1.2). This phase takes approximately 20 days, with each stage lasting five days²⁵. The predominant events of the exponential growth phase include, but are not limited to, recruitment and selection of a dominant follicle followed by ovulation of a pre-ovulatory follicle⁷.

1.1.7 Recruitment

The term ‘recruitment’ is used throughout literature to define two separate events. “Initial recruitment” refers to the entry of primordial follicles into the growing phase and occurs continuously throughout reproductive life beginning during fetal development and continuing to menopause. “Cyclic recruitment” refers to the process whereby a small cohort of antral follicles is rescued from atresia via FSH-induced growth. Although both

definitions outline a process of recruitment, for the purposes of this review the term recruitment refers to “cyclic recruitment”.

The demise of the corpus luteum during the late luteal phase results in remarkable changes within the ovary including, but not limited to, a decrease in progesterone, estradiol and inhibin A allowing for an increase in FSH approximately 12 days after the preceding midcycle LH surge^{10,36,37}. Follicle stimulating hormone must increase 10 to 30% above basal levels in order to rescue a cohort of 1 to 15 Class 5 follicles, at similar but not identical stages of development, from atresia^{10,26,38-41} (Table 1.1). Although all follicles are suspected to have equal potential for maturation, only the follicles at advanced stages of development during the intercycle gonadotropin rise are recruited for further follicular development²². Prolonged increases of FSH above threshold or extremely high levels of FSH result in higher than average numbers of follicles being recruited, such as during hyperstimulation protocols of IVF treatment²². The FSH threshold varies between individuals, but appears to remain relatively constant within individuals.

The recruited cohort is comprised of follicles that left the resting pool, by chance, at approximately similar times several months earlier²². The best knowledge, to date, suggests that the continual entry of primordial follicles into the growth phase ensures a cohort of follicles are developmentally capable of responding to the intercycle increase in FSH¹⁰; however, the recent finding of follicular waves suggests that two to three cohorts of follicles are recruited at separate times during a single ovarian cycle^{42,43}. Recruitment of a cohort of follicles is preceded by an increase in FSH, suggesting that FSH plays a large role in follicle recruitment⁴². Further research is needed to determine the exact physiologic mechanisms and biologic factors responsible for follicle recruitment in humans.

The largest follicles present at the beginning of the follicular phase possess the greatest number of FSH receptors, which in turn provides these follicles with a low FSH threshold³⁸. Large follicles have a competitive advantage over smaller follicles because large follicles can respond to lower levels of FSH earlier than smaller follicles. Responses to increasing FSH include an increase in granulosa cell mitosis and glycosaminoglycan production (increases the volume of the antral cavity), induction of gene expression of granulosa cell FSH receptors and nonsteroidal growth factors including the insulin like growth factor system, fibroblast growth factor, transforming growth factor- β , activin and the aromatase enzyme complex; however, this complex is not fully engaged until follicles exceed 10 mm in diameter^{10,44-46}.

1.1.8 Selection

Selection is the process by which one follicle from the recruited cohort is physiologically “selected” to attain “dominance” and continue development to ovulation, with the remaining non-selected follicles of the cohort undergoing atresia. The process of selection ensures the species specific ovulatory quota of follicles develop⁴⁷. Although humans develop two to three follicular waves per ovarian cycle, only the wave that initiates development during the late luteal phase typically produces one pre-ovulatory sized follicle resulting in subsequent ovulation^{42,43}.

Selection of the pre-ovulatory follicle from the cohort of recruited follicles occurs between days 5 to 7 of the menstrual cycle⁴². However, the diameter at which selection occurs is debatable; Gougeon (1989) suggested follicles are selected between 5.5 to 8.2 mm in diameter (Class 6), Chikazawa *et al.* (1986) reported follicles are selected at 4.7 ± 0.2 mm in diameter (Class 5); whereas, Macklon and Fauser, (1999) Pache *et al.*, (1990) van

Santbrink *et al.*, (1995) and Baerwald *et al.* (2003) suggested follicles are selected at approximately 10 mm in diameter (Class 6)^{7,29,43,46,48,49} (Table 1.1). Follicle diameter at the beginning of the follicular phase ranges from 4 to 8 mm in diameter and few morphological differences are observed between follicles <8 mm. Taken together, this data is interpreted to mean that follicle selection does not occur before follicles reach 8 mm in diameter⁵⁰.

At the time of selection, the selected follicle can be differentiated from the other healthy follicles of the cohort by its larger size, higher mitotic index, detectable amounts of FSH and an appreciable amount of estrogen in the follicular fluid^{50,51}. Gougeon and Lefevre suggested that the largest follicle present at the beginning of the follicular phase is selected for dominance, because the selected follicle typically has the highest mitotic index of all follicles within the cohort, thus preventing smaller follicles from making up the growth delay⁵⁰. Once selected the follicle is defined as a “dominant” follicle and can be differentiated from the other follicles due to its larger size, morphology, increased secretion of estrogen and inhibin and complete induction of aromatase^{46,49,52-55}. The mechanisms responsible for selection of a single dominant follicle have not been fully elucidated; however, researchers suggest that decreasing levels of FSH in concert with increasing levels of estrogen are the primary regulators of selection^{56,57}.

1.1.9 Maturation of the Dominant Follicle Destined to Ovulate

Once selected the dominant follicle continues increasing in size through accumulation of follicular fluid and proliferation of granulosa and theca cells until it reaches Class 7 (8-16 mm in diameter) followed by Class 8 (18-20 mm in diameter)¹⁰ (Figure 1.1). The dominant follicle undergoes its most profound transformation during the

last 10-15 days of development⁷. The final two weeks of follicular growth are associated with a 12 mm increase in diameter⁷. To put this into perspective, the follicle takes more than 330 days to reach 6 mm in diameter from initiation of growth but takes 10 days to increase its size by 12 mm in diameter.

Soon after selection, the dominant follicle transforms from an androgen producing structure to an estrogen producing structure; therefore, the androgen:estrogen ratio of the follicular fluid decreases due to increased aromatase expression and subsequent estrogen production¹⁰. Systemic estrogen levels begin increasing approximately five days before the mid-cycle gonadotropin surge^{42,58,59}. Ultrasonographic visualization of the “dominant” follicle coincides with the initial increase in plasma estradiol concentrations⁴⁹. The majority of systemic estrogen present during the mid-to-late follicular phase is produced by the dominant follicle as demonstrated by dramatically elevated levels of estrogen in the venous effluent of the ovary containing the dominant follicle, and a significant correlation between increasing concentrations of serum estradiol and growth of the dominant follicle^{49,58}. The increasing levels of estrogen synergistically act with FSH to further stimulate granulosa cell proliferation and stimulate the effects cAMP in an autocrine fashion^{44,60}.

Continued dominant follicle development is maintained by autocrine and paracrine growth factors that stimulate increased vasculature of the dominant follicle and FSH responsiveness, which allows the follicle to sustain growth and development in the face of waning levels of FSH⁶¹. Further growth is supported via the expression of LH receptors during the mid-to-late follicular phase, at a time when LH concentrations begin to increase^{62,63}. Luteinizing hormone receptors are predominantly expressed on the mural

granulosa cells adjacent to the basal lamina, placing them in close proximity to the vascular supply of the theca interna⁶³. By day nine, the vasculature of the theca interna within the dominant follicle is two times that of any other follicle providing preferential delivery of gonadotropins to the newly formed LH receptors of the mural granulosa cells⁶⁴. Binding of FSH and LH to their respective receptors produces similar cellular responses since both receptors are coupled to a cAMP signaling system⁶⁵. Thus, increasing LH concentrations during the mid-follicular phase sustains dominant follicle growth and development by stimulating similar cellular pathways to that of FSH binding to FSH receptors. Furthermore, FSH and LH receptors have an additive effect when the receptors are not saturated, thus providing continued gonadotropin support in the face of declining FSH and increasing LH levels⁵⁹. Zeleznik suggests the decreased dependency of the dominant follicle on FSH may be the result of the acquisition of LH receptors on granulosa cells⁵⁹.

The dominant follicle is suggested to cause atresia of the subordinate follicles by one of two mechanisms: (i) the dominant follicle secretes a factor that directly inhibits subordinate follicular growth and development or (ii) the dominant follicle indirectly causes atresia of the subordinate follicles through negative feedback mechanisms⁶⁶. The dominant follicle produces increasing levels of estrogen and inhibins which suppresses FSH release from the anterior pituitary thus withdrawing the gonadotropin support needed to sustain follicular development of subordinate follicles^{36,67}. The lack of gonadotropin support results in atresia of all but the dominant follicle⁶¹.

Dominant follicle growth is associated with granulosa cell mitosis and antrum fluid accumulation²⁶. The theca layer undergoes increased vascularization and hypertrophy until ovulation⁷. During Class 8 the basement membrane becomes less visible, mitosis of the

granulosa cells dramatically declines and the granulosa cells and their nuclei increase in diameter⁵². Upon reaching Class 8, the follicle is considered mature and will ovulate if stimulated by a gonadotropin surge; if a gonadotropin surge does not occur than the follicle regresses.

1.1.10 Ovulation

Ovulation begins at the time of the gonadotropin surge and involves local alterations in and around the 15 to 28 mm graafian follicle until the follicle ruptures releasing the fertilizable oocyte^{10,42,43,52,68}. The complex process of ovulation takes approximately 36 to 38 hours in humans and involves biochemical, morphological and physiological changes, all of which have not been completely elucidated⁶⁸.

The mid-cycle estradiol peak initiates organization of the granulosa cells, followed by disorganization of the granulosa layer during preludeinization of the follicle^{7,52}. The onset of the mid-cycle gonadotropin surge stimulates the oocyte (which is arrested in dictyate stage of prophase I) to complete its first meiotic division and become arrested in prophase II as a secondary oocyte²⁶. An LH threshold must be reached and maintained for 14 to 27 hours for full maturation of the oocyte to occur⁶⁹. Oocyte Maturation Inhibitor is suggested to inhibit oocyte maturation before the mid-cycle gonadotropin surge. The mid-cycle gonadotropin surge suppresses the action of oocyte maturation inhibitor, allowing meiosis to proceed to prophase II⁷¹. The LH surge is terminated by negative feedback of progesterone and 17 β -hydroxyprogesterone on the hypothalamo-pituitary-ovarian axis^{10,70}.

The midcycle gonadotropin surge also suppresses granulosa cell mitosis, stimulates large lacunae formation within the granulosa cells, stimulates a decrease in estrogen and

androgen concentrations in follicular fluid and stimulates granulosa cell luteinization as well as synthesis of prostaglandin E_2 and $F_{2\alpha}$ and other eicosanoids^{16,72}. The exact role of prostaglandin E_2 and $F_{2\alpha}$ is unknown⁷¹. Further, the LH surge activates a number of intraovarian regulatory systems (Figure 1.3) that act synergistically to induce vascular changes and degrade the extracellular matrix through the dissociation of fibroblasts and collagen of the theca externa and tunica albuginea on the apex of the follicle^{68,68}. The vascular changes stabilize or increase the liquid pressure within the follicle to avoid collapse of the follicle when the follicle is leaking fluid followed by rupture⁷³.

Few morphological changes occur in the follicle wall until a few hours before ovulation⁷⁴. Hours before ovulation blood vessels from the theca interna invade the, once avascular, granulosa layer. Extra-vascular blood cells are observed within the extracellular spaces around the fibroblasts⁷⁵. Follicular fluid volume increases immediately before ovulation without any significant changes in pressure⁷⁰. Minutes before follicular rupture, a stigma forms in the apical region of the follicle wall due to thinning of the collagen layers and degradation of the connective tissue elements. Immediately before follicle rupture, the surface epithelium becomes necrotic and sloughs off the apex of the follicle⁷⁶.

Ovulation is often likened to an inflammatory event due to the presence and involvement of inflammatory cells. The LH surge stimulates the production of interleukin-1 and chemokines which attract leukocytes, neutrophils and macrophages to work together to aid in the degradation of the extra cellular matrix⁶⁸.

Two theories of ovulation - the pressure theory and the smooth muscle theory - predominated during the first half of the 20th century. The pressure theory states an increase in intrafollicular pressure due to vasodilatation and ruptured blood vessels,




Figure 1.3: Overview of LH-induced pathways in the ovulatory cascade. LH induces synthesis of mediators that promote either degradation of the extracellular matrix (ECM) and/or vascular changes (permeability increase, blood flow increase). These changes lead to a decreased tensile strength and a positive intrafollicular pressure. *BK*, Bradkinin; *GRO*, growth regulating oncogene; *HI*, histamine; *IL*, interleukin; *LT*, leukotriene; *MCP*, monocyte chemotactic protein; *MMP*, matrix metalloproteinase; *NO*, nitric oxide; *P*, progesterone; *PA*, plasminogen activator; *PAF*, platelet activating factor; *PG*, prostaglandin; *VEGF*, vascular endothelial growth factor. (from Branstrom, 2004).

increases in intrafollicular osmotic pressure and increases in follicular fluid volume cause follicular rupture⁷⁷⁻⁷⁹. However, researchers have disproved the pressure theory by reporting that intrafollicular pressure does not increase during the few hours leading to ovulation but remains between 15 - 20 mm Hg^{76,80}.

The smooth muscle theory is defined as a contraction in smooth muscle contained in the follicular wall, inducing ovulation⁷⁴. In the early 1900's, researchers reported the presence of smooth muscle cells in the follicular wall, however the muscle could not be chemically or electrically stimulated to induce ovulation^{81,82}. In 1919, Corner suggested the “smooth muscle cells” of the follicle wall were actually long spindle-shaped fibroblasts enveloped in collagenous fibrils⁸³. Technological advances in polarization microscopy supported this report when Claesson revealed that the birefringence characteristic of muscle cells was not present in follicle walls but birefringence typical of connective tissue was⁸⁴. To date, there is no convincing evidence to suggest ovarian contractions are essential to ovulation. However, rhythmic ovarian contractions are occasionally observed near the time of ovulation, suggesting smooth muscle contractions may play a role in ovulation⁷⁴.

The proteolytic enzyme theory is the currently accepted theory for the mechanism of ovulation⁷⁴. This theory states that a small portion of the follicular wall, known as the apex, is digested by enzymes until the distensibility of the wall decreases to the point that it can no longer sustain the constant intrafollicular pressure of 15 to 20 mm Hg, resulting in rupture of the follicular wall to release the mature oocyte. Progesterone, FSH and LH induce synthesis of mediators and activate proteolytic enzymes in an orderly sequence to digest the collagen within the follicle wall and to decrease the distensibility of the apex

(Figure 1.3)⁸⁵. Granulosa and theca interna cells produce plasminogen activator in response to the mid-cycle gonadotropin surge. Plasminogen activator activates plasminogen to plasmin, in the follicular fluid. Plasmin subsequently generates collagenases which digest collagen at the apex of the follicular wall⁷⁰. The changes that occur at the ovulatory site have been described as a pathophysiological process because the dense collagen layer of the tunica albuginea and theca externa is disrupted⁸⁶. Once the stigma of the follicular wall ruptures, the follicular fluid and oocyte evacuate the antral cavity.

1.1.11 Duration of Human Folliculogenesis

Follicular development from primordial follicle to ovulation takes approximately 12 menstrual cycles²⁶ (Figure 1.1). Initially, follicular development is a slow process. It is estimated that a primordial follicle takes > 150 days to develop into a primary follicle and >120 days for the transition from the primary to secondary stage of follicle development²⁶. The speed at which follicles progress through each stage of development increases dramatically once the secondary follicle develops. It takes 65 days for a secondary follicle to progress to Class 5, five more days are needed for selection to occur, followed by 15 days of maturation to the pre-ovulatory sized follicle¹⁰. Gougeon suggested that follicular development from Class 1 (pre-antral) to Class 8 (pre-ovulatory) takes approximately 85 days¹⁰ (Figure 1.2).

1.1.12 Summary

The knowledge of the basic biology and physiologic processes underlying reproductive function, in women, has grown exponentially since de Graaf defined the ovarian follicle and oocyte⁸⁷. However, we do not yet completely understand the

complexity, and intricacies of the ovary and ovarian follicle. New dynamic, interdisciplinary research techniques are providing researchers the tools to uncover the mysteries of reproductive organs in women. For example, follicular wave development was recently documented in humans^{42,43}. Further research is needed to determine the physiologic and endocrine processes responsible for initiation and maintenance of waves. New research findings regarding the biology and physiologic mechanisms associated with reproductive functioning will allow us to develop safer, more efficacious hormonal contraception and infertility treatments.

1.2 Ultrasonographic Imaging of the Ovaries and Uterus

1.2.1 Overview of Ultrasound Imaging

The introduction of gray-scale ultrasonography has revolutionized how clinicians and researchers examine ovarian follicular development. Before the introduction of ultrasonography, tissue samples were examined using histological techniques that are time consuming and result in destruction of the tissue as well as only providing information about a single point in time. Further, histological studies are ethically difficult in live humans. Ultrasound provides a direct, non-invasive and atraumatic tool to observe the dramatic morphological changes that occur within the reproductive organs without interfering with the physiological processes of these organs while minimizing discomfort to the individual^{88,89}. Further ultrasound can be used to detect minute differences in morphology and physiologic state of reproductive organs thus eliminating the need for surgery⁹⁰.

Ultrasonography is based on the ability of tissue structures to reflect high frequency sound waves^{91,92}. The ultrasound machine is composed of a transducer, a computer processor and a monitor screen. The transducer contains piezoelectric crystals that expand and contract to produce a high frequency sound wave when stimulated by an electrical current. The sound wave propagates into the tissue until it is reflected back towards the transducer after collision with a tissue interface. The degree of wave reflection is associated with tissue density and is represented by shades of gray ranging from black to white. Dense structures (e.g. cervix) reflect the majority of sound waves and therefore appear white or hyperechoic whereas fluid-filled structures appear black or hypoechoic because they propagate sound waves⁹³. Waves which are not reflected back to the transducer are scattered, refracted or absorbed into the tissue⁹¹. The reflected sound wave returns to the piezoelectric crystal within the transducer causing the piezoelectric crystal to compress followed by the subsequent generation of an electrical signal. The electric signal is processed for display in the receiver and then stored as binary digits or “bits” in a digital scan converter.

Ultrasound images are produced when the stored information from the digital scan converter is converted to an electrical signal. The electrical signal causes an electron gun to expel an electron beam onto a phosphor screen resulting in the emission of light. The horizontal movement of the electron beam forms raster lines. Vertical scanning lines are subsequently produced when the electron beam of the raster line turns on and off⁹¹. The intersection of a vertical scanning line with a raster line produces a pixel. Each pixel represents a discrete tissue reflector. Pixel brightness is displayed as one of 256 shades of grey (black = 0 and white = 255) and is related to the amplitude of the reflected signal or tissue density⁹¹. Currently, ultrasound machines usually display images of 480 x 640 pixels.

Each ultrasound image is created by the processing and displaying of numerous sound beams which have been focused to increase lateral resolution and optimize viewing⁹².

The primary reason for performing transvaginal ultrasound is to monitor ovarian follicular maturation and ovulation during natural menstrual cycles and controlled ovarian hyperstimulation and ovulation induction during infertility treatments⁹³. Current infertility investigations utilize transvaginal ultrasonography to track ovarian follicular development and ovulation, aid in invasive ultrasound guided procedures, detect early pregnancy, examine pathologies and assess the uterus and ovaries for anomalies such as cysts, tumors, fibroids and endometriomas⁹⁰. The uterus and ovaries are easily examined using B-mode (brightness mode) transvaginal ultrasound, particularly due to the close proximity of the organs to the transducer during ultrasound examination.

1.2.2 Ultrasonographic Characteristics of the Ovaries

The ovaries are visualized as a pair of almond shaped structures (3 cm x 2 cm x 1 cm) that lie on either side of the uterus⁹³. They are typically located posterior to the broad ligament, anterior to the iliac vessels and ureters and inferior to the uterine tube⁹³. The ovaries are secured in the peritoneal space by the ovarian and suspensory ligaments⁹³. Each ovary is supplied with blood by an ovarian branch of the adnexal branch of the uterine artery⁹³. Ovaries have a coarse low-level echo pattern which is interspersed with anechoic areas representing ovarian follicles, cysts or corpora lutea⁹³. Mature ovarian follicles measure approximately 20 to 24 mm in diameter⁹³. Ovarian follicles appear as round anechoic spheres surrounded by a thin hyperechoic follicle wall⁹³.

Morphological changes associated with impending ovulation can easily be detected using two-dimensional transvaginal ultrasonography. The cumulus-oophorus expands and can be observed in up to 80% of follicles 12 to 24 hours before ovulation⁸⁹. The apex of the follicle wall thins and the deep internal portion of the follicle wall thickens beginning approximately three hours before ovulation⁸⁸. The follicle wall becomes less echogenic (i.e., darker) as the tissue layer expands and becomes loosely organized and vascularization increases in preparation for ovulation⁸⁸. The increased vascularization can be visualized using Doppler ultrasonography⁹³. The follicle flattens out or becomes irregularly shaped in association with expansion and crenulation of the follicle wall⁸⁸. Approximately 15 to 20 minutes before ovulation a stigma forms at the follicular apex followed by the rupture of the follicle and the rapid release of approximately 50% of the follicular fluid within 15 seconds^{89,3}. Complete evacuation of follicular fluid ranges from six seconds to >18 minutes in follicles that completely expel their follicular fluid⁸⁹. The point of follicular rupture can be observed for up to a week following ovulation⁹⁰.

Corpora lutea are observed in the ovarian location where the follicle was formerly observed immediately following follicle collapse using transvaginal ultrasonography^{89,94,95}. The wall of the corpus luteum becomes highly vascularized and thickens and folds during luteinization⁹⁴. The corpus luteum is typically described as having mid-range echogenicity⁹⁶; the outer surface (i.e., luteal wall) has a more echogenic echotexture than the relatively hypoechogenic central portion which is either cystic (i.e., hypoechoic) or solid (i.e., hyperechoic) in structure⁹⁴. Approximately 60% of women hemorrhage into the developing corpus luteum following ovulation resulting in the formation of a corpus hemorrhagicum⁹⁷. If pregnancy does not occur, the corpus luteum begins to regress two to five days before the following menstrual period begins⁹⁴. Regression of the corpus luteum

involves a decrease in cell size and degenerative changes in the nuclei of luteinized cells as well as fatty degeneration⁹⁴. The vascular supply decreases and fibrosis is observed⁹⁴. The cells of the corpus luteum ultimately degenerate into a amorphous hyaline mass, held together by strands of connective tissue; this structure is defined as a corpus albicans⁹⁴. Complete regression of the corpus albicans occurs over the following few menstrual cycles⁹⁴

Ovulatory failure can result in the formation of ovarian cysts, luteinized unruptured follicles and hemorrhagic anovulatory follicles⁹⁰. Anovulatory follicles possess characteristic echotexture that can be used to assess follicular health. Anovulatory follicles generally have thin highly echoic (i.e., bright), clearly demarcated follicular walls of uniform thickness with an echotexture that is characteristic of a cohesive tissue layer⁸⁸. However, echoic structures protruding into the antral cavity as well as free floating in the antral cavity are commonly observed⁹⁰. The increased gray-scale values of the follicular wall may be associated with decreases in vascularity⁸⁸. The cumulus-oocyte complex is not evident in anovulatory follicles⁸⁸. Anovulatory follicles do not form a stigma nor do they change shape⁸⁸. These follicles generally develop past normal ovulatory diameter (i.e., >25 mm) remain static for one to several days and then regress without luteinization⁹⁰. Luteinized unruptured follicles generally have thick follicular walls with hazy indistinct borders between the antrum/wall interface. These follicle walls have similar echotexture to luteinized tissue⁹⁰. Luteinized unruptured follicles typically regress in a similar time period to normal corpus luteum regression⁹⁰. Hemorrhagic anovulatory follicles are characterized by hemorrhage into the antral cavity followed by the formation of fibrin network within the antrum⁹⁰.

1.2.3 Ultrasonographic Characteristics of the Uterus

The uterus is a pear-shaped, hollow, muscular organ with thick walls and an average length of 7.5 cm, a depth of 2.5 cm and a width of 5 cm at its widest point⁹³. The uterus lies posterior to the urinary bladder and anterior to the rectum and has a homogenous echotexture with echoes of medium intensity^{90,93}. The uterine cavity appears as a transverse slit in sagittal section and a triangle in transverse section with the opposing layers of the endometrium appearing as an echogenic line in the central uterine cavity⁹³. The echotexture of the endometrium varies throughout the menstrual cycle and is related to the circulating concentrations of estrogen and progesterone⁹⁰. The echotexture of the myometrium does not change during the menstrual cycle⁹⁰.

1.2.4 Computer Assisted Image Analysis

Currently, researchers are developing new techniques to evaluate ultrasound image attributes to elucidate the physiologic status of ovarian follicles and corpora lutea with a single non-invasive ultrasound exam⁹⁸. The development of non-invasive techniques will result in immediate improvement in the clinical management of infertility patients⁹⁸.

Each ultrasound image is composed of thousands of discrete picture elements or pixels⁹⁹. The human eye can perceive smooth transitions in shades of gray, but can only distinguish between 18 to 20 shades of gray, therefore, most of the gray-scale information contained within an ultrasound image can not be evaluated by the human eye¹⁰⁰. Ultrasound image analysis overcomes subjective human evaluation of ultrasound images by using a series of processing steps and complex computer algorithms to quantify echotextural characteristics within the image⁹⁸. The image attributes can then be correlated

to physiologic status of ovarian structures. The validity of the image analysis technique has been verified through correlation of ultrasound image attributes with histologic attributes in animal models¹⁰¹⁻¹⁰³. The ultimate goal of image analysis techniques is to provide clinicians and researchers with a tool to assess the physiology underlying ovarian follicular growth and development with a single ultrasound exam⁹⁹.

Three image attributes are typically quantified during analysis. These include, but are not limited to: (i) numerical pixel value (NPV) defined as the mean pixel gray-scale value of the sampled pixels, (ii) pixel heterogeneity (PH) defined as the standard deviation of the mean gray-scale values of the sampled pixels, and (iii) the area under the curve (AUC) defined as the total sum of the gray-scale values within the sampled area. Spot metering, linear and time-series analyses, and regional surface analyses are techniques utilized to sample ultrasound image attributes of ovarian structures^{98,99}. Caution must be taken when performing all analyses to avoid placing sampling lines on image artifacts (e.g., enhanced through transmission, shadowing, specular echoes, refraction and beam width artifacts) that may falsely increase or decrease image attribute values resulting in inaccurate interpretation of the physiologic status of the ovarian structure.

1.2.5 Spot Metering

The simplest imaging technique utilizes a small circle to isolate and quantify pixels in an area of interest^{98,99}. The computer program determines the precise gray-scale value of the pixels within the sample area and provides output in the form of image attributes such as NPV, PH and AUC. This technique is used to compare different areas within the same follicle or the same area of the follicle at different time points^{98,99}. For example portions of the follicle wall or corpus luteum may be quantified to evaluate characteristics of follicular

growth and regression, impending ovulation, atresia and luteal development and regression^{98,99,101-105}.

1.2.6 Line and Time Series Analysis

A computer-generated line (one or more pixels wide) is drawn across a desired region of the follicle or luteal structure^{98,99}. The intensity of each pixel within the line are displayed in a graphical format comparing distance versus pixel value^{98,99}. This technique is commonly used to observe changes in the follicle wall of a single follicle or many follicles over time^{101,106}. To increase the precision and accuracy of analysis image attributes of many lines at different locations of the follicle wall can be averaged to obtain a single image attribute.

Time series analysis of the same follicle may be done by concatenating individual linear pixel intensity graphs into a single image^{98,99}. The composite image undergoes shading algorithms to provide a three-dimensional graph which compares follicle diameter, pixel intensity and time⁹⁸. Evaluation of the surface features can provide clues regarding the physiologic health of the follicle. Echotexture of the follicular wall and antrum can be assessed as the follicle progresses through different stages of growth and regression⁹⁹.

1.2.7 Region Analysis

Region analysis is the most promising technique to evaluate the physiological status of a follicle⁹⁸. This technique involves overlaying a pixel-by-pixel mesh onto a selected region of the follicle to produce a three-dimensional image^{98,99}. A computer-generated skin can be placed on top of the mesh framework to provide a topographical image. The image can be further enhanced by applying shading algorithms to the topographical image.

Shading highlights detail and enhances perception of surface features such as texture or the portion of the image comprised of echo intensities of interest. Region analysis may develop into a clinical tool to instantly assess ultrasound image attributes associated with the health and viability of a follicle.

1.3 Ovarian Follicular Development during Oral Contraceptive Use

1.3.1 The Introduction of Oral Contraceptives

Contraceptive choices radically changed for women in 1957, when the Food and Drug Administration approved the first menstrual regulator, Enovid™, which contained synthetic estrogen (150 µg mestranol) and synthetic progestin (9.85 mg norethynodrel)¹⁰⁷. Enovid™ was initially introduced as a menstrual regulator to navigate around secular and religious tenets against the use of birth control. Interestingly, Enovid's™ packaging initially carried a warning that it induced contraceptive properties including, but not limited to, inhibition of ovulation¹⁰⁸. Soon after Enovid™ was introduced, the number of women experiencing menstrual irregularities and disorders dramatically increased, likely due to the fact that the only legal method of obtaining birth control in many American States was under the guise of menstrual irregularities¹⁰⁸. In 1960, the Food and Drug Administration approved Enovid™ as an oral contraceptive. The effects Enovid™ had on ovarian function were not completely known. However, it was hypothesized that administration of synthetic progestin created a pseudo-pregnancy that prevented ovulation while the estrogen component provided cycle control to reduce unscheduled bleeding.

1.3.2 Characteristics of Oral Contraceptives

Prior to 1960, non-steroidal contraceptives were the only available contraception to prevent pregnancy. The introduction of Enovid™, revolutionized contraceptive use by providing women with more contraceptive choices. Today, OC are the most commonly used, reversible contraceptive in the world¹⁰⁹. Combined OC have evolved to include different progestins with lower androgenic activity and mestranol has been replaced with EE; thus, virtually all currently used OC combine ≤ 35 μg EE with a synthetic progestin¹¹⁰. The progestin component of combined OC is thought to directly affect ovarian function, suppress the mid-cycle LH surge and subsequent ovulation, decrease the permeability of the cervical mucus and endometrial receptivity for embryo implantation, and decrease tubal and uterine motility causing a delay in gamete transport¹¹¹. The estrogen component is postulated to directly affect the ovary, suppress FSH release, inhibit ovulation and provide endometrial stability leading to predictable bleeding patterns. The extent of pituitary-ovarian suppression appears to be related to the dose of EE¹¹¹. For example, OC containing ≥ 30 μg EE suppress follicular development better than an OC containing 20 μg EE. Further research is required to determine the exact mechanisms of action that estrogen and progestin have on the reproductive organs during OC use. Progestin-only OC are also available as a contraceptive choice. However, progestin-only OC have lower efficacy than combined OC so they are typically used for special cases, particularly in lactating women or women with sensitivity to EE.

Conventional OC administration consists of a 28 day cycle comprised of 21 daily active pills followed by a 7 day hormone free interval (HFI). This 28-day administration scheme was implemented to mimic the physiological event of monthly menstruation and

provides only the illusion of natural menstrual cyclicity. The purpose of inducing a menstrual bleed during OC use was to increase the acceptability of OC even though it has no reported physiologic benefit. Currently, researchers are examining the efficacy, acceptability and physiologic effects of replacing the HFI with seven daily active pills, in a continuous dosing scheme¹¹²⁻¹³².

Oral contraceptives are generally prescribed in one of three dosing fashions: (i) monophasic, wherein each active pill contains the same concentration of steroids; (ii) biphasic and (iii) triphasic, changes in estrogen concentration are dependent on the OC type wherein the concentration of progestin increases by one (biphasic), or two (triphasic), increments as the cycle progresses from Day 1 to 28.

1.3.3 Follicular Development during Oral Contraceptive Use

Twenty-one studies were reviewed to determine the effect of administering 20 to 40 µg of exogenous EE in combination with various progestins on the hypothalamo-pituitary-ovarian axis^{112,133-148,149,152-154}. Follicular development ≥ 10 mm in diameter was observed in all 17 studies, which utilized ultrasound to examine follicular diameter during OC use^{112,133-148}. Follicular development ≥ 10 mm increases the chances of “escape” ovulation during OC use, since follicles are physiologically selected at 10 mm for preferential growth and ovulation during natural cycles¹⁴⁹. The high incidence of dominant follicle development during compliant OC use, in conjunction with the report of OC failure rates ranging from 16-40% in subgroups of women attending family planning clinics, suggests that the current conventional OC dosing schemes do not completely suppress follicular development and should be improved to decrease the current “real-life” failure rates^{150,151}. Furthermore, 15 of the 21 studies reviewed reported follicular

development to ostensibly ovulatory diameter^{133,134,136,137,139-144,147,148,152-154}. Eight of the 21 studies observed ovulation during compliant OC use^{135,139,142,144,146,148,153,154}. No pregnancies were reported; however, only 3 of the 8 studies reported pregnancy rates. Follicles which develop to pre-ovulatory diameter during OC use likely do not ovulate due to suppression of the mid-cycle gonadotropin surge or the inability of the follicle to respond to LH due to the effects of progesterone on the population or sensitivity of LH receptors¹³³. The variable ovulatory ability of follicles during compliant OC use can not yet be explained. Further studies examining changes in gonadotropins, in the presence of an ovulatory-sized follicle, as well as morphological changes of pre-ovulatory sized follicles may help to elucidate some of the mechanisms associated with ovulation during compliant OC use.

Most dominant follicles which developed to pre-ovulatory diameter during compliant OC use regressed^{133,134,139-141,143,144,148}. However, some follicles develop to pre-ovulatory diameter in association with pre-ovulatory levels of estrogen^{133,146}. Further, follicles which develop to ovulatory diameter have similar ultrasound image attributes and are ultrasonographically indistinguishable from comparable natural-cycle follicles^{155,156}. Similarities in ultrasound image attributes between natural cycle follicles and follicles which develop under the suppressive effect of OC can be interpreted to mean that follicles which develop during OC use have similar physiologic status to natural cycle follicles; hence, ovulations can occur resulting in pregnancy and OC failure.

1.3.4 Follicular Development during the Hormone Free Interval

Conventional OC regimens provide a seven day HFI to induce a withdrawal bleed during each 28-day cycle and decrease exposure to exogenous hormones. Numerous studies have reported dominant follicle development during the HFI^{133,140,147,156-158} with a

number of these follicles continuing development to pre-ovulatory diameter^{133,140,158}. Over 85% of dominant follicle development is initiated during the HFI¹³³ and ovulation of up to 50% of pre-ovulatory sized follicles has been reported¹⁵⁸. Ultra low dose OC (≤ 20 μg EE) appear to increase the risk of dominant follicle development during the HFI^{133,147}.

The seven day absence of exogenous hormones allows pituitary-ovarian activity to recover to levels observed during the early follicular phase of the natural menstrual cycle, particularly during administration of ultra-low dose OC^{133,145,156,157,159-164}. Follicle-stimulating hormone often rises above the threshold for ovarian stimulation during the HFI, allowing for gonadotropin-dependent follicular growth^{133,156,160,164}. Initiation of active dosing pills following the HFI causes a decrease in FSH regardless of the presence of a dominant follicle¹¹¹. If a dominant follicle is not present after initiation of active dosing pills, then folliculogenesis is completely suppressed. If a dominant follicle is present, then follicle growth usually continues after initiation of the OC strip due to the decreased dependence of dominant follicles on gonadotropins^{160,164}. In the presence of an ovulatory sized follicle contraceptive efficacy is dependent on inhibition of the pre-ovulatory LH surge and the secondary contraceptive benefits of OC, which include, decreased permeability of the cervical mucous to suppress the entry of spermatozoa into the uterus, decreased endometrial receptivity for embryo implantation, and tubal and uterine motility causing a delay in gamete transport¹⁰⁹.

Decreasing the duration of the HFI or replacing some hormone-free days with administration of EE suppresses follicular development better than conventional dosing schemes^{126,142,145,147,165}. For example, decreasing the length of the HFI to four or five days during ultra low dose (≤ 20 μg EE) OC administration decreases ovarian activity and

estradiol levels better than conventional dosing schemes^{145,147,165}. Similarly, replacing the last five inert pills during the HFI with pills containing 10 µg EE reduces follicular growth compared to the conventional OC dosing scheme^{126,142}. Taken together, these findings are interpreted to mean that shortening or omitting the HFI would prevent a rebound in gonadotropins and increase contraceptive efficacy by decreasing the risk of dominant follicle development and subsequent contraceptive failure.

1.3.5 Follicular Development after Prolongation of the Hormone Free Interval

Prolonging the HFI through missed OC doses increases the risk of “escape” ovulation compared to doses missed during mid-cycle^{157,161-163,166,167}. Prolongation of the HFI provides more than seven days of unsuppressed follicular development. The longer the HFI is extended past seven days, the greater the risk of pre-ovulatory follicular development. For example, estradiol levels continue increasing if the HFI is extended to 11 days^{120,157}. In addition, mean estradiol concentrations continue to increase, or remain static after reinitiation of OC following a ten day HFI, compared to a decrease in estradiol levels once OC are initiated after the seven day HFI¹⁵⁷. It is suggested that extending the HFI past seven days increases the number of dominant follicles (≥ 10 mm in diameter) that develop, as reflected by the higher estradiol levels following a ten day HFI¹⁵⁷. Prolongation of the HFI likely increases the risk of “escape” ovulation and subsequent conception due to increased dominant follicle development in combination with reduced secondary contraceptive benefits.

Ovulation was observed in five of the ten studies which examined follicular development following prolongation of the HFI, however, no pregnancies were reported^{120,162,163,168,169}. Follicles which develop to ≥ 18 mm in diameter, after the extension

of the HFI, are probably capable of ovulation because these follicles can be induced to ovulate when stimulated with human Chorionic Gonadotropin¹⁷⁰.

1.3.6 Follicular Development after Missed Doses

The risk of “escape” ovulation after missing doses of OC is largely dependent on the number of consecutive doses missed, the stage of the cycle where the OC were missed and the type of progestin contained in the OC. Pituitary-ovarian suppression increases with the number of consecutive OC taken with maximum suppression typically occurring at the end of a 21-day OC cycle, although seven consecutive days of OC administration can adequately suppress ovarian activity¹⁶⁸. Differences in the type of progestins and their associated half-life can affect the number of consecutive doses that may be missed before the risk of “escape” ovulation increases. Oral contraceptives comprised of progestins with longer half-lives appear to better maintain contraceptive properties following a higher number of consecutive missed doses than progestins with shorter half lives. For example, an OC containing levonogestrel, which has a relatively long half life of 29 hours, maintains contraceptive efficacy for four days of consecutive missed doses, compared to an OC containing desogestrel, which has a half life of 16 hours, and can maintain contraceptive efficacy for only two consecutive missed doses^{166-169,171-174}.

Differences between “escape” ovulation rates following missed dosing may also be due to individual variation in the effect the OC has on the hypothalamo-pituitary-ovarian negative feedback system. It is important to note that the small sample size of the above studies may not have included individuals with greater susceptibility to “escape” ovulation; therefore, large-scale studies would be required to estimate the incidence of “escape” ovulation in association with the timing and number of missed OC doses. Up to 74% of

women report omitting ≥ 1 OC during each cycle¹⁷⁵⁻¹⁷⁸. The high omission rate in combination with OC failure following missed doses, particularly missed doses that prolong the HFI suggest that a more efficacious OC should be developed that is capable of maintaining high efficacy following missed OC doses.

1.3.7 Follicular Development during “Sunday Start” Initiation Schemes

“Sunday Start” initiation schemes prolong the initiation of OC to the first Sunday during menses, compared to immediate start initiation schemes which administer OC on Day 1 of menses. “Sunday Start” schemes were designed to increase user acceptability by suppressing menstruation during weekends when most sexual activity is presumed to occur. Physiologically dominant follicles (≥ 10 mm) are commonly observed during the first seven days of the natural menstrual cycle¹⁴⁹. Utilization of “Sunday Start” regimens can increase the chances of OC failure because follicles can attain dominance during the HFI and continue developing to pre-ovulatory diameter once active OC are re-initiated, up to one week after the onset of menses^{133,144,156}. The risk of follicle development, ovulation and pregnancy in women using “Sunday Start” regimens has not been thoroughly examined.

1.3.8 Follicular Development during Three Different Regimens of Oral Contraceptive use

Schlaff *et al.*, are the only group to date to use ultrasonography to examine ovarian follicular and endometrial development during continuous dosing schemes¹²⁶. This study examined ovarian follicular development ≥ 8 mm in diameter with transvaginal ultrasonography during the use of three different OC dosing schemes: (i) 21 days of 20 μ g

EE + 100 µg levonorgestrel followed by seven days of inert pills, (ii) 20 µg EE + 150 µg desogestrel followed by two days of placebo then 10 µg EE for five days, (iii) 28 days of 20 µg EE + 150 µg desogestrel for two 28 day cycles. The results of the study were interpreted to mean, that continuous OC use provided greatest follicular suppression, in both the number and size, of follicles developing ≥ 8 mm in diameter. The conventional group provided the least amount of suppression, in both follicle number and size, and the conventional dosing scheme with estrogen added to the HFI provided intermediate suppression of follicle number and size. The findings of this study further reinforce the idea of shortening or omitting the HFI to suppress follicular development past the physiological stage of selection.

1.3.9 Inhibiting Menstruation

Many clinicians, researchers and anthropologists propose that monthly menstruation is unnecessary and actually increases health risks to women¹⁷⁹. Thomas and Ellertson suggest that monthly menstruation is not the historical norm¹³². For example, primitive women menstruated 66% less than the typical modern-day woman. The increase in menstrual frequency in modern women is suggested to be due to evolutionary progression resulting in an earlier onset of menarche, later age of first birth, fewer pregnancies, shorter periods of lactation and a later onset of menopause in modern women compared to primitive women¹¹⁹. Eaton *et al.*, reported that late menarche, high parity, early age at first birth and early age at menopause are protective characteristics for breast and gynecologic cancers¹⁸⁰. It would then follow that suppressing menstruation would also provide women with protection from these cancers¹⁸⁰.

Inhibiting menstruation reduces undesirable menstrual-related symptoms which are reported to be the most common gynecologic complaint in American women aged 18 to 50 years¹⁸¹. Undesirable menstrual symptoms include dysmenorrhea, headache, migraine, asthma, premenstrual syndrome, acne and anemia¹³¹. Thirty one percent of American women report spending approximately 10 days annually in bed due to menstrual morbidity¹⁸¹. Menstrual morbidity also affects society as a whole. Menstrual disorders decrease productivity by 25%, and are estimated to cost eight percent of the total wage bill in the United States¹³². Thomas and Ellertson adequately summarized the status of menstrual related disturbances in today's modern industrialized society when they stated, "there can be no other disease or condition that affects so many people on such a regular basis with consequences at both the societal and individual level, which is not prioritized in some way by health professionals or policy makers"¹³².

1.3.10 Women's Attitudes towards Inhibiting Menstruation

Most women in industrialized nations prefer to have a menstrual period with a frequency of every three months or not at all^{116,182,183}. Women's attitudes toward inhibiting menstruation are culture-dependent. Glasier *et al.* reported women's acceptability to inhibiting menstruation varied depending on their country of residence¹⁸³. For example, 6% of women living in Hong Kong compared to 37% of Scottish women prefer to be amenorrheic¹⁸³. Whereas 15-41% of women from Germany, Denmark and Australia prefer to inhibit menstruation^{116,125,184}. Common findings between the studies reviewed were: (i) that most women do not like menstruation, but (ii) less than half of women would actively inhibit menstruation. Menstrual related adverse events were the most commonly reported reason for disliking menstruation. The reported adverse events associated with

menstruation included: inconvenience, menstrual related symptoms, fatigue, acne, premenstrual syndrome, headaches and migraines^{130,183}. Women who preferred monthly menstrual cycles falsely believed that monthly menstruation was “natural” and ensured them that they remained fertile but were not pregnant^{125,183}. Women who have experienced amenorrhea, during continuous OC dosing, reported fewer menstrual complaints, better hygiene, higher quality of life and less blood loss^{122,124,182}.

Ten percent to 65% of women stated optimal bleeding frequency would be every three months if they could use OC to control their menstrual frequency^{116,125,183,184}. Curiously, the majority of women who actually participated in studies designed to evaluate continuous OC dosing schemes on ovarian function and patient acceptability preferred to continue with the continuous regimen after study completion^{112,123}. It appears that women are initially reluctant to initiate continuous dosing schemes but once initiated they prefer continuous OC administration to conventional dosing schemes.

1.3.11 Non-contraceptive Benefits of Oral Contraceptives

Oral contraceptives were initially marketed for the treatment of menstrual disturbances. Ironically, this therapeutic use does not appear in Food and Drug Administration approved labeling for currently marketed OC¹⁸⁵. Oral contraceptives are commonly prescribed to provide beneficial health benefits and to treat a variety of gynecologic disorders in addition to preventing pregnancy. The health benefits of OC include: (i) providing 99% effective contraception, (ii) treating a number of gynecologic symptoms and (iii) preventing some gynecologic and other medical conditions¹⁸⁶.

Oral contraceptives protect women from primary and secondary dysmenorrhea and menorrhageia, menstrual cycle irregularities, iron deficient anemia, ectopic pregnancy, perimenstrual migraines, menses-related epilepsy and pregnancy related complications^{109,185}. Oral contraceptives appear to aid in the prevention of osteopenia and may be used to manage a number of gynecologic disorders including dysfunctional uterine bleeding, persistent anovulation, premature ovarian failure, functional ovarian cysts, and pelvic pain^{109,185}.

Long term OC use decreases the risk of developing uterine fibroids, endometriosis, recurrent ovarian cysts and acute Pelvic Inflammatory Disease by 50-70%¹⁰⁹. Long-term OC use also helps to protect women from iron deficient anemia, benign breast lumps, toxic shock syndrome, premenstrual syndrome, breast cancer, endometrial cancer and ovarian cancer, acne and hirsutism¹⁸⁷.

A number of OC protective benefits increase with increasing duration of OC use. Results from a recent large-scale study which examined the risk of reproductive cancers in OC users were interpreted to mean, that a history of OC use significantly reduced the risk of gynecologic cancers with the risk decreasing with increased duration of OC use¹⁸⁸. For example, the risk of ovarian cancer decreases by 40% after four years of OC use, 54% after eight years and 60% after 12 years¹⁸⁹. Similarly, the risk of endometrial adenocarcinoma decreases by 56% after four years of OC use, 67% after eight years and 72% after 12 years¹⁹⁰. The protective benefits of OC against ovarian and endometrial cancer can persist for up to 20 years after discontinuation of OC use¹⁹¹⁻¹⁹⁴.

1.3.12 Return to Fertility following Discontinuation of Oral Contraceptives

Oral contraceptives are one of the only forms of contraception that inhibit ovulation by physiologically suppressing the hormonal cues required for follicular development and ovulation. Furthermore, OC are the contraceptive of choice for women in most industrialized nations¹⁰⁹. Therefore, it is essential to determine any residual effects OC may have on reproductive function once they are discontinued. Differences in study design and population demographics among studies make it difficult to compare the return to fertility following discontinuation of OC. However, it is apparent that previous OC use temporarily delays conception, but does not permanently affect fertility. A two to three month delay in conception following discontinuation of OC is commonly observed compared to discontinuation of non-hormonal contraception (i.e., intrauterine device, diaphragm, condom)¹⁹⁵⁻²⁰⁴. In contrast, a single study conducted in Malaysian women reported no difference between conception rates of women discontinuing hormonal or non-hormonal contraception²⁰⁵.

Researchers report that approximately half of all women (39%-56%) conceive within three months of discontinuing OC compared to almost two-thirds (54% - 65%) for previous users of intrauterine devices, diaphragms, condoms and “other” contraceptive methods^{200,205,206}. Furthermore, conception rates are similar two years after discontinuation of OC compared to discontinuation of non-hormonal contraceptives (90-99% versus 98%, respectively)^{200,201,203,205}. Conception rates following discontinuation of contraceptives, both hormonal and non-hormonal, should be compared to conception rates during natural cycles to determine the true residual effect contraceptives have on the return to fertility. For example, during natural cycles approximately 57% of women conceive within one

month of unprotected intercourse, 72% within six months, 85% within one year and 93% within two years²⁰⁷. It appears that conception rates return to normal expected values within two years of discontinuing contraception.

The delay in the return to fertility following discontinuation of OC is due to both biological and behavioral factors. Post-pill anovulation or dysfunctional ovulation following discontinuation of OC may explain the delay in fertility^{198, 208}; however, this is unlikely because approximately 98% of women ovulate within three months following discontinuation of OC¹¹⁰. The concentration of EE can effect the median time to conception following discontinuation of OC. For example OC with EE doses $\geq 50 \mu\text{g}$ increase the median time to conception following discontinuation of OC by one month compared to OC containing $< 50 \mu\text{g}$ EE¹⁹⁵. However, this factor is likely not responsible for the delay in fertility since OC containing $\geq 50 \mu\text{g}$ EE accounted for $< 2\%$ of retail prescriptions written for OC in 1998 in the United States¹¹⁰. Another mechanism responsible for the delay in fertility following discontinuation of OC may be due to continued hypothalamic suppression for a short period of time following discontinuation of OC.

A women's parity can affect the delay in fertility following discontinuation of OC because nulliparous women took slightly longer to conceive than multiparous women^{197,198,201,203,208,209}; however, this difference was reversed in Asian women^{200,205}. Oral contraceptives are often prescribed for non-contraceptive reasons (i.e., cycle regularity). Therefore, a higher proportion of women with infertility issues may use OC compared to non-hormonal contraceptives resulting in a falsely inflated interval of infertility following discontinuation of OC. Conception rates decline as age increases in both men and women,

thus an older couple would likely take longer to conceive than a younger couple with similar health characteristics^{198,208}.

Behavioral factors can also affect conception rates. For example, the timing and frequency of intercourse, recall errors in determining when contraception was discontinued and “rounding up” while reporting the time at which conception occurred. Accidental pregnancies that occur during non-hormonal contraceptive use are more likely to be reported as planned which would artificially decrease the time to conception in non-hormonal contraceptive users. Women who discontinue OC may take longer to conceive because they are more likely to refrain from attempting to conceive during the few months following contraceptive use to decrease the risk of residual effects of OC on the developing fetus. It appears that the delay in fertility is likely due to a combination of both biological and behavioral factors. Further research is needed to determine the exact mechanisms of action responsible for the delay in fertility following discontinuation of OC.

A number of researchers have reported conception rates follow an oscillatory pattern following discontinuation of OC with increases in conception rates occurring at approximately three to four month intervals^{199,200,202,209}. Janerich *et al.* suggest three different explanations for the oscillations in conception rates: (i) OC acts as a synchronizing agent resulting in previously unrecognized natural oscillatory cycles approximately four menstrual cycles in length, (ii) oscillations are caused by the transition of the reproductive organs from a suppressed state of functioning to an unsuppressed state, (iii) intrauterine mortality following OC use results in an infertile period²⁰². It is possible that the oscillations may be due to recall errors whereby women preferentially rounded their preconception intervals at one-quarter and one-half year^{199-201, 203}. Closer scrutiny of Pardthaisong and Gray’s data

suggests that they did not observe true “peaks” in conception rates but simply increases in conception rates three and six months following discontinuation of OC²⁰⁰. Harlap and Baras reported conception rates do not follow an oscillatory pattern²⁰³. These contradictory findings suggest that further research is needed to determine if conception rates exhibit an oscillatory pattern following discontinuation of OC use.

1.3.13 Summary

Oral contraceptives have radically changed the way women approach contraception. Initially OC were introduced to regulate menstrual disturbances and provide women with relief from menstrual related adverse events. It appears that attempts to decrease the exposure to exogenous hormones results in inferior follicular suppression, particularly during the HFI or following missed doses. It is unknown at this time as to why some follicles ovulate during compliant OC use while others regress. Much research has examined various aspects of OC composition and function; however, we are far from completely understanding the exact mechanisms responsible for ovarian and uterine suppression during OC use.

Most women desire changes to their menstrual patterns whether it is a decrease in menstrual related side effects or changes to bleeding frequency. Continuous OC use is associated with high acceptability and effectiveness while providing women with the desired changes in menstrual patterns. Ovarian follicular development and the associated endocrine profiles have not yet been critically examined during continuous OC use. Further research needs to examine endometrial development and ovarian follicular growth, regression and ovulation during both conventional and continuous OC dosing schemes to develop a more effective, better accepted OC. Furthermore, the information could be

used to develop new contraceptive technologies which could provide more contraceptive choices for women.

It has been well established that discontinuation of OC results in a two to three month lag in fertility compared to non-hormonal contraceptives. Many hypotheses to explain the delay in fertility following discontinuation of OC have been elucidated; however, an acceptable mechanism of action to explain the decrease in fertility has not yet been suggested. A better understanding of the exact effect OC administration has on the reproductive organs would likely aid in the explanation of the delay in fertility following discontinuation of OC.

Chapter 2

GENERAL OBJECTIVES AND HYPOTHESES

The general objectives of the studies contained in this thesis were:

1. to assess ultrasonographic image attributes of dominant ovarian follicles during the final stages of development prior to ovulation in natural cycles and prior to peak estradiol concentrations for dominant anovulatory follicles during OC cycles;
2. to characterize the development and ovulation of ovarian follicles and related endocrine changes, during and following discontinuation of the suppressive effects of continuous and conventional OC dosing schemes; and
3. to elucidate the mechanisms of action responsible for the delay in fertility following discontinuation of OC.

The research hypotheses tested were:

1. Image attributes of follicles from natural cycles differ quantitatively from follicles that developed under the suppressive effects of OC.
2. Continuous OC dosing schemes better suppress follicular development than conventional OC dosing schemes.
3. A longer time interval to ovulation occurs following discontinuation of OC compared to the first day of menses to ovulation in natural cycles.

Chapter 3

ULTRASOUND IMAGE ATTRIBUTES OF HUMAN OVARIAN DOMINANT FOLLICLES DURING NATURAL AND ORAL CONTRACEPTIVE CYCLES

RL Birtch, OA Olatunbosun, AR Baerwald and RA Pierson

Women's Health Imaging Research Laboratory

Department of Obstetrics, Gynecology and Reproductive Sciences

University of Saskatchewan

Room 4519 Royal University Hospital

Saskatoon, Saskatchewan, Canada S7N 0W8

3.1 Abstract

Objective: Computer-assisted analyses were used to examine ultrasound image attributes of human dominant ovarian follicles that developed during natural and oral contraceptive cycles. We hypothesized that image attributes of natural cycle follicles would differ quantitatively from those in oral contraceptive cycles and that oral contraceptive cycle follicles would possess image attributes indicative of atresia.

Methods: Dominant ovarian follicles of 18 clinically normal women were compared using image analysis techniques for the seven days before ovulation during a natural cycle (n=9) or the seven days before peak estradiol in women using oral contraception (n=11) in a retrospective study. Follicles were analyzed using region and line techniques designed to compare the image attributes of numerical pixel value, pixel heterogeneity and area under the curve.

Results: Numerical pixel value was higher in oral contraceptive cycle follicles with region analysis and tended to be higher with line analysis ($p=0.005$ and $p=0.06$, respectively). No differences were observed in area under the curve and pixel heterogeneity measured with either technique, between natural and oral contraceptive cycle follicles.

Conclusions: The increased numerical pixel value of oral contraceptive cycle follicles and lack of differences in pixel heterogeneity and area under the curve values between natural cycle and oral contraceptive cycle follicles did not support the hypothesis that oral contraceptive cycle follicles would show ultrasonographically detectable signs of atresia. Image attributes observed in oral contraceptive cycle follicles were not clearly indicative of

atresia nor were they large enough to preclude preovulatory physiologic status in oral contraceptive cycle follicles.

3.2 Introduction

Diagnostic gray-scale ultrasonography has revolutionized the study of ovarian biology in animals and humans because it allows researchers and clinicians to assess the development of individual follicles in a direct, non-invasive, and atraumatic manner without interruption or distortion of ovarian function¹. Prior to the introduction of ultrasonography, histological slices of ovarian tissue were used to elucidate ovarian follicular development; however, histologic investigation only provides information about a single time point and does not permit assessment of follicular function over time. Further, histology cannot be used for time-series studies in humans.

Animal models have been developed to elucidate the basic mechanisms of ovarian function in humans and to overcome ethical objections of some aspects of research in humans. To date, however, no appropriate animal models are available to elucidate the physiological effects of oral contraceptives (OC) on human ovarian function due to species specific differences in the metabolism of the exogenous estrogen and progestins used to control reproductive function. Non-invasive techniques do not yet exist that will allow for the determination of the physiological status of individual ovarian follicles with a single observation. However, new technologies involving computer assisted image analysis to elucidate a follicle's physiologic status show promise^{1,2}.

Quantitative changes in ultrasound image echotexture as indicators of physiological function of ovarian structures have been described in domestic animal models³⁻⁸. The validity of the image analysis technique has been verified through correlation of ultrasound

image attributes with histologic attributes^{3,4,8}. Similar studies in humans are objectionable ethically; however, information generated in animal studies may be applied to human imaging based studies^{3-6,9,10}. The overall goal of this line of research in our laboratory is to elucidate physiologic status of dominant follicles with non-invasive ultrasonography in humans. Imaging-based techniques that could be used to determine follicular health would obviate the ethical and logistical limitations associated with ovarian function research in women.

It has recently been reported that women grow follicles in two or three follicular waves during each natural menstrual cycle^{11,12}. The pattern of folliculogenesis is similar in women to those observed in several species of domestic animals (bovine, equine, caprine and ovine)^{10,13-17}. Follicular waves, in humans, are characterized by an increase in the number of follicles ≥ 5 mm in diameter, occurring in association with the growth of at least two follicles to ≥ 6 mm in diameter¹¹. Growth of all follicles in the cohort continues until one follicle is physiologically selected as the dominant follicle. The dominant follicle continues its development to pre-ovulatory diameter while the remaining follicles in the cohort undergo atresia. The dominant follicle will ovulate if the appropriate hormone signals (i.e., mid-cycle luteinizing hormone surge) are provided. If the hormone signals which trigger ovulation are not provided, the dominant follicle enters a static phase and remains approximately the same diameter until it enters the regressing phase, when it decreases in diameter until it is no longer detectable.

Dominant follicles develop in women during adherent use of OC, with most dominant follicles initiating growth during the hormone free interval¹⁸⁻²². Ovulatory follicles that develop during natural menstrual cycles are presumed to be healthy because

they usually ovulate. It is not known whether dominant follicles that arise during OC use have the same physiologic status or ovulatory capacity as natural preovulatory follicles.

The primary objective of the present study was to assess ultrasonographic image attributes of dominant ovarian follicles during the final stages of development in natural menstrual cycles and OC cycles. We hypothesized that image attributes of follicles from natural cycles will quantitatively differ from OC cycle follicles and that the image attributes of OC cycle follicles would be consistent with those indicative of atresia.

3.3 Materials and Methods

This study was a retrospective, observational study designed to evaluate and compare ultrasound image attributes of dominant ovarian follicles (≥ 10 mm in diameter) during natural and OC cycles. Images of twenty ($n=20$) dominant follicles were analyzed. The images were obtained in two previous studies designed to characterize ovarian follicular wave dynamics during natural cycles^{12,13} and OC cycles²². Both study protocols were initially approved by the University of Saskatchewan Ethical Review Board. The inclusion and exclusion criteria of both studies were similar. Participants were assessed, by history and physical examination, to be healthy women of reproductive age (28.0 ± 0.14 years, natural cycles; 24.5 ± 0.02 years, OC cycles; mean \pm SEM). All women in both studies had a history of normal menstrual cycles and did not use OC for a minimum of three months before participating. In the OC trial, one of three different OC formulations were administered to thirty six women for three consecutive 28-day cycles; (i) 20 μ g ethinyl estradiol (21)/100 μ g levonogestrel (21) ($n=7$), (ii) 30 μ g ethinyl estradiol (21)/150 μ g desogestrel (21) ($n=2$), or (iii) 35 μ g ethinyl estradiol (21)/180 μ g norgestimate (7)/215 μ g norgestimate (7)/250 μ g norgestimate (7) ($n=2$). Nine women grew 11 dominant follicles

during compliant OC use. Two women grew dominant follicles during two separate cycles of OC-use; therefore, images from eleven dominant, ostensibly, ovulatory follicles were analyzed in the present study²². Images of nine dominant follicles from nine volunteers were randomly selected from natural cycle data to act as controls^{11,12}. Blood samples were drawn every third day for women in the natural cycle trial and every second day once a follicle reached ≥ 14 mm diameter for women in the OC cycle trial.

A high resolution ultrasound instrument equipped with 5-9 MHz multi-frequency intravaginal convex array transducer (ATL Ultramark HDI 5000, Advanced Technologies Laboratories, Bothwell, WA, USA) was used. Settings of the ultrasound instrument that affect image attributes (beam focus, overall time-gain, near-field and far-field gain) were standardized to the same predetermined standards for both studies. Each image was digitally acquired and transferred into a customized computer database during the ultrasound examinations. Images of the dominant follicle acquired in largest cross-sectional diameter with the fewest image artifacts were selected for image analysis. All image analyses were performed by the same individual (RLB). Blinding was not possible because each image contained identifying study information.

Image attributes of dominant follicles were analyzed using a graphics workstation equipped with a customized software (SYNERGYNE 2©, Saskatoon, SK, Canada) integrating complex algorithms designed for ultrasonographic image analysis^{1,2}. Each image was analyzed with two different techniques: (i) region analysis, and (ii) line analysis designed to quantify gray-scale values of selected regions^{1,2}. Three image attributes were quantified: (i) numerical pixel value (NPV) defined as the mean pixel gray-scale value of the sampled pixels, (ii) pixel heterogeneity (PH) defined as the standard deviation of the mean

gray-scale values of the sampled pixels, and (iii) area under the curve (AUC) defined as the total sum of the gray-scale values within the sampled region.

Briefly, region analyses involve overlaying a computer-generated grid onto a selected area of the 2-dimensional image of a follicle to generate a 3-dimensional framework representing processed pixel intensities. Placing a computer-generated opaque “film” or blanket over the wire framework representing pixel values comprising the ultrasound image yields a 3-dimensional contoured surface. This technique allows discriminatory examination of the surfaces and rapid visual assessment of ultrasonographic attributes associated with follicle health (state of viability or atresia)². Region analyses were used to measure NPV, PH and AUC within a region of the follicle wall. A one-pixel-wide line was used to outline and isolate the largest continuous portion of follicular wall extending from the peripheral antrum to the stroma with the fewest image artifacts. The antrum-wall interface was defined as the last pixel along the line in which a sequential rise in gray-scale occurred⁴⁵.

Line analysis places a line across a specified section of the image of the follicle to produce a graph of the pixel intensities along the line displayed. The graph depicts the amplitude of the echoes located along the line³. Line analysis was used to measure NPV, PH and AUC of a single line across the follicle wall from the antrum-wall interface to the ovarian stroma using two straight three-pixel wide lines. The two linear measurements were taken between the 4 and 9 o'clock positions of the follicle image.

Ovulation was defined as the disappearance of a follicle greater than 15 mm in diameter identified the previous day and confirmed with visualization of a corpus luteum^{12,13,24,25}. Ovulation was used as a reference point (Day 0) to standardize the data for

natural cycle follicles. No follicles ovulated during OC cycles; therefore, OC cycle follicles were standardized to the day of peak estradiol concentration (Day 0) which was also defined as the last day of the growth phase. The day of peak estradiol concentration for each individual was determined by reviewing the estradiol profiles for each woman in the OC trial²².

Ultrasound images were available for each of the seven days leading to ovulation for women in the natural cycle study and approximately every second day for seven days leading to peak estradiol levels for women participating in the OC trial. Data were standardized by aligning data from Day 0 as defined for each group. Image attributes on each of the seven days (Days -1 to -7) leading to ovulation during the natural cycle were compared to the corresponding days (Day -1 to -7) leading to peak estradiol concentrations during the OC cycle. Data were inadequate for statistical comparison of image attributes among the three different OC formulations, therefore data were combined.

Image attributes were compared using repeated measures analysis of variance (PROC MIXED, SAS/STAT, *v8*) for main effects of time and follicle type. Significance was set at $p < 0.05$. Results are expressed as the mean \pm SEM.

3.4 Results

Peak estradiol-17 β concentrations for OC cycle follicles were 170.1 ± 30.4 pg/ml (range, 35.1 – 364.5 pg/ml)²². Mean follicle diameter of OC cycle follicles at peak estradiol concentrations was 20.3 ± 2.0 mm. Mean estradiol concentrations for natural cycle follicles on Day -1 were 190.8 ± 19.6 pg/ml (range 20.0 - 340 pg/ml)¹¹. Mean follicle diameter of natural cycle follicles on Day -1 was 21.1 ± 1.1 mm. Mean growth profiles for

natural and OC cycle follicles are displayed in Figure 3.1. Ultrasonographic images of a natural cycle follicle one day before ovulation and an OC cycle follicle on the day of peak estradiol are shown (Figure 3.2, a and b, respectively).

Numerical pixel values were higher ($p=0.005$) for OC cycle follicles versus natural cycle follicles using region analyses and tended to be higher ($p=0.06$) using line analysis for the seven days prior to Day 0. Oral contraceptive cycle follicles had visually similar NPV for both region and line analyses; however, the values were initially high and then decreased to a nadir at Day -3 (region analysis) or Day -4 (line analysis) after which they increased until Day -1 and subsequently decreased on Day 0 (Figure 3.3 a, b). Numerical pixel values for natural cycle follicles progressively increased from Day -7 (Region analysis; 31.64 ± 4.26 , Line analysis; 41.66 ± 10.49) to Day 0 using line analysis (64.03 ± 6.37 ; $p=0.01$) and tended to increase (43.80 ± 5.30 ; $p=0.08$) with region analysis (Figure 3.3 a, b).

Pixel heterogeneity values were not different between natural and OC cycle follicles for either region or line analyses ($p=0.113$ and $p=0.515$, respectively). No changes were observed over the seven days prior to Day 0.

Area under the curve evaluated using line analyses tended to be higher ($p<0.09$) in OC cycle follicles; however, no differences were observed ($p=0.23$) in follicle type using region analyses. Values for AUC for both natural and OC cycles increased as the interval to Day 0 decreased.

Nadirs in image attributes for the values representing AUC and PH were observed on Day -4 (Figure 3.3 c-f).




Figure 3.1: Growth profiles of natural and OC cycle follicles




Figure 3.2: Ultrasonographic images of a natural cycle and OC cycle follicles. (a) Natural cycle follicle on Day 0, (b) OC cycle follicle on Day 0.




Figure 3.3: Graphical representation of NPV, PH and AUC. Mean \pm SEM (a, b) numerical pixel value (c,d) pixel heterogeneity and (e, f) area under the curve obtained by region analysis (a, c, e) and line analysis (b, d, f) of natural cycle and OC-cycle follicles.

3.5 Discussion

The study of ovarian follicular dynamics in women taking hormonal contraceptives is a relatively new research area with profound clinical relevance. Follicular development in up to 50% of new OC cycles and up to a 25% ovulation rate have been reported¹⁸. Most follicular development observed in OC cycles is initiated during the hormone free interval of the OC cycle²². The objective of this study was to assess the indicators of follicular physiological status in women by comparing ultrasound image attributes of human dominant ovarian follicles leading to ovulation in natural cycles or peak estradiol concentrations in OC cycles. Numerical pixel values representing the relative brightness of the elements comprising the ultrasound image were the only image attributes that differed between natural and OC cycle follicles. Morphologic changes indicative of atresia in animal models are typically represented by high values of NPV^{4,6}. These morphologic changes include but are not limited to: (i) an increase in the number of multivesicular bodies, (ii) lipid droplets and vacuoles within granulosa cells, (iii) dilation of the smooth endoplasmic reticulum and golgi apparatus and (iv) thecal cell hypertrophy/degeneration; which, when taken together, appear to affect the tissue properties enough to change the image attributes^{25,26}. Although NPV were greater in OC cycle follicles, the increased values were not high enough to indicate poor physiologic status as described in studies using animal models^{4,6}. The hypotheses that image attributes of natural and OC cycle would quantitatively differ and that OC cycle follicles would possess image attributes characteristic of atresia were only partially supported.

An interesting common observation in all image attributes of OC follicles that were evaluated fell to a nadir at Day -4, suggesting that an important physiological event occurs

approximately four days before peak estradiol concentrations were attained. The image attributes of the values reflected in NPV and AUC in both natural and OC cycle follicles tended to increase from Day -4 to Day 0. This observation may be interpreted to mean that the follicles in both natural and OC cycles have similar physiologic status and undergo similar changes during the final stages of development. Classically described, ovulatory changes include thickening of the follicle wall, development of lipid inclusion granulosa and theca cells, hypertrophy of theca cells and increased vascularization of the theca layer^{27,28}. Taken together, these developmental changes may be reflected as increases in AUC as the follicle wall thickens and increases in NPV as the follicle wall develops to fulfill its biological functions. Further research is needed to determine the physiologic changes responsible for changes in image attributes.

No OC cycle follicles analyzed in the present study ovulated. However, we suggest that follicles which develop during compliant OC use may differ in ovulatory potential because ovulation has been documented in up to 25% of follicles which develop to ostensibly ovulatory diameter during compliant OC use¹⁸. Differences in OC formulations (i.e. estradiol concentrations and progestin type and associated activity) may have different physiological effects on follicular development and subsequent ovulatory ability, and individual responses to the different estrogen levels and the various progestins used in OC formulations may affect ovulatory ability differently. The authors were unable to test this hypothesis directly in the present study. Variations in image attributes of OC cycle follicles may be due to differences in physiologic status and ovulatory ability. Further research to determine the physiological mechanisms responsible for differences in ovulatory ability of OC cycle follicles needs to be undertaken.”

Studies in domestic animals have demonstrated that ultrasound image attributes of ovarian structures are related to their physiologic function^{3,4,8}. The present study provides rationale for exploring the hypothesis that the same is true for humans. In order to have a complete understanding of the relationship between image attributes and follicular development in humans, we must assess all stages of follicular development throughout the menstrual cycle, prediction of dysfunctional follicular development (i.e., hemorrhagic anovulatory follicles) and the effects of different OC formulations on follicle development. Once the association between image attributes and various conditions of follicular development are determined, follicular status could be assessed with a single ultrasound examination, obviating many ethical constraints that currently prevent progress in human ovarian follicular research.

Ovarian follicles provide a unique endocrine environment fundamental to normal oocyte development and competence. Abnormal follicular development can lead to incompetent oocytes; therefore it follows that image attributes of the follicle wall may be related to oocyte competence. Currently, image attributes only provide us with information about the physiologic status of the follicular wall. Image analyses do not provide information about the health and viability of the oocyte; however, this area is under active investigation⁷.

The primary objective of this research was to evaluate and compare ultrasound image attributes of dominant follicles that develop during natural cycles and OC cycles. We were not able to examine the effect of different OC formulations on image attributes due to constraints imposed by the study design. It is hoped that future research will explore the effects of different OC formulations on the image attributes of dominant

follicles. Research to evaluate physiologic status may well hinge upon follicular response to administration of ovulation inducing doses of recombinant human chorionic gonadotropin in women who develop dominant follicles during OC cycles in concert with development of an animal model to test the biological effects of varying doses of ethinyl estradiol or different progestins on follicle and oocyte status.

In conclusion, similarities in image attributes between natural and OC cycle follicles provides preliminary evidence that ultrasound image attributes of human follicles are associated with physiologic status during the growth phase and that follicles which develop during OC cycles have image attributes similar to those of natural cycle follicles. Only one of the three image attributes studied differed between natural and OC cycle follicles. The changes observed in OC cycle follicles were not clearly indicative of atresia nor were they large enough to preclude preovulatory physiologic status in OC cycle follicles.

3.6 Acknowledgments

The authors would like to thank the research volunteers who participated in the original research utilized in the current study. Appreciation is also expressed to John Deptuch, in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of Saskatchewan for his technical guidance and support. Funding for this project was provided by the Canadian Institutes of Health Research.

3.7 References

1. Pierson R, Adams G. Computer-Assisted Image Analysis, Diagnostic Ultrasonography and Ovulation Induction: Strange Bedfellows. *Theriogenology*. 1995;43:105-112.

2. Singh J, Adams G, Pierson R. Promise of New Imaging Technologies for Assessing Ovarian Function. *Animal Reproduction Science*. 2003;78:371-399.
3. Singh J, Pierson R, Adams G. Ultrasound Image Attributes of the Bovine Corpus Luteum: Endocrine and Functional Correlates. *Journal of Reproduction and Fertility*. 1997;109:35-44.
4. Singh J, Pierson R, Adams G. Ultrasound Image Attributes of Bovine Ovarian Follicles and Endocrine and Functional Correlates. *Journal of Reproduction and Fertility*. 1998;112:19-29.
5. Tom J, Pierson R, Adams G. Quantitative Echotexture Analysis of Bovine Corpora Lutea. *Theriogenology*. 1998;40:1345-1352.
6. Tom J, Pierson R, Adams G. Quantitative Echotexture Analysis of Bovine Ovarian Follicles. *Theriogenology*. 1998;50:339-346.
7. Vassena R, Adams G, Mapletoft R, Pierson R, Singh J. Ultrasound Image Characteristics of Ovarian Follicles in Relation to Oocyte Competence and Follicular Status in Cattle. *Animal Reproduction Science*. 2003;76:25-41.
8. Duggvathi R, Bartlewski P, Pierson R, Rawlings N. Luteogenesis in Cyclic Ewes: Echotextural, Histological, and Functional Correlates. *Biology of Reproduction*. 2003;69:634-639.
9. Adams G, Pierson R. Bovine Model for Study of Ovarian Follicular Dynamics in Humans. *Theriogenology*. 1995;43:113-120.
10. Ginther O, Gastal E, Bergfelt D, Baerwald A, Pierson R. Comparative Study of the Dynamics of Follicular Waves in Mares and Women. *Biology of Reproduction*. 2004;71:1195-1201.
11. Baerwald A, Adams G, Pierson R. Characterization of Ovarian Follicular Wave Dynamics in Women. *Biology of Reproduction*. 2003;69:1023-1031.
12. Baerwald A, Adams G, Pierson R. A New Model for Ovarian Follicular Development during the Human Menstrual Cycle. *Fertility and Sterility*. 2003;80:116-120.
13. Ginther O, Kastelic J, Knopf L. Composition and Characteristics of Follicular Waves during the Bovine Oestrus Cycle. *Animal Reproduction Science*. 1989;20:187-200.
14. Sirois J, Fortune J. Ovarian Follicular Dynamics during the Estrous cycle in Heifers Monitored by Real-time Ultrasonography. *Biology of Reproduction*. 1988;139:308-317.
15. Bister J, Noel B, Perrad B, Mandiki S, Mbayahaga J, Paquay R. Control of Ovarian Follicles Activity in the Ewe. *Domestic Animal Endocrinology*. 1999;17:315-328.

16. Donadeu F, Ginther O. Follicular Waves and Circulating Concentrations of Gonadotropins, Inhibin, and Oestradiol during the Anovulatory Season in Mares. *Reproduction*. 2002;124:875-885.
17. Evans A. Characteristics of Ovarian Follicle Development in Domestic Animals. *Reproduction in Domestic Animals*. 2003;38:240-246.
18. Pierson R, Archer D, Moreau M, Shangold G, Fisher A, Creasy G. Ortho Evra/ Evra versus Oral Contraceptives: Follicular Development and Ovulation in Normal Cycles and After and Intentional Dosing Error. *Fertility and Sterility*. 2003;80:34-32.
19. Hoogland J, Skouby S. Ultrasound Evaluation of Ovarian Activity under Oral Contraceptives. *Contraception*. 1993;47:583-590.
20. Killick S, Eyong E, Elstein M. Ovarian Follicular Development in Oral Contraceptive Cycles. *Fertility and Sterility*. 1987;48(3):409-413.
21. Van Heusden A, Fauser B. Activity of the Pituitary-Ovarian Axis in the Pill-Free Interval during use of Low-Dose Combined Oral Contraceptives. *Contraception*. 1999;59:237-243.
22. Baerwald A, Olatunbosun O, Pierson R. Ovarian Follicular Development is Initiated during the Hormone-free Interval of Oral Contraceptive Use. *Contraception*. 2004;70:371-377.
23. Hanna M, Pierson R. Ultrasonographic Morphology of the Human Preovulatory Follicle Wall. *Ultrasound International*. 1999;5:5-13.
24. Pierson R, Martinuk S, Chizen D, Simpson C. Ultrasonographic Visualization of the Human Ovulation. In: Evers J, Heineman M, eds. *Proceeding of the 7th Renier de Graaf Symposium*. Maastricht, The Netherlands: Elsevier Publishers (Biomedical Division); 1990:73-79.
25. Billig H, Chun S-Y, Eisenhauser K, Hsueh A. Gonadal Cell Apoptosis: Hormone-Regulated Cell Demise. *Human Reproduction Update*. 1996;2:103-117.
26. Hurwitz A, Adashi E. Ovarian Follicular Atresia as an Apoptotic Process. In: Adashi E, Leung P, eds. *The Ovary*. New York: Raven Press; 1993:473-486.
27. Gougeon A. Some Aspects of the Dynamics of Ovarian Follicular Growth in the Human. *Acta Europaea Fertilitatis*. 1989;20:185-192.
28. Gougeon A. Dynamics of Follicular Growth in the Human: A Model from Preliminary results. *Human Reproduction*. 1986;1:81-87.

Chapter 4

OVARIAN FOLLICULAR DYNAMICS DURING AND AFTER CONTINUOUS VERSUS CONVENTIONAL DOSING SCHEMES

RL Birtch, OA Olatunbosun and RA Pierson

Women's Health Imaging Research Laboratory
Department of Obstetrics, Gynecology and Reproductive Sciences
University of Saskatchewan
Room 4519 Royal University Hospital
Saskatoon, Saskatchewan, Canada S7N 0W8

4.1 Abstract

Objective: Characterize ovarian follicular and endometrial development during conventional versus continuous oral contraceptive (OC) dosing regimens to explore follicular development during the hormone free interval and examine follicular development following OC discontinuation.

Methods: Transvaginal ultrasonography and blood sampling were done to ascertain ovarian function.

Results: Fewer follicles >4 mm developed during continuous versus conventional OC use ($p=0.006$). No dominant follicles developed during continuous OC use versus eight dominant follicles (16.1 ± 3.3 mm) during the conventional OC regimen. Two of eight (25%) dominant follicles ovulated. All dominant follicles began development during the HFI. Following discontinuation of OC ovulation took approximately five days longer when compared to natural cycles.

Conclusion: Continuous OC regimens more effectively prevent dominant follicle development and breakthrough ovulation. The slight delay in time to ovulation following OC discontinuation and natural cycles could be attributed to suppression of follicle wave activity.

4.2 Introduction

Since their introduction in the late 1950's, oral contraceptives (OC) have been traditionally prescribed in schemes consisting of 28 day cycles comprised of 21 daily active pills followed by a seven day hormone free interval. The conventional dosing scheme was

developed to mimic the physiologic event of monthly menstruation in nonpregnant women and to provide the illusion of natural menstrual cyclicality. The hormone free interval is reported to have no physiologic benefit, but was initially included to increase user acceptability¹. Oral contraceptive withdrawal symptoms associated with the hormone free interval include: bleeding, pain, breast tenderness, bloating, swelling, migraines, premenstrual syndrome, acne, back pain, dysmenorrhea, anemia, increased use of analgesics and a higher incidence of follicular cyst development^{2,3}.

Twenty-eight years ago, Loudon *et al.* reported that three months of continuous OC use suppressed monthly menstruation, was accepted by women and prevented pregnancy in all study volunteers⁴; yet no changes in OC regimens were introduced⁵. Since then, the efficacy and acceptability of continuous dosing schemes have been examined⁶⁻¹⁷; however, the physiologic effect of continuous OC use on follicular and endometrial development has been examined in only two studies^{5,18}.

Ultrasonography allows assessment of ovarian follicular development at key points, such as during the hormone free interval, and may be combined with hormone assays and image analysis techniques to determine the physiologic status of a follicle¹⁹⁻²¹. The loss of endocrine suppression during the hormone free interval is suggested to provide an environment conducive to follicular development due to increases in endogenous follicle stimulating hormone (FSH)^{2,22}. Dominant follicles have been observed during adherent OC use^{2,23-27} and a proportion of these follicles continue development to pre-ovulatory diameter^{2,23,25,27-29}. It has been shown that over 85% of dominant follicle development is initiated during the hormone free interval² and ovulation of up to 50% of pre-ovulatory sized follicles, depending on the OC formulation, has been reported²⁷.

Ultrasonography has been used to assess the ovarian activity during continuous OC use in only one known study. Schlaff *et al.* compared follicular development during two consecutive 28-day cycles of either: (i) 20 µg ethinyl estradiol (EE)/100 µg levonorgestrel for 21 days followed by a seven day hormone free interval, (ii) 20 µg EE/150 µg desogestrel followed by two days of placebo then 10 µg EE for five days, or (iii) 28 days of 20 µg EE /150 µg desogestrel¹⁸. Weekly ultrasound examinations in combination with endocrine profiles were used to monitor follicular development ≥ 8 mm in diameter. Dosing schemes with a seven day hormone free interval provided the least follicular suppression¹⁸. The proportion of follicles which manifested dominance and the number of “escape” ovulations during the three dosing schemes, were not reported. An intensive ultrasound examination schedule in combination with endocrine profiles has not yet been used to examine ovarian follicular and endometrial development during continuous OC dosing schemes.

Since their introduction, OC have become the most popular reversible contraception chosen by women residing in industrialized nations³⁰. Therefore, it is essential to determine if OC have residual effects on reproductive function following their discontinuation when fertility is desired. Fertility is temporarily reduced for approximately two to three months following discontinuation of conventional OC compared to discontinuation of non-hormonal contraceptives (i.e., intrauterine device, diaphragm, or condom)³¹⁻⁴⁰. Approximately half of all women (39% - 56%) conceive within three months of discontinuing conventionally administered OC^{36,41,42} which is slightly lower than for women using other methods of contraception (e.g., intrauterine device, diaphragm and

“other” contraceptive methods; 54% - 65%)⁴¹. Follicular kinetics following discontinuation of continuous OC dosing schemes apparently have not yet been examined.

The objectives of the present study were to characterize ovarian follicular and endometrial development during and following discontinuation of conventional versus continuous regimens of two different OC formulations using high-resolution transvaginal ultrasonography. We hypothesized that the continuous OC dosing scheme would better suppress ovarian follicular development during the first three cycles of use and that the interval from discontinuation of OC to ovulation would be longer than that from menstruation to ovulation in natural cycles.

4.3 Materials and Methods

The present study was a randomized, single center trial. Informed consent was obtained from all volunteers before performing any study procedures. The study protocol was approved by the University of Saskatchewan Biomedical Ethics Review Board. Thirty-six women between the ages of 18 and 35 (24.4 ± 0.7 years and BMI 24.3 ± 0.9 ; mean \pm SEM) were enrolled. Volunteers were assessed to be healthy women by history and physical examination. Information on body mass index, gravidity, parity, and previous OC use were collected from each woman. Women were excluded if they smoked, were pregnant or lactated within 6 months of enrolling in the study, had used OC in the previous two months, had a history of irregular menstrual cycles, were using contraindicated medications, or were planning surgery during the study period.

Each woman received one of two different monophasic OC formulations in a continuous or conventional dosing scheme for three 28-day cycles. The four study groups were:

- (i) 30 µg EE /150 µg levonogestrel (LNG) (21 days and 7 day HFI; n=8);
- (ii) 30 µg EE/150 µg LNG (28 days; n=9);
- (iii) 35 µg EE/250 µg norgestimate (NGM; 21 days and 7 day HFI; n=8);
- (iv) 35 µg EE /250 µg NGM (28 days; n=11).

Oral contraceptives were initiated on the first day of menses during Cycle 1. The conventional regimen consisted of 21 days of daily active pills followed by a seven day hormone free interval. The continuous regimen consisted of 28 daily active pills with no hormone free interval. Women did not take OC during the fourth and final cycle of the study.

Ovarian follicular and endometrial development were monitored throughout the study with high-resolution transvaginal ultrasonography (ATL HDI 5000, Advanced Technologies Laboratories, Bothwell, WA, USA) as described¹⁹. Approximately 90% of the examinations were performed by one individual (RLB). A second investigator (RAP) performed examinations when the primary ultrasonographer was unavailable. Diameters of all follicles ≥ 2 mm, endometrial thickness and echotextural pattern (i.e., M, A, B, C or D) were recorded during each ultrasound examination^{19,20,43}.

The scanning schedule was designed to capture key physiological processes of follicular and endometrial development and was based on previous studies which characterized follicular wave dynamics during natural and OC cycles^{2,19,20}. Monitoring began on Cycle 1 day 7 and continued every seven days for the first 21 days of Cycle 1.

After Cycle 1 Day 21, an every third day ultrasound scanning schedule was followed until Cycle 3 Day 28. If a follicle grew ≥ 14 mm in diameter during Cycles 1 to 3, daily blood sampling and ultrasound examinations were performed until the physiologic status of the follicle was determined [i.e., ovulation, regression or haemorrhagic anovulatory follicle (HAF)]. Ovulation was defined as the disappearance of a follicle ≥ 15 mm in diameter detected ultrasonographically the previous day followed by the subsequent visualization of a corpus luteum^{44,45}.

Ultrasound examinations for Cycle 4 began on Cycle 4 Day 2 and continued every second day. Daily ultrasound examinations commenced when a follicle reached ≥ 16 mm in diameter and continued until the physiologic fate of the follicle was determined. Blood samples were taken during Cycle 4 when a follicle first reached 18 ± 1 mm and 20 ± 1 mm, and were assayed for estradiol-17 β . A final ultrasound examination and blood sample were completed six to nine days post-ovulation to image the corpus luteum and correlate corpus luteum morphology to serum progesterone levels⁴³.

Data from 18 women who participated in a previous study designed to characterize ovarian follicular wave dynamics during natural cycles were selected randomly and used as historical controls for comparison of Cycle 4 endpoints^{19,20}. Inclusion and exclusion criteria and ultrasound imaging techniques for the natural cycle study were similar to the present study. Cycle 4 Day 1 was defined as the first day of menses during natural cycles or the first day following cessation of OC for follicles developing after discontinuation of OC. The first day following discontinuation of OC was chosen as the comparator for Cycle 4 Day 1 because the high incidence of unscheduled bleeding at the time of OC

discontinuation made it difficult to accurately determine Day 1 of menses in women discontinuing OC.

Volunteers were assigned a diary card for all four cycles to record OC initiation, missed pills, concomitant medication used during each cycle, menstrual patterns and adverse events. Diary cards were reviewed with each volunteer at the conclusion of each cycle. Oral contraceptive use was reviewed during each visit to minimize missed doses.

The growth profiles of all follicles which grew ≥ 4 mm were retrospectively determined as described and graphed for each dosing scheme^{2,19,20,44,45}. The day of selection was defined as the day prior to the manifest of dominance. The day dominance was manifest was defined as the day the largest follicle of the cohort surpassed all other follicles by ≥ 2 mm in diameter. Pre-ovulatory diameter was defined as diameter the day before ovulation was observed.

Repeated measures analyses of variance were used to compare follicle diameter, endometrial thickness and pattern between regimens during Cycles 1 to 3 (PROX MIXED, SAS/STAT software, 2004). Mann-Whitney U tests were used to examine differences in bleeding patterns during Cycles 1 to 3 and to compare Cycle 4 endpoints between continuous and conventional regimens (SPSS Version 12, 2004). Kruskal-Wallis tests were used to compare estradiol-17 β concentrations of follicles 18 ± 1 mm and endpoints during Cycle 4, among OC study groups and the reference cycles (SPSS Version 12, 2004). Significance was set at $p < 0.05$. Results are expressed as the mean \pm SEM.

4.4 Results

Data for all endpoints were analyzed initially for differences between OC formulations within a dosing scheme as well as differences between the continuous and conventional dosing schemes. No statistical differences were observed within dosing schemes; therefore, data were combined.

Cycles 1-3

Overall, fewer follicles developed during continuous OC use than conventional OC use ($p < 0.001$). Follicle number, regardless of size, decreased as time progressed from Cycles 1 to 3 for both continuous and conventional regimens ($p < 0.001$). More follicles > 4 mm in diameter were observed during conventional OC use compared to continuous OC use ($p = 0.006$). The number of follicles > 4 mm during conventional OC use increased during the hormone free interval of Cycles 1 through 3 ($p < 0.001$; Figure 4.1). Representative follicular growth profiles from continuous and conventional regimens are shown (Figure 4.2). Little to no follicular development was observed during continuous dosing schemes whereas follicular development was initiated during the hormone free interval of conventional dosing schemes.

More dominant follicles (≥ 10 mm) developed during conventional OC than continuous OC use (8 versus 0, respectively; $p = 0.01$). All dominant follicles began growing during the hormone free interval. Five dominant follicles developed during the use of 30 μg EE (21)/150 μg LNG (21) and three dominant follicles development during the use of 35 μg EE (21)/250 μg NGM (21). One dominant follicle from each conventionally administered OC ovulated (25%; Figure 4.3). The follicle which ovulated in the 30 μg EE (21)/150 μg LNG (21) group had no detectable estradiol output for the No




Figure 4.1: Follicle numbers for follicles ≤ 4 mm, and > 4 mm in diameter during continuous and conventional OC use Cycles 1 to 3.




Figure 4.2: Representative follicular growth profiles during (a) continuous and (b) conventional OC use.




Figure 4.3: Growth profiles and serum estradiol concentrations of follicles that ovulated during adherent conventional OC use.

seven days prior to its ovulation. A corpus luteum was visualized ultrasonographically and the serum progesterone level observed on Day 6 post-ovulation was 0.79 ng/ml. The follicle which ovulated in the 35 µg EE (21)/250 µg NGM (21) group exhibited clinically normal serum estradiol concentrations for the pre-ovulatory period. The progesterone level observed on Day 8 post-ovulation was 3.5 ng/ml.

Endometrial thickness for the continuous OC groups remained stable from Cycles 1 to 3 (Figure 4.4). Decreases in endometrial thickness attributed to menstrual bleeding were observed during the hormone free interval of the conventional OC groups (Figure 4.4). No differences were observed between continuous and conventional dosing schemes for endometrial thickness ($p=0.57$) or endometrial pattern ($p=0.71$).

Women using continuous OC experienced more total days of flow and spotting ($p<0.05$) than women using conventional OC. No differences were observed between continuous and conventional regimens during Cycle 1 in the number of days of spotting, light flow or heavy flow ($p>0.46$). Women using continuous OC experienced more days of spotting in Cycle 2 and 3 ($p<0.006$), more days light flow in Cycle 2 ($p=0.03$) and tended to have more days of light flow in Cycle 3 ($p=0.09$). Women using continuous OC had fewer days of heavy flow in Cycle 2 ($p=0.01$) and tended to have fewer days of heavy flow in Cycle 3 ($p=0.08$). Differences were not observed in the number of days of spotting, light flow or heavy flow between the two OC formulations within a dosing scheme ($p=0.10$).

Cycle Four

One woman was excluded from analysis of Cycle 4 endpoints because she did not experience menses, or an ovulatory event, by Cycle 4 Day 63 (12 standard deviations from




Figure 4.4: Endometrial thickness during Cycles 1 to 3 during continuous and conventional OC use.

the mean). Therefore, 35 women were included in the analysis of Cycle 4 endpoints following discontinuation of conventional OC (n=15) and continuous OC (n=20).

Cycle 4 endpoints are shown in Table 4.1. Selection took approximately three days longer ($p < 0.001$) and dominance was manifest approximately two days later ($p < 0.001$) following discontinuation of OC than for natural cycles. Irrespective of their groups it took approximately five days longer for follicles to ovulate once OC were discontinued compared to natural cycle follicles ($p < 0.001$).

In the conventional dosing group, 14 of the 15 women (93%) grew pre-ovulatory sized follicles (Table 4.1). Twelve of 14 follicles (86%) ovulated and the remaining two follicles (14%) formed a HAF. The woman who did not develop a pre-ovulatory follicle during Cycle 4 had developed a dominant follicle during the hormone free interval which reached pre-ovulatory diameter mid-cycle, persisted and regressed. In the continuous dosing group, all women developed a pre-ovulatory sized follicle (100%; Table 4.1). Thirteen of the 20 women (65%) developed a single pre-ovulatory follicle which ovulated and four women (20%) grew two pre-ovulatory sized follicles. Three of the four women with two dominant follicles had one follicle that ovulated and one follicle that regressed; the fourth woman formed a HAF and the remaining follicle regressed. One woman (5%) grew three pre-ovulatory sized follicles during Cycle 4; two of which ovulated and one regressed. The remaining two women developed a HAF.

Serum estradiol concentrations at a follicle diameter of 18 ± 1 mm were analyzed from 15 of the 17 women (88%) following continuous OC, 11 of the 12 women (92%) following conventional OC and 14 of the 18 women (78%) from natural cycles. Two women in the continuous OC group and one woman in the conventional OC group were

Table 4.1: Selection of the dominant and subordinate follicles (mean \pm SEM), day to ovulation (mean \pm SEM), estradiol concentrations, and follicle growth rates in natural cycles and in women following discontinuation of conventional and continuous OC regimens.

	Continuous OC	Conventional OC	Natural Cycles
Day of selection	13.1 \pm 0.7 ^a	13.0 \pm 1.1 ^a	8.6 \pm 0.5 ^b
Day dominance was manifest	12.1 \pm 0.3 ^a	12.7 \pm 0.6 ^a	9.6 \pm 0.5 ^b
Days to ovulation from Day 1 menses (natural) or discontinuation of OC	20.3 \pm 0.7 ^a	20.5 \pm 1.0 ^a	15.1 \pm 0.5 ^b
Days to ovulation from dominance	7.1 \pm 0.5 ^a	7.5 \pm 0.5 ^a	6.5 \pm 0.3 ^a
Dominant follicle diameter (mm)	14.2 \pm 0.7 ^a	14.0 \pm 1.1 ^a	12.3 \pm 0.4 ^a
Ovulatory diameter (mm)	21.4 \pm 0.8 ^a	21.2 \pm 0.8 ^a	21.8 \pm 0.7 ^a
# females developing pre-ovulatory (>14 mm) sized follicles (%)	20/20 (100) ^a	14/15 (93) ^a	15/15 (100) ^a
Follicle Growth Rate (mm/day)	1.1 ^a	1.1 ^a	1.4 ^b
Estradiol concentration* (pg/ml)	172.5 \pm 22.0 ^a	178.3 \pm 23.2 ^a	105.6 \pm 2.7 ^b
Progesterone concentrations 6-9 days post ovulation (ng/ml)	12.3 \pm 12.5 ^a	16.8 \pm 19.0 ^a	--

*Serum estradiol concentrations were measured when follicles were 18 \pm 1 mm in OC cycles and 18 \pm 2 mm in natural cycles

^{a,b} Within rows values with no common superscripts are different
Significance indicated at p<0.05

unable to provide a blood samples when the dominant follicle was 18 ± 1 mm and a stratified blood sampling schedule during the natural cycle study prevented the determination of serum estradiol concentrations at the comparable follicular diameter for four preovulatory follicles. Serum estradiol concentrations at 18 mm are shown in Table 4.1. No differences in estradiol concentrations were observed between OC formulations within a dosing scheme ($p>0.26$), or following discontinuation of continuous versus conventional dosing schemes ($p=0.74$); however, women discontinuing OC in the present study exhibited higher ($p<0.03$) estradiol concentrations than observed in the natural cycle reference cycles.

Blood samples taken six to nine days following ovulation were obtained from 15 of the 17 women (88%) in the continuous OC group and ten of the 12 women (83%) in the conventional OC group. Two women from each OC dosing scheme were unable to provide a blood sample. Serum progesterone levels are listed in Table 4.1. In the continuous OC group, nine of 15 women (60%) had clinically normal progesterone levels (i.e., 6-24 ng/ml); five of the 15 women (33%) had progesterone levels <6 ng/ml and the remaining woman (7%) had progesterone levels >24 ng/ml. In the conventional OC group, six of the ten women (60%) had clinically normal levels of progesterone; two (20%) had progesterone levels <6 ng/ml and two (20%) had progesterone levels >24 ng/ml. Progesterone levels did not differ between OC formulations within a dosing scheme ($p>0.60$) or between dosing schemes ($p=0.22$).

4.5 Discussion

Our hypothesis that a continuous OC regimen would suppress follicular development more effectively than conventional OC dosing was supported. The number

of follicles ≤ 4 mm in diameter did not differ between dosing schemes; however, continuous OC dosing suppressed the development of follicles >4 mm and did not permit dominant follicle development. The number of follicles, regardless of size, decreased slightly as the duration of OC use increased suggesting that the suppressive effects of OC on follicular populations increases with prolonged use. We suggest that a decrease in the number of developing follicles may be attributed to recruitment of fewer follicles into the growing pool due to increased hypothalamo-pituitary-ovarian axis suppression with each subsequent cycle of OC administration. Further research needs to examine the idea that increased duration of OC use is correlated to progressively increased suppression of follicular development, particularly during the hormone free interval.

All dominant follicles that developed during conventional OC use initiated their growth during the hormone free interval, consistent with a previous report that 86% of dominant follicles initiated their development during the hormone free interval². A new follicular wave is initiated by a nadir in circulating FSH levels followed by two to three days of increase¹⁹. Fauser *et al.* have demonstrated that the lowest FSH concentrations of the HFI are from Day 1 to 3 and are followed by five days of increasing FSH levels²². Thus, we suggest that follicular development in OC cycles is manifest by this mechanism. Initiation of the next pill strip following the hormone free interval results in decreased FSH concentrations regardless of the presence of a dominant follicle⁴⁶. However, it is clear that the decreased dependence of the dominant follicle on gonadotropins allows some follicles to continue developing to preovulatory diameter and to ovulate if the proper hormonal cues are present, while subordinate follicles undergo atresia^{2,27,47-53}. Conventional dosing schemes appeared to provide cyclic increases in FSH during each hormone free interval resulting in follicular growth >4 mm, whereas continuous dosing schemes maintained

suppression of gonadotropins to basal levels resulting in suppression of most follicular growth >4 mm.

It was interesting that the number of follicles ≤ 4 mm in diameter did not differ between continuous and conventional OC regimens. Follicles ≤ 4 mm require basal levels of gonadotropins to sustain growth but are not yet fully responsive to cyclic changes in gonadotropins⁵⁴. The total number of follicles ≤ 4 mm in diameter did not increase during the hormone free interval of conventional OC use²². We suggest that OC do not affect the basal level of gonadotropins required to allow follicles into the recruitable pool, but do suppress endogenous cyclic increases in gonadotropins. An environment with basal levels of gonadotropins would permit follicular development ≤ 4 mm in diameter but would suppress follicular development >4 mm, consistent with our observations.

Our hypothesis that follicles would take longer to ovulate following discontinuation of OC than following initiation of menses during natural cycles was supported. It took longer for selection, dominance to become manifest and ovulation, irrespective of the OC dosing scheme. It has been well established that follicles which develop during natural cycles are recruited and begin to grow during the late luteal phase⁵⁴. The longer interval to selection, dominance and ovulation in follicles following cessation of OC may be due to follicular recruitment occurring before the first day of menses during natural cycles and after the comparable time point in follicles following discontinuation of OC. It is also possible that OC synchronize follicular wave development such that follicles are at an earlier stage of development and take longer to attain selection, dominance and ovulation than natural cycle follicles. The difference between the times of selection, dominance and ovulation was only a few days and could not explain the two to three month lag in fertility

following discontinuation of OC. We interpreted these data to mean that other mechanisms are responsible for the delay in fertility.

The serum estradiol levels were higher in women in the OC groups compared to women in natural cycles. However, the estradiol concentration from follicles developing during natural cycles and following OC cessation were both well within the clinically normal range, suggesting that follicles from both groups were physiologically similar. Further research is needed to determine if the elevated level of estrogen following discontinuation of OC negatively affects follicular development and oocyte competence. In a previous study, follicles which developed during natural and OC cycles had similar ultrasound image attributes which was interpreted to mean that follicles which developed during different hormonal conditions had similar physiologic function²¹. Further support for this hypothesis is by the observations of follicle development and ovulation in women during compliant use of several types of currently prescribed OC²⁷. Similarities in the size of dominant follicles at selection, dominance and ovulation, as well as similarities in the interval from the manifestation of dominance to ovulation between natural cycle follicles and follicles which develop following discontinuation of OC further supports the hypothesis of similar physiologic function between these follicle types.

Clinically abnormal progesterone concentrations were observed following ovulation in approximately 40% of women following discontinuation of OC. Thus, reduced fertility following discontinuation of OC may be hypothesized to be due to luteal dysfunction following ovulation. This is only one possible explanation for the delay in fertility and further investigations are required before a cause and effect relationship could be established.

Factors other than anovulation in the cycle following OC cessation are likely responsible for the two to three month lag in the return to fertility. It is possible that previous OC use has negative residual effects on oocyte growth and development resulting in reduced oocyte competence. Novel image analysis techniques are currently under development to determine the physiologic status of a follicle and oocyte competence with a single ultrasound examination^{21,55-57}. For example, in a recent study, ultrasound image attributes of subordinate follicles in cattle were correlated to oocyte competence⁵⁷. Although image analysis is in an early stage of development, it demonstrates promise as a clinical tool to evaluate oocyte competence and physiologic status of a follicle in a non-invasive manner⁵⁶.

We expected to observe marked differences in endometrial thickness and endometrial pattern between continuous and conventional dosing schemes, particularly during the hormone free interval. However, both dosing schemes appeared to suppress endometrial development similarly. Each cycle of conventional dosing was typically associated with four to seven days of menstrual bleeding. We propose that similar endometrial patterns between dosing schemes was due to the high incidence of unscheduled bleeding observed during continuous dosing schemes. It has been suggested that cycle control during continuous regimens increases with prolonged use^{5,8,17}; further research is needed to determine if increasing the duration of continuous dosing schemes would result in markedly different patterns of endometrial development and unscheduled bleeding episodes with these OC formulations.

In conclusion, continuous dosing schemes with 30 and 35 µg EE OC completely suppressed dominant follicle development better than the commonly used conventional

dosing scheme. All follicular development was initiated during the hormone free interval. Continuous OC dosing did not allow development of dominant follicles, thus reducing or eliminating the possibility of break through ovulation. We suggest that follicles which develop following discontinuation of OC have similar physiologic status to natural cycle follicles due to similarities in follicular diameter and the interval from dominance to ovulation. The brief delay in ovulation following discontinuation of OC can not explain lower conception rates following cessation of OC.

4.6 References

1. Wiegratz I, Kuhl H. Long-cycle Treatment with Oral Contraceptives. *Drugs*. 2004;64:2447-2462.
2. Baerwald A, Olatunbosun O, Pierson R. Ovarian Follicular Development is Initiated during the Hormone-Free Interval of Oral Contraceptive Use. *Contraception*. 2004;70:371-377.
3. Sulak P, Scow R, Preece C, Riggs M, Kuehl T. Hormone Withdrawal Symptoms in Oral Contraceptive Users. *Obstetrics and Gynecology*. 2000;95:261-266.
4. Loudon N, Foxwell M, Potts D, Guild A, Short R. Acceptability of an Oral Contraceptive that Reduces the Frequency of Menstruation: the Tri-Cyclic Pill Regimen. *British Medical Journal*. 1977;2:487-490.
5. Miller L, Hughes H. Continuous Combination Oral Contraceptive Pills to Eliminate Withdrawal Bleeding: A Randomized Trial. *Obstetrics and Gynecology*. 2003;101:653-661.
6. de Voogd W. Postponement of Withdrawal Bleeding with a Monophasic Oral Contraceptive Containing Desogestrel and Ethinyl estradiol. *Contraception*. 1991;44(2):107-112.
7. Sillem M, Schneidereit R, Heithecker R, Mueck A. Use of an Oral Contraceptive Containing drospirenon in an Extended Regimen. *The European Journal of Contraception and Reproductive Health Care*. 2003;8:162-169.
8. Cachrimanidou A, Hellber D, Nilsson S, Waldenstrom U, Olsson S, Sikstrom B. Long-interval Treatment Regimen with a Desogestrel-containing Oral Contraceptive. *Contraception*. 1993;48:205-216.

9. Kornaat H, Geerdink M, Klitsle J. The Acceptance of a 7-week Cycle with a Modern Low-dose Oral Contraceptive (Minulet). *Contraception*. 1992;45:119-127.
10. Hamerlynck J, Vollebregt J, Doornebos C, Mutendam P. Postponement of Withdrawal Bleeding in Women using Low-dose Combined Oral Contraceptives. *Contraception*. 1987;35:199-205.
11. Kovacs G, Rusden J, Evans A. A Trimonthly Regimen for Oral Contraceptives. *The British Journal of Family Planning*. 1994;19:274-275.
12. Sulak P, Carl J, Gopalakrishnan I, Coffee A, Kuehl T. Outcomes of Extended Oral Contraceptive Regimens with a Shortened Hormone-free Interval to Manage Breakthrough Bleeding. *Contraception*. 2004;70:281-287.
13. Sulak P, Cressman B, Waldrop E, Holleman S, Kuehl T. Extending the Duration of Active Oral Contraceptive Pills to Manage Hormone Withdrawal Symptoms. *Obstetrics and Gynecology*. 1997;89:179-183.
14. Sulak P, Kuehl T, Oritz M, Shull B. Acceptance of Altering the Standard 21-day/7-day Oral Contraceptive Regimen to Delay Menses and Reduce Hormone Withdrawal Symptoms. *American Journal of Obstetrics and Gynecology*. 2002;186:1142-1149.
15. Wiegatz I, Hommel H, Zimmermann T, Kuhl H. Attitude of German Women and Gynecologists Towards Long-cycle Treatment with Oral Contraceptives. *Contraception*. 2004;69:37-42.
16. Kwiecien M, Edelman A, Nichols M, Jensen J. Bleeding Patterns and Patient Acceptability of Standard or Continuous Dosing Regimens of a Low-dose Oral Contraceptive: A Randomized Trial. *Contraception*. 2003;67:9-13.
17. Anderson F, Hait H, Group TSS. A Multi-center, Randomized Study of an Extended Cycle Oral Contraceptive. *Contraception*. 2003;68:89-96.
18. Schlaff W, Lynch A, Hughes H, Cedars M, Smith D. Manipulation of the Pill-free Interval in Oral Contraceptive Pill Users: The Effect on Follicular Suppression. *American Journal of Obstetrics and Gynecology*. 2004;190(4):943-951.
19. Baerwald A, Adams G, Pierson R. Characteristics of Ovarian Follicular Wave Dynamics in Women. *Biology of Reproduction*. 2003;69:1023-1031.
20. Baerwald A, Adams G, Pierson R. A New Model for Ovarian Follicular Development during the Human Menstrual Cycle. *Fertility and Sterility*. 2003;80:116-122.
21. Birtch R, Olatunbosun O, Baerwald A, Pierson R. Ultrasound Image Attributes of Human Ovarian Dominant Follicles during Natural and Oral Contraceptive Cycles. *Reproductive biology and endocrinology*. 2005;3(12).

22. Fauser B, Van Heusden A. Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences. *Endocrine Reviews*. 1997;18:71-106.
23. Hoogland J, Skouby S. Ultrasound Evaluation of Ovarian Activity under Oral Contraceptives. *Contraception*. 1993;47:583-590.
24. Elomaa K, Rollan R, Brosens I, Moorrees M, Deprest JTJ, Lahteenmaki P. Omitting the First Oral Contraceptive Pills of the Cycle Does Not Automatically Lead to Ovulation. *American Journal of Obstetrics and Gynecology*. 1998;179:41-46.
25. Killick S, Eyong E, Elstein M. Ovarian Follicular Development in Oral Contraceptive Cycles. *Fertility and Sterility*. 1987;48(3):409-413.
26. Van Heusden A, Fauser B. Activity of the Pituitary-Ovarian Axis in the Pill-Free Interval during use of Low-Dose Combined Oral Contraceptives. *Contraception*. 1999;59:237-243.
27. Pierson R, Archer D, Moreau M, Shangold G, Fisher A, Creasy G. Ortho Evra/ Evra versus Oral Contraceptives: Follicular Development and Ovulation in Normal Cycles and After and Intentional Dosing Error. *Fertility and Sterility*. 2003;80:34-42.
28. Killick S. Ovarian Follicles During Oral Contraceptive Cycles: Their Potential for Ovulation. *Fertility and Sterility*. 1989;52:580-582.
29. Spona J, Elstein M, Feichtinger W, Sullivan H, Ludicke F, Muller U, Dusterberg B. Shorter Pill-free Interval in Combined Oral Contraceptives Decreases Follicular Development. *Contraception*. 1996;54:71-77.
30. Dickey R. *Managing Contraceptive Pill Patients*. 8th edition. Durant: EMIS, Inc. Medical Publishers; 1997.
31. Bracken M, Hellenbrand K, Holford T. Conception Delay after Oral Contraceptive Use: The Effect of Estrogen Dose. *Fertility and Sterility*. 1990;53(1):21-27.
32. Chasan-Taber L, Willett W, Stampfer M, Spiegelman D, Rosner DA, Hunter DJ, Colditz GA, Manson JE. Oral Contraceptives and Ovulatory Causes of Delayed Fertility. *American Journal of Epidemiology*. 1997;146(3):258-265.
33. Fraser I, Weisberg E. Fertility Following Discontinuation of Different Methods of Fertility Control. *Contraception*. 1982;26(4):389-415.
34. Vessey M, Wright N, McPherson K, Wiggins P. Fertility after Stopping Different Methods of Contraception. *British Medical Journal*. 1978;1:265-267.
35. Wolfers D. The Probability of Conception after Discontinuance of Oral Contraception: A Note on "Oral Contraception, Coital Frequency, and the Time

- Required to Conceive," by Westoff, Bumpass, and Ryder. *Social Biology*. 1970;17(1):57-59.
36. Pardthaisong T, Gray R. The Return of Fertility Following Discontinuation of Oral Contraceptive in Thailand. *Fertility and Sterility*. 1981;35(5):532-534.
 37. Linn S, Schoenbaum S, Monson R, Rosner B, Ryan K. Delay in Conception for Former 'Pill' Users. *Journal of the American Medical Association*. 1982;247(5):629-632.
 38. Janerich D, Lawrence C, Jacobson H. Fertility Patterns after Discontinuation of Use of Oral Contraceptives. *The Lancet*. 1976;1(7968):1051-1053.
 39. Harlap S, Baras M. Conception-Waits in Fertile Women after Stopping Oral Contraceptives. *International Journal of Fertility*. 1984;29(2):73-80.
 40. Spira A. [Fertility Following Hormonal Contraception (author's translation)]. *Contraception Fertility and Sex (Paris)*. 1983;11(7-8):903-907.
 41. Weisberg E. Fertility after Discontinuation of Oral Contraceptives. *Clinical Reproduction and Fertility*. 1982;1:261-272.
 42. Hassan J, Kulenthran A, Thum Y. The Return of Fertility after Discontinuation of Oral Contraception in Malaysian Women. *Medical Journal of Malaysia*. 1994;49(4):364-368.
 43. Baerwald A, Adams G, Pierson R. Form and Function of the Corpus Luteum during the Human Menstrual Cycle. *Journal of Ultrasound in Obstetrics and Gynecology*. 2005;*In Press*.
 44. Pierson R, Chizen D. Transvaginal Ultrasonographic Assessment of Normal and Aberrant Ovulation. In: Jaffe R, Pierson R, Abramowicz J, eds. *Imaging in infertility and reproductive endocrinology*. Philadelphia: J.B. Lippincott Company; 1994:129-142.
 45. Hanna M, Chizen D, Pierson R. Characteristics of Follicular Evacuation during Human Ovulation. *Ultrasound Obstetrics and Gynecology*. 1994;4:488-493.
 46. Van Heusden A, Fauser B. Residual Ovarian Activity during Oral Steroid Contraception. *Human Reproduction Update*. 2002;8:345-358.
 47. Coney P, Del Conte A. The Effects of Ovarian Activity of a Monophasic Oral Contraceptive with 100 microgram levonorgestrel and 20 microgram ethinyl estradiol. *American Journal of Obstetrics and Gynecology*. 1999;181:53-58.
 48. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M. Ovulation and Follicular Development Associated with Three Low-Dose Oral Contraceptives: A Randomized Controlled Trial. *Obstetrics and Gynecology*. 1994;83:29-34.

49. Killick S, Fitzgerald C, Davis A. Ovarian Activity in Women Taking an Oral Contraceptive containing 20 micrograms Ethinyl Estradiol and 150 micrograms Desogestrel: Effects of Low Estrogen Doses during the Hormone-free Interval. *American Journal of Obstetrics and Gynecology*. 1998;179:S18-24.
50. Schwartz J, Creinin M, Pymar H, Reid L. Predicting Risk of Ovulation in New Start Oral Contraceptive Users. *American College of Obstetrician and Gynecologists*. 2002;99:177-182.
51. van der Does J, Exalto N, Dieben T, Bennink H. Ovarian Activity Suppression by Two Different Low-Dose Triphasic Oral Contraceptives. *Contraception*. 1995;52:357-361.
52. Young R, Snabes M, Frank M, Reilly M. A Randomized, Double-Blind, Placebo-Controlled Comparison of the Impact of Low-Dose and Triphasic Oral Contraceptives on Follicular Development. *American Journal of Obstetrics and Gynecology*. 1992;167:678-682.
53. Zeleznik A. Follicle Selection in Primates: "Many are Called but Few are Chosen". *Biology of Reproduction*. 2001;65:655-659.
54. Gougeon A. Regulation of Ovarian Follicular Development in Primates: Facts and Hypotheses. *Endocrine Reviews*. 1996;17:121-155.
55. Pierson R, Adams G. Computer-assisted Image Analysis, Diagnostic Ultrasonography and Ovulation Induction: Strange Bedfellows. *Theriogenology*. 1995;43:105-112.
56. Singh J, Adams G, Pierson R. Promise of New Imaging Technologies for Assessing Ovarian Function. *Animal Reproduction Science*. 2003;78:371-399.
57. Vassena R, Adams G, Mapletoft R, Pierson R, Singh J. Ultrasound Image Characteristics of Ovarian Follicles in Relation to Oocyte Competence and Follicular Status in Cattle. *Animal Reproduction Science*. 2003;76:25-41.

Chapter 5

GENERAL DISCUSSION

Men and women have been preventing pregnancy and controlling their fertility through the use of many different forms of contraception for thousands of years²¹⁰. By the late 1800's, many types of contraceptives were available in Canada, including but not limited to, abstinence, vaginal sponges, withdrawal, condoms, diaphragms, douching, prolonged lactation, the rhythm method, sterilization and abortion²¹⁰. These methods of contraception have improved greatly since their introduction, and are still used currently by many Canadians.

It was not until the early 1960's that oral contraceptives (OC) were introduced to the Canadian market; however, birth control was not legalized until 1969²¹⁰. Secular and religious stigmas against contraception were highly prevalent during the late nineteenth and early twentieth century. Many of these stigmas presently continue to influence the large-scale dissemination of information about different contraceptive choices such that the majority of Canadian women are unaware of most of their contraceptive options²¹¹. Canadians are interested in learning about new contraceptive choices; however, stigmas and personal embarrassment associated with sexual relations and contraception prevent many individuals from becoming informed.

The demand to manipulate human ovarian follicular development is on the rise. The number of women desiring contraception to inhibit pregnancy is increasing²¹². Ironically, the number of women requiring artificial reproductive technologies is also increasing²¹³. A better understanding of the physiologic mechanisms responsible for the growth, development and ovulation of ovarian follicles will allow us to understand how different hormones, factors and proteins can alter reproductive function, and this information would allow us to develop more acceptable, efficacious contraceptive techniques or new artificial reproductive technologies to improve pregnancy rates during infertility treatment.

The studies contained in this thesis evaluated and compared the ultrasound image attributes of dominant ovarian follicles during natural and OC cycles; as well as, characterized changes in follicular and uterine development during the use and following discontinuation of two different OC dosing schemes. The findings of these studies provide the rationale for further examination and development of image analysis techniques as a clinical diagnostic tool and the development of more efficacious OC dosing schemes.

5.1 Follicular Development during Continuous and Conventional Oral Contraceptive Use

Administration of exogenous, synthetic estrogen in combination with different progestins causes atresia of follicles during the initial cycle of use, followed by suppression of follicular growth in subsequent cycles. An OC primary mechanism of action is to prevent follicular growth and ovulation in 99.9% of users when taken exactly as directed¹⁰⁹. However, “real-life” failure rates are reported to be up to 80 times higher (3-8%) than rates

reported for perfect use^{109,214-216}. The decrease in OC efficacy during “real-life” use is suggested to be due to many factors including: user non-adherence, not reading and/or misunderstanding product information, administration of OC with concomitant medication, gastrointestinal upset, high body mass index and inter/individual and intra-individual metabolism of the exogenous hormones.

User non-adherence accounts for approximately 20% of unintended pregnancies in the United States²¹⁷. Poor OC adherence includes missing doses, taking doses in the improper order, sporadic use, not using back up contraception when indicated and initiating a new package early or late²¹⁷. Up to 74% of women report missing ≥ 1 OC per 28-day cycle^{175,176,178}. User non-adherence contributes to increased OC failure rates, bleeding irregularities and a three-fold increase in the risk of unintended pregnancy^{178,214,215}. Furthermore, problems caused by non-adherence typically result in many women discontinuing OC and failing to use a substitute contraceptive, or adopting a less effective method¹⁷⁷. Non-adherence is particularly prevalent during the transition from one pill package to the next, an occurrence that takes place 13 times per year with conventional dosing schemes²¹⁸. The use of continuous dosing decreases the number of transitions per year which may lead to increased user adherence and a decreased risk of pill failure. We suggest that an OC ought to be developed that has the ability to accommodate “real-life” use, while maintaining an efficacy rate of 99.9%.

Follicular development during OC use is largely attributed to uninhibited gonadotropin suppression during the hormone free interval, such that by the end of the hormone free interval levels of FSH increase above the threshold for gonadotropin dependent follicular growth¹⁶⁰. Reinitiation of the next pill strip results in decreases in FSH

and subsequent atresia of most follicles; however, if a dominant follicle is present it may continue development to pre-ovulatory diameter and ovulation^{133,135,139,142,144,146,148,158}, if the proper hormonal cues are present²¹⁹. We used high-resolution transvaginal ultrasonography to serially track and compare ovarian follicular development during the administration of continuous versus conventional dosing schemes to determine if replacing the hormone free interval with active dosing pills would better suppress follicular development than conventional dosing schemes, and thus provide a more efficacious OC (Chapter 4). Continuous OC dosing schemes suppressed follicular development >4 mm better than conventional dosing schemes and completely prevented dominance from being manifest (Chapter 4). Conversely, conventional dosing schemes allowed eight follicles to manifest dominance and two dominant follicles to subsequently ovulate (Chapter 4). All dominant follicles initiated growth during the hormone free interval (Chapter 4). We interpreted this data to mean, that continuous dosing schemes provide a more effective contraceptive than conventional dosing, by completely suppressing follicles from attaining dominance and ultimately preventing ovulation and subsequent OC failure.

Follicles $\leq 4\text{mm}$ are not fully responsive to gonadotropins^{9,57}. Therefore, increased levels of gonadotropins associated with missed doses would likely have little effect on follicles $\leq 4\text{ mm}$. We observed very little follicular development >4 mm during continuous OC use compared to conventional use (Chapter 4). We interpreted this data to mean that more consecutive doses of OC could be missed before follicular growth was initiated during continuous OC dosing schemes compared to conventional dosing schemes. Further research needs to examine the number of consecutive doses that can be omitted during continuous dosing schemes before follicular development >10 mm is observed.

A new model of follicular dynamics in women suggests that women develop two to three follicular waves of follicles ≥ 4 mm during each menstrual cycle^{56,149}. Waves of small antral (1-3 mm) follicles in bovine ovaries have been observed in association with circulating increases in endogenous FSH²²⁰. Furthermore, the dominant follicle can be identified retrospectively at 1 mm in diameter in bovine ovaries²²⁰. Since cattle are commonly used as human models it follows that follicular waves of small antral follicles may occur in humans⁹⁸. Currently, we do not know if OC suppress waves of follicular development. Further studies should examine if OC suppress follicular waves, particularly waves of small antral follicles, as these follicles are generally not fully responsive to cyclic increases in gonadotropins. Residual effects of previous OC use on follicular wave development should also be examined. A further understanding of wave dynamics in humans may aid in the development of more efficacious OC that could target specific stages of follicular growth to prevent ovulation. A contraceptive of this nature would decrease a women's exposure to exogenous hormones by only administering hormones at key physiological time points, instead of throughout the entire ovarian cycle.

We have documented that ultrasound image attributes of dominant follicles during natural and OC cycles are similar during the mid-to-late growth phase (Chapter 3). Area under the curve, pixel heterogeneity and numerical pixel value were evaluated in the study. The only difference observed between the three image attributes was increased values of numerical pixel value for OC cycle follicles versus natural cycle follicles. Although numerical pixel value were greater in OC cycle follicles, the increased values were not high enough to indicate poor physiologic status as described in studies using animal models^{101,221,222}. Furthermore, follicles which develop to pre-ovulatory diameter during adherent OC use have markedly similar growth profiles and serum estradiol-17 β levels to

natural cycle follicles at similar stages of development^{133,156}. Taken together, we interpret this data to mean that follicles that develop under the suppressive effects of OC have similar physiologic function and ovulatory capacity as natural cycle follicles at similar stages of development. Currently, we do not know why some pre-ovulatory sized follicles ovulate and others do not during OC use. Further research should examine if luteinizing hormone secretion differs between women who do, and do not ovulate, during OC use. Examining an association between luteinizing hormone secretion and ovulation would enhance our understanding of the physiologic mechanisms of action associated with OC use and aid in the development of an OC that could prevent ovulation in the entire population of women using OC.

The health and viability of oocytes which develop during OC use has not yet been examined. However, we suggest that oocytes which develop and ovulate during OC use have similar health and viability to natural cycle oocytes because pregnancies have been reported during OC use^{223,224}. Additional research should examine the health and viability of oocytes that develop during compliant OC use. An appropriate animal model would need to be developed to examine the effects of exogenous synthetic estrogen and progestin on oocyte competence due to ethical constraints preventing research of this nature on human oocytes. Results of a recent study performed in cattle, were interpreted to mean that image attributes of the follicle wall are correlated to oocyte competence²²². Further development of image analysis techniques could lead to a clinical tool that is capable of determining oocyte health and viability in a non-invasive manner during stimulation cycles for infertility treatment. A clinical tool of this nature would have the potential to decrease the costs associated with infertility treatment and increase pregnancy rates by ensuring only competent oocytes were utilized during clinical treatment.

5.2 Menstrual Regulation during Continuous and Conventional Oral Contraceptive Use

Menstruation is simply a by-product of ovarian function. OC were initially developed as menstrual regulators, and as such, had to induce menstruation once every 28-day cycle. Currently, most women believe that monthly menstruation is necessary to maintain reproductive health and that menstruation during OC use is due to the same physiologic mechanisms that induce menstruation during natural, spontaneous cycles^{123,125}. Furthermore, women falsely believe that monthly menstruation during OC use confirms they are not pregnant and remain fertile^{123,125}.

Clinicians, researchers and anthropologists would argue that the current state of monthly menstruation is unnecessary to maintain reproductive health^{132,185}. For example, primitive women menstruated 66% less than the typical modern-day woman. The increase in menstrual frequency in modern women is suggested to be due to evolutionary progression resulting in an earlier onset of menarche, later age of first birth, fewer pregnancies, shorter periods of lactation and a later onset of menopause compared to primitive women¹¹⁹. The increased frequency of menstruation in modern day women and the associated large fluctuations in hormones, is thought to be associated with the development of many illnesses, including menstrual morbidity, endometriosis, anemia, uterine fibroids and cancers of the reproductive organs¹⁸⁴. It is suggested that the constant level of exogenous hormones provided by continuous OC dosing schemes and the associated state of amenorrhea is a healthier alternative to monthly menstruation because it would result in a decrease of many illnesses associated with hormone fluctuations and menstruation.

Women's attitudes towards inhibiting menstruation are age and culture dependent^{116,183}. The percentage of women desiring amenorrhea increases with increasing age¹¹⁶. Most women (81%) of Western or Western-oriented cultures desire a change to the duration or frequency of menses^{116,123,125,182}, with approximately 40% of women preferring not to menstruate^{116,182,183}. Conversely, the majority (42- 71%) of African and Asian women would prefer to menstruate on a monthly basis, with only approximately 18% of these women preferring to inhibit menstruation¹⁸³. The most common reasons for wanting to suppress menstruation include: convenience, decreased menstrual related complaints, better hygiene, higher quality of life and less blood loss¹⁸²; whereas, the desire to menstruate on a monthly basis appeared to be associated with strong cultural beliefs. For example, most Nigerian women (81%) stated that monthly menstruation rids the body of bad blood¹⁸³.

Cycle control, defined as the occurrence of spotting or breakthrough bleeding is one of the key factors contributing to the acceptability of a contraceptive method²²⁵. Poor cycle control is highly correlated to discontinuation of OC²²⁶. Studies designed to compare bleeding characteristics of women using continuous versus conventional dosing schemes reported higher dropout rates in the continuous dosing group due to a higher incidence of unscheduled bleeding^{112,113,122}. Interestingly, most women who have administered OC in a continuous manner report preferring the inconvenience of unscheduled bleeding to monthly scheduled withdrawal bleeding^{112,113,115,122,123,227}.

We reported that women who used conventional dosing schemes experienced fewer days of unscheduled bleeding than women using continuous dosing schemes, during the first three cycles of OC use (Chapter 4). Cycle control during continuous OC use is

reported to increase with increased duration of use, such that breakthrough bleeding is comparable between continuous and conventional dosing schemes containing ethinyl estradiol (EE) and levonorgestrel by approximately 9 months of use^{112,113,124}. We did not observe a decrease in unscheduled bleeding as the duration of OC use increased; however, the study design only permitted observation during the initial three cycles of OC use. Further investigations should examine the effects of prolonged continuous OC use on bleeding patterns and health.

We did not observe a difference in cycle control during continuous or conventional dosing between levonogestrel and norgestimate (Chapter 4). Cycle control is related to the half-life of the progestin; generally, the longer the half-life the greater the cycle control¹¹⁰. We suggest that similarities in the half-life (15 hours) of levonorgestrel and norgestimate are responsible for the similarities we observed in cycle control during both continuous and conventional OC dosing schemes (Chapter 4)¹¹⁰. The dose of EE does not appear to effect cycle control during continuous OC dosing schemes^{112,124} (Chapter 4); however, few studies are available to compare the effects of the dose of EE on cycle control during continuous OC use. It appears that continuous administration of exogenous EE and progestin during continuous OC dosing schemes maintains continual endometrial suppression and good cycle control which ultimately over rides the need for high doses of EE.

The duration of continuous OC use and the type of progestin administered appears to effect the time required to induce amenorrhea. Progestins are reported to directly exert their effects at the uterus; therefore, differences in bioavailability, serum half-life and relative binding affinity can alter the progestin's effect on the uterus²²⁸. The histologic

appearance of the endometrium during progesterone administration resembles that of an early pregnant uterus; the epithelium is thin and atrophic without mitosis, few blood vessels are present, the stroma is thick and decidualized, and the glands are poorly developed²²⁸.

Comparison of studies which examined cycle control during continuous OC use with different OC formulation containing the same dose of EE but different progestins reveal that desogestrel and gestodene provide the greatest cycle control of all progestins tested. Spotting and break through bleeding occurred less frequently with desogestrel and gestodene compared to levonorgestrel. Furthermore, amenorrhea was induced in 81% of women within two consecutive 28 day cycles of 30 µg EE / 75 µg gestodene and 52-75% of women were amenorrheic within two consecutive 28 day cycles of 30 µg EE / 150 µg desogestrel^{115,117}. Only 42% of women were amenorrheic within 12 consecutive 28 day cycles of 30 µg EE/ 150 µg levonorgestrel^{112,227}. Furthermore, we did not observe amenorrhea during three 28-day cycles of continuous OC dosing of 30 µg EE/ 150 µg levonorgestrel or 35 µg EE/ 250 µg norgestimate (Chapter 4). Superior cycle control with gestodene and desogestrel compared to levonorgestrel and norgestimate is likely due to gestodene's and desogestrel's higher affinity for progesterone receptors, a lower affinity for androgen receptors, a higher selectivity of action, and a higher potency at the level of the endometrium²²⁸.

5.3 Return to Fertility following Discontinuation of Oral Contraceptives

Oral contraceptives are the reversible contraceptive of choice of women in industrialized nations¹⁰⁹. Approximately half of Canadian women (49%) use OC as their method of contraception²¹¹. Due to the high popularity of OC it is essential to determine if

OC have residual effects on ovarian function following their discontinuation. It has been established that women who discontinue OC take two to three months longer to conceive than women who discontinue other types of contraceptive therapies (i.e., intrauterine device, diaphragm, or condom)¹⁹⁵⁻²⁰⁴. Few studies have examined the physiologic mechanisms responsible for the delay in fertility following discontinuation of OC.

We used highly sophisticated transvaginal ultrasonography to serially monitor ovarian follicular development following discontinuation of both continuous and conventional dosing schemes (Chapter 4). Most women ovulated following discontinuation of OC, suggesting that the two to three month delay in the return to fertility is not due to anovulation (Chapter 4). Furthermore, we suggest that follicles which develop following discontinuation of OC have similar physiologic function to follicles which develop during spontaneous natural cycles due to similarities in follicle diameter at selection, dominance and ovulation as well as the time to ovulation once the follicle manifest dominance (Chapter 4). Pre-ovulatory follicles that develop following discontinuation of OC are suggested to have equal potential to natural cycles to create a viable conception and pregnancy.

Interestingly, follicles which developed following discontinuation of OC took slightly longer to be selected, manifest dominance and ovulate, compared to follicles which develop during spontaneous natural cycles (Chapter 4). We suggest that this delay is due to wave synchronization of follicles during OC administration. During spontaneous natural cycles a cohort of follicles is recruited for growth and development during the late luteal phase, such that gonadotropin dependent follicles are commonly observed on Day 1 menstruation. The delay to ovulation following discontinuation of OC may be due to

follicular recruitment occurring before the first day of menses during natural cycles and after Day 1 in follicles following discontinuation of OC (Chapter 4). The delay in ovulation was not great enough to explain the two to three month delay in fertility. Further research is needed to determine the exact physiologic mechanisms associated with the delay in fertility.

5.4 Development of Novel Methods of Contraception

The once daily administration scheme of OC has a number of disadvantages, such as fluctuations of hormone plasma levels which can increase the incidence of hormone related side effects and increase non-adherence rates²²⁹. Many women regard the adherence required by daily OC to be a drawback to the use of OC and would prefer a contraceptive with a longer dosing interval²²⁹. Women report that the ideal contraceptive would be: efficacious, safe, easy to use, have few side effects and provide excellent cycle control²³⁰. A weekly transdermal patch containing norelgestromin and EE; (Ortho Evra: Ortho-McNeil, Raritan, NJ), and a monthly vaginal ring containing etonogestrel and EE (NuvaRing; Organon, West Orange, NJ) have been introduced within the past 5 years in response to women's requests²³⁰.

The contraceptive transdermal patch delivers 20 µg EE and 150 µg norelgestromin to the bloodstream every 24 hours through a 20 cm² transdermal patch²³¹. The patch is applied once a week for three consecutive weeks followed by one patch-free week¹⁵⁸. Transdermal contraceptive patch use is reported to have higher adherence rates and greater cycle control while maintaining or increasing contraceptive efficacy compared to OC^{158,232,233}.

The vaginal ring delivers 15 µg EE and 120 µg etonogestrel per day in a continuous manner such that daily peaks in serum concentrations are only observed at the beginning of each cycle compared to daily peaks observed during OC use²³⁰. A cycle consists of wearing the ring vaginally for three consecutive weeks followed by removal of the ring for one week²³⁰; however, the vaginal ring maintains its efficacy for up to seven weeks of continuous use^{234,235}.

New contraceptive methods such as the transdermal patch and vaginal ring are only the beginning of new contraceptive choices. Both administration schemes provide patient acceptability equal to or greater than OC administration, suggesting that women are open to utilizing new, novel administration schemes as long as the schemes are easier to use, provide equal or greater efficacy, have few side-effects and maintain cycle control equal to or greater than OC. Furthermore, bioavailability of the exogenous hormones is increased with these administration schemes because gastrointestinal metabolism and the first pass effect are avoided resulting in decreased doses required to maintain ovarian suppression and thus exposure to exogenous hormones is decreased²²⁹.

Modern day women are interested in new, novel contraceptive therapies; however, many modern women do not completely understand their own reproductive function, nor do they realize the number of contraceptive choices available to them²¹¹. Health care professionals must ensure women are informed about their own reproductive function, contraceptive methods and how each contraceptive method effects reproductive functioning. “Real life” OC use appears to decrease contraceptive efficacy. The studies in this thesis are interpreted to mean that follicles that develop during OC use have similar physiologic function to natural cycle follicles, such that follicles that develop during OC

use are capable of ovulating resulting in subsequent pregnancy and pill-failure, if the secondary contraceptive characteristics of OC are not maintained. New contraceptive methods ought to be developed to maintain extremely low failure rates during “real life” use. Continuous OC dosing schemes, vaginal rings and transdermal patches all appear to be superior methods of contraception with respect to cycle control, ease of use, efficacy and associated side-effects compared to conventional dosing schemes. Finally the return to fertility following discontinuation of OC does not appear to be due to lack of anovulation. Further investigations should examine the physiologic mechanisms associated with the delay in fertility following cessation of OC.

5.5 Overall Conclusions

The following hypothesis was not supported.

- 1) Taken together, there was inadequate support for the hypothesis that ultrasound image attributes of human ovarian dominant follicles from natural cycles quantitatively differed from follicles which developed under the suppressive effects of OC.

The following hypotheses were supported:

- 2) Continuous OC dosing schemes better suppress follicular development than conventional OC dosing schemes due to greater hypothalamic-pituitary-ovarian axis suppression.
- 3) Follicles take longer to ovulate following discontinuation of OC compared to natural cycle follicles.

5.6 General References

1. Jocelyn H, Setchell B. Regnier de Graaf on the Human Reproductive Organs: A New Treatise Concerning the Generative Organs of Women. *Journal of Reproduction and Fertility*. 1972;17 Supp:77-189.
2. Carter J. History of biology. In, *vol. 2000*: Netscape; 1999.
3. Baker T. A Quantitative and Cytological Study of Germ Cells in Human Ovaries. *Proceedings of the Royal Society of Britain*. 1963;158:417-433.
4. Adashi E. The Ovarian Follicular Apparatus. In: Adashi E, Rock J, Rosenwaks Z, eds. *Reproductive Endocrinology, Surgery, and Technology*. Vol 1. Philadelphia: Lippincott-Raven Publisher; 1996:18-40.
5. Gondos B, Westergaard L, Byskov A. Initiation of Oogenesis in teh Human Fetal Ovary, Ultrastructural and Squash Preparation Study. *American Journal of Obstetrics and Gynecology*. 1986;155:189-195.
6. Gougeon A. Dynamics for Human Growth: Morphologic, Dynamic and Functional Aspects. In: Leung P, Adashi E, eds. *The Ovary*. 2 ed. San Diego: Elsevier Academic Press; 2004:25-43.
7. Gougeon A. Some Aspects of the Dynamics of Ovarian Follicular Growth in the Human. *Acta Europaea Fertilitatis*. 1989;20(4):185-192.
8. Lintern-Moore S, Peters H, Moore G, Faber M. Follicular Development in the Infant Human Ovary. *Journal of Reproduction and Fertility*. 1974;9:53-64.
9. Gougeon A. Some Aspects of the Dynamics of Ovarian Follicular Growth in the Human. *Acta Europaea Fertilitatis*. 1989;20:189-194.
10. Gougeon A. Regulation of Ovarian Follicular Development in Primates: Facts and Hypotheses. *Endocrine Reviews*. 1996;17(2):121-155.
11. Block E. A Quantitative Morphological Investigations of the Follicular System in Newborn Female Infants. *Acta Anatomica*. 1953;17:201-206.
12. Faddy M, Gosden R, Gougeon A, Richardson S, Nelson J. Accelerated Disappearance of Ovarian Follicles in Mid-life: Implications for Forecasting Menopause. *Human Reproduction*. 1992;7:1342-1346.
13. Forabosco A, Sforza C, de Pol A, Vizzotto L, Marzona L, Ferrario V. Morphometric Study of the Human Neonatal Ovary. *The Anatomical Record*. 1991;231:201-208.

14. Gougeon A, Ecochard R, Thalabard J. Age-related Changes of the Population of Human Ovarian Follicles: Increase in the Disappearance Rate of Non-Growing and Early-Growing Follicles in Aging Women. *Biology of Reproduction*. 1994;50:653-663.
15. Chabbert-Buffet N, Bouchard P. The Neuroendocrine Regulation of the Human Ovarian Cycle. *Chronobiology International*. 2001;18(6):893-919.
16. Fritz M, Speroff L. The Endocrinology of the Menstrual Cycle: the Interaction of Folliculogenesis and Neuroendocrine Mechanisms. *Fertility and Sterility*. 1982;38(5):509-529.
17. Glasier A, Baird D, Hillier S. FSH and the Control of Follicular Growth. *Journal of Steroid Biochemistry*. 1989;32(18):167-170.
18. Roy S. Regulation of Ovarian Follicular Development: A Review of Microscopic Studies. *Microscopy Research and Technique*. 1997;27:83-96.
19. Oktay K, Briggs D, Gosden R. Ontogeny of Follicle-Stimulating Hormone Receptor Gene Expression in Isolated Human Ovarian Follicles. *Journal of Clinical Endocrinology and Metabolism*. 1997;5(7):967-978.
20. Bassett D. The Changes in the Vascular Pattern of the Ovary of the Albino Rat during the Estrous Cycle. *American Journal of Anatomy*. 1943;73:252-292.
21. Channing C, Kammerman S. Characteristics of Gonadotropin Receptors of Porcine Granulosa Cells During Follicle Maturation. *Endocrinology*. 1973;92:531-540.
22. Fauser B, Van Heusden A. Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences. *Endocrine Reviews*. 1997;18(1):71-106.
23. Hodgen G. Biological Basis of Follicular Growth. *Human Reproduction*. 1989;4(Supplement):37-46.
24. Edwards R. Follicular Fluid. *Journal of Reproduction and Fertility*. 1974;37:189-219.
25. Gougeon A. Rate of Follicular Growth in the Human Ovary. In: Rollard R, Van Hall E, Hillier S, McNatty K, Schoemakes J, eds. *Follicular Maturation and Ovulation*. Amsterdam: Excerpta Medica; 1982:155-163.
26. Gougeon A. Dynamics of Follicular Growth in the Human: a Model from Preliminary Results. *Human Reproduction*. 1986;1(2):81-87.
27. Roy S, Treacy B. Isolation and Long-term Culture of Human Preantral Follicles. *Fertility and Sterility*. 1993;59:783-790.

28. Hirshfield A. Development of Follicle in the Mammalian Ovary. *International Review of Cytology*. 1991;124:43-101.
29. Macklon N, Fauser B. Aspects of Ovarian Follicle Development Throughout Life. *Hormone Research*. 1999;52:161-170.
30. Covan A. Ovarian Follicular Activity in Late Pregnancy. *Journal of Endocrinology*. 1970;48:235-240.
31. Nelson W, Forks G, Greene R. Some Observations on the Histology of the Human Ovary during Pregnancy. *American Journal of Obstetrics and Gynecology*. 1958;76:66-90.
32. Polhemus D. Ovarian Maturation and Cyst Formation in Children. *Pediatrics*. 1953;11:588-594.
33. Schoot B, Coelingh Bennink J, Mannaerts B, Lamberts S, Bouchard P, Fauser B. Human Recombinant Follicle Stimulating Hormone Induces Growth of Preovulatory Follicles without Concomitant Increase in Androgen and Estrogen Biosynthesis in a Woman with Isolated Gonadotropin Deficiency. *Journal of Clinical Endocrinology and Metabolism*. 1992;74:1471-1473.
34. Schoot B, Harlin J, Shoham Z, et al. Recombinant Human Follicle-Stimulating Hormone and Ovarian Response in Gonadotropin-Deficient Women. *Human Reproduction*. 1994;9:1237-1242.
35. Valdes-Dapena M. The Normal Ovary of Childhood. *Annals of the New York Academy of Sciences*. 1967;34:597-613.
36. de Kretser D, Hedger M, Loveland K, Phillips D. Inhibins, Activins and Follistatin in Reproduction. *Human Reproduction Update*. 2002;8(6):529-541.
37. Hall J, Schoenfeld D, Martin K, Crowley W. Hypothalamic Gonadotropin-releasing Hormone Secretion and Follicle Stimulating Hormone Dynamic during the Luteal-follicular Transition. *Journal of Clinical Endocrinology and Metabolism*. 1992;74:600-607.
38. McNatty K, Hillier S, van den Boogaard A, Trimbo-Kemper T, Reichert L, Van Hall E. Follicular Development during the Luteal Phase of the Human Menstrual Cycle. *Journal of Clinical Endocrinology and Metabolism*. 1983;56(1):1022-1031.
39. Monniaus D, Huet C, Besnard N, et al. Follicular Growth and Ovarian Dynamics in Mammals. *Journal of Reproduction and Fertility*. 1997;51(Supplement):2-23.
40. Hillier S. Current Concepts of the Roles of Follicle Stimulating Hormone and Luteinizing Hormone in Folliculogenesis. *Human Reproduction*. 1994;9:188-191.

41. Brown J. Pituitary Control of Ovarian Function- Concepts Derived from Gonadotropin Therapy. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 1978;18:47-54.
42. Baerwald A, Adams G, Pierson R. Characterization of Ovarian Follicular Wave Dynamics in Women. *Biology of Reproduction*. 2003;69:1023-1031.
43. Baerwald A, Adams G, Pierson R. A New Model for Ovarian Follicular Development during the Human Menstrual Cycle. *Fertility and Sterility*. 2003;80(1):116-122.
44. Scheele F, Schoemaker J. The Role of Follicle-stimulating Hormone in the Selection of Follicles in Human Ovaries: A Survey of the Literature and a Proposed Model. *Gynecologic Endocrinology*. 1996;10:55-66.
45. Macklon N, Fauser B. Regulation of Follicle Development and Novel Approaches to Ovarian Stimulation for IVF. *Human Reproduction Update*. 2000;6(4):307-312.
46. Pache T, Wladimiroff J, de Jong F, Hop W, Fauser B. Growth Patterns of Nondominant Ovarian Follicles during the Normal Menstrual Cycle. *Fertility and Sterility*. 1990;54(4):638-642.
47. Goodman A, Hodgen G. The Ovarian Triad of the Primate Menstrual Cycle. *Recent Progress in Hormone Research*. 1983;39:1-73.
48. Chickazawa K, Araki S, Tamada T. Morphological and Endocrinological Studies on Follicular Development during the Human Menstrual Cycle. *Journal of Clinical Endocrinology and Metabolism*. 1986;62(2):305-313.
49. van Santbrink E, Hop W, van Dessel T, de Jong F, Fauser B. Decremental Follicle-stimulating Hormone and Dominant Follicle Development during the Normal Menstrual Cycle. *Fertility and Sterility*. 1995;64(1):37-43.
50. Gougeon A, Lefevre B. Evolution of the Diameters of the Largest Healthy and Atretic Follicles during the Human Menstrual Cycle. *Journal of Reproduction and Fertility*. 1983;69:497-502.
51. McNatty K. Ovarian Follicular Development from the Onset of Luteal Regression in Humans and Sheep. In: Rolland R, van Hall E, Hillier S, McNatty K, Schoemaker J, eds. *Follicular Maturation and Ovulation*. Amsterdam: Excerpta Medica; 1982:1-18.
52. Bomsel-Helmreich O, Gougeon A, Thebault A, et al. Healthy and Atretic Human Follicles in the Preovulatory Phase: Differences in Evolution of Follicular Morphology and Steroid Content of Follicular Fluid. *Clinical Endocrinology and Metabolism*. 1979;48(4):686-694.

53. van Dessel H, Schipper I, Pache T, van Geldorp H, de Jong FH, Fauser BC. Normal Human Follicle Development: An Evaluation of Correlations with Oestradiol, Androstenedione and Progesterone Levels in Individual Follicles. *Clinical Endocrinology (Oxford)*. 1996;44:191-198.
54. Erickson G, Yen S. New Data on Follicle Cells in Polycystic Ovaries: A Proposed Mechanism for the Genesis of Cystic Follicles. *Seminars in Reproductive Endocrinology*. 1984;2:231-243.
55. Zeleznik A, Benyo D. Control of Follicular Development, Corpus Luteum Function, and the Recognition of Pregnancy in Higher Primates. In: Knobil E, Neil J, eds. *The Physiology of Reproduction*. New York: Raven Press; 1994:781-782.
56. Baerwald A, Adams G, Pierson R. Characteristics of Ovarian Follicular Wave Dynamics in Women. *Biology of Reproduction*. 2003;69:1023-1031.
57. Gougeon A. Regulation of Ovarian Follicular Development in Primates: Facts and Hypotheses. *Endocrine Reviews*. 1996;17:121-155.
58. di Zerega G, Marut E, Turner C, Hodgen G. Asymmetrical Ovarian Function during Recruitment and Selection of the Dominant Follicle in the Menstrual Cycle of the Rhesus Monkey. *Journal of Clinical Endocrinology and Metabolism*. 1981;51(4):698-701.
59. Zeleznik A. Follicle Selection in Primates: "Many are called but few are Chosen". *Biology of Reproduction*. 2001;65(3):655-659.
60. Erickson G. An Analysis of Follicle Development and Ovum Maturation. *Seminars in Reproductive Endocrinology*. 1986;4:233-254.
61. McGee E, Hsueh A. Initial and Cycle Recruitment of Ovarian Follicles. *Endocrine Reviews*. 2000;21(2):200-214.
62. Zeleznik A, Kubik C. Ovarian Responses in Macaques to Pulsatile Infusion of Follicle Stimulating Hormone and Luteinizing Hormone: Increased Sensitivity of the Maturing Follicle to FSH. *Endocrinology*. 1986;119:2025-2032.
63. Yamoto M, Shima K, Nakano R. Gonadotropin Receptors in Human Ovarian Follicles and Corpora Lutea throughout the Menstrual Cycle. *Hormone Research*. 1992;37([Suppl]1):5-11.
64. Zeleznik A, Schuler H, Reichert L. Gonadotropin-binding Sites in the Rhesus Monkey Ovary: Role of the Vasculature in the Selective Distribution of Human Chorionic Gonadotropin to the Preovulatory Follicle. *Endocrinology*. 1981;109(2):356-362.
65. Erickson G, Danforth D. Ovarian Control of Follicle Development. *American Journal of Obstetrics and Gynecology*. 1995;2(2):736-747.

66. Fortune J. Ovarian Follicular Growth and Development in Mammals. *Biology of Reproduction*. 1994;50:225-232.
67. Groome N, Illingworth P, O'Brien M. Measurement of Dimeric Inhibin B throughout the Human Menstrual Cycle. *Journal of Clinical Endocrinology and Metabolism*. 1996;81:1401-1405.
68. Brannstrom M. Potential Role of Cytokines in Ovarian Physiology: The Case of Interleukin-1. In: Leung P, Adashi E, eds. *The Ovary*. 2nd ed. Amsterdam: Elsevier Academic Press; 2004:261-271.
69. Zeleinski-Wooten M, Hutchison J, Chandrasekher Y, Wolf D, Stouffer R. Administration of Human Luteinizing Hormone (hLH) to Macaques after Follicular Development: Further Titration of LH Surge Requirements for Ovulatory Changes in Primate Follicles. *Journal of Clinical Endocrinology and Metabolism*. 1992;75(2):502-507.
70. Speroff L, Glass R, Kase N. Regulation of the Menstrual Cycle. *Clinical Gynecologic Endocrinology and Infertility*. Baltimore: Lippincott Williams & Wilkins; 1999:226-230.
71. Hodgen G. Neuroendocrinology fo the Normal Menstrual Cycle. *Journal of Reproductive Medicine*. 1989;34(1 (Supplement)):68-75.
72. Chabbert-Buffet N, Djakoure S, Maitre C, Bouchard P. Regulation of the Human Menstrual Cycle. *Frontiers in Endocrinology*. 1998;19:151-186.
73. Matousek M, Mitsube K, Mikuni M, Brannstrom M. Inhibition of Ovulation in the Rat by a Leukotriene B(4) Receptor Antagonist. *Molecular Human Reproduction*. 2001;7:35-42.
74. Espey L, H, ed. *Ovulation*. 2nd ed. New York: Raven Press; 1994. Knobil E, Neill J, eds. *The Physiology of Reproduction*; No. 1.
75. Espey L, Coons P, Marsh J, LeMaire W. Effect of Indomethacin on Preovulatory Changes in the Ultrastructure of Rabbit Graafian Follicles. *Endocrinology*. 1981;108:1040-1048.
76. Espey L. Ultrastructure of the Apex of the Rabbit Graafian Follicle durign the Ovulatory Process. *Endocrinology*. 1967;81:267-276.
77. Heape W. Ovulation and Degeneration of the Ova in the Rabbit. *Proceedings of the Royal Society of London. Series B. Biological sciences*. 1905;76:260-268.
78. Smith J. Rupture of Graafian Follicles. *American Journal of Obstetrics and Gynecology*. 1937;33:820-827.

79. Zachariae F, Jensen C. Studies on the Mechanism of Ovulation. Histochemical and Physicochemical Investigations on Genuine Follicular Fluids. *Acta endocrinologica*. 1958;27:343-355.
80. Blandau R, Rumery R. Measurements of Intrafollicular Pressure in Ovulatory and Preovulatory Follicles of the Rat. *Fertility and Sterility*. 1963;14:330-341.
81. Kraus S. Observations on the Mechanism of Ovulation in the Frog, Hen and Rabbit. *Western journal of surgery, obstetrics, and gynecology*. 1947;55:424-437.
82. von Winiwarter H, Sainmont G. Nouvelles Recherches sur l'ovogenese et L'organogense de L'ovarie des Mammiferes Chat. *Archives de biologie*. 1909;24:627-651.
83. Corner G. On the Origin of the Corpus Luteum of the Sow from both Granulosa and Theca Interna. *American Journal of Anatomy*. 1919;26:117-183.
84. Claesson L. Is there any Smooth Musculature in the Wall of the Graafian Follicle? *Acta anatomica*. 1947;3:295-311.
85. Yoshimura Y, Santulli R, Atlas S, Fujii S, Wallach E. The Effects of Proteolytic Enzymes on in vitro Ovulation in the Rabbit. *American Journal of Obstetrics and Gynecology*. 1987;157(2):468-475.
86. Espey L, H, Bellinger A, Healy J. Ovulation: An Inflammatory Cascade of Gene Expression. In: Leung P, Adashi E, eds. *The Ovary*. 2nd ed. San Diego: Elsevier Academic Press; 2004:145-165.
87. Baerwald A. *Human Ovarian Follicular Dynamics during Natural Menstrual Cycles and Oral Contraceptive Cycles*. Saskatoon: Department of Obstetrics, Gynecology and Reproductive Sciences, University of Saskatchewan; 2003.
88. Martinuk S, Chizen D, Pierson R. Ultrasonographic Morphology of the Human Preovulatory Follicle Wall Prior to Ovulation. *Clinical Anatomy*. 1992;5:339-352.
89. Hanna M, Chizen D, Pierson R. Characteristics of Follicular Evacuation during Human Ovulation. *Ultrasound in Obstetrics & Gynecology*. 1994;4:488-493.
90. Pierson R, Chizen D. Transvaginal Diagnostic Ultrasonography in Evaluation and Management of Infertility. *Journal SOGC: Journal of the Society of Obstetricians and Gynecologists of Canada*. 1991.
91. Ginther O. *Ultrasonic Imaging and Animal Reproduction: Fundamentals*. Vol 1. Crossplains: Equiservices Publishing; 1995.
92. Zagzebski J. Physics and Instrumentation. In: Sabbagha R, ed. *Diagnostic Ultrasound Applied to Obstetrics and Gynecology*. 3rd ed. Philadelphia: J.B. Lippincott Company; 1994:3-56.

93. Hearn-Stebbins B, Jaffe R, Brown H. Ultrasonographic Evaluation of Normal Pelvic Anatomy. In: Jaffe R, Pierson R, Abramowicz J, eds. *Imaging in Infertility and Reproductive Endocrinology*. Philadelphia: J.B. Lippincott Company; 1994:1-21.
94. Backstrom T, Nakata M, Pierson R. Ultrasonography of Normal and Aberrant Luteogenesis. In: Jaffe R, Pierson R, Abramowicz J, eds. *Imaging in Infertility and Reproductive Endocrinology*. Philadelphia: J.B. Lippincott Company; 1994:143-154.
95. Pierson R, Chizen D. Transvaginal Ultrasonographic Assessment of Normal and Aberrant Ovulation. In: Jaffe R, Pierson R, Abramowicz J, eds. *Imaging in infertility and reproductive endocrinology*. Philadelphia: J.B. Lippincott Company; 1994:129-142.
96. Parsons A. Imaging the Human Corpus Luteum. *Journal of Ultrasound in Medicine*. 2001;20:811-819.
97. Pierson R, Martinuk S, Chizen D, Simpson C. Ultrasonographic Visualization of Human Ovulation. In: Evers J, Heineman M, eds. *From Ovulation to Implantation*. Amsterdam: Excerpta Medica; 1990:73.
98. Pierson R, Adams G. Computer-assisted Image Analysis, Diagnostic Ultrasonography and Ovulation Induction: Strange Bedfellows. *Theriogenology*. 1995;43:105-112.
99. Singh J, Adams G, Pierson R. Promise of New Imaging Technologies for Assessing Ovarian Function. *Animal Reproduction Science*. 2003;78:371-399.
100. Baxes G. Fundamentals of Digital Image Processing. *Digital Image Processing: Principles and Applications*. New York: Wiley; 1994:13-36.
101. Singh J, Pierson R, Adams G. Ultrasound Image Attributes of Bovine Ovarian Follicles and Endocrine and Functional Correlates. *Journal of Reproduction and Fertility*. 1998;112:19-29.
102. Singh J, Pierson R, Adams G. Ultrasound Image Attributes of the Bovine Corpus Luteum: Endocrine and Functional Correlates. *Journal of Reproduction and Fertility*. 1997;109:35-44.
103. Duggvathi R, Bartlewski P, Pierson R, Rawlings N. Luteogenesis in Cyclic Ewes: Echotextural, Histological, and Functional Correlates. *Biology of Reproduction*. 2003;69:634-639.
104. Tom J, Pierson R, Adams G. Quantitative Echotexture Analysis of Bovine Corpora Lutea. *Theriogenology*. 1998;40:1345-1352.
105. Tom J, Pierson R, Adams G. Quantitative Echotexture Analysis of Bovine Ovarian Follicles. *Theriogenology*. 1998;50:339-346.

106. Birtch R, Olatunbosun O, Baerwald A, Pierson R. Ultrasound Image Attributes of Human Ovarian Dominant Follicles during Natural and Oral Contraceptive Cycles. *Reproductive Biology and Endocrinology*. 2005;in press.
107. Pincus G, Rock J, Garcia C, Rice Whira E, Pamaqua M, Rodriques I. Fertility Control with Oral Medication. *American Journal of Obstetrics and Gynecology*. 1958;75:1333-1346.
108. Daniels M. http://www.pbs.org/wgbh.amex.pill/gallery/gal_pill_01.html. The Pill. Accessed 16 Feb, 2005.
109. Dickey R. *Managing Contraceptive Pill Patients*. 8th ed. Durant: EMIS, Inc. Medical Publishers; 1997.
110. Wallach M, Grimes D. *Modern Oral Contraception: Updates from The Contraception Report*. Totowa: Emron; 2000.
111. Van Heusden A, Fauser B. Residual Ovarian Activity during Oral Steroid Contraception. *Human Reproduction Update*. 2002;8:345-358.
112. Anderson F, Hait H, Group TSS. A Multi-center, Randomized Study of an Extended Cycle Oral Contraceptive. *Contraception*. 2003;68:89-96.
113. Cachrimanidou A, Hellber D, Nilsson S, Waldenstrom U, Olsson S, Sikstrom B. Long-interval Treatment Regimen with a Desogestrel-containing Oral Contraceptive. *Contraception*. 1993;48:205-216.
114. Coutinho E, Segal S. *Is Menstruation Obsolete?* New York: Oxford University Press; 1999.
115. de Voogd W. Postponement of Withdrawal Bleeding with a Monophasic Oral Contraceptive Containing Desogestrel and Ethinylestradiol. *Contraception*. 1991;44(2):107-112.
116. den Tonkelaar I, Oddens B. Preferred Frequency and Characteristics of Menstrual Bleeding in Relation to Reproductive Status, Oral Contraceptive Use, and Hormone Replacement Therapy. *Contraception*. 1999;59:357-362.
117. Hamerlynck J, Vollebregt J, Doornebos C, Mutendam P. Postponement of Withdrawal Bleeding in Women using Low-dose Combined Oral Contraceptives. *Contraception*. 1987;35:199-205.
118. Henzel M, Lake Polan M. Avoiding Menstruation: A Review of Health and Lifestyle Issues. *Journal of Reproductive Medicine*. 2004;49:162-174.
119. Kaunitz A. Menstruation: Choosing Whether. and When. *Contraception*. 2000;62:277-284.

120. Killick S, Bancroft K, Oelbaum S, Morris S, Elstein M. Extending the Duration of the Pill-free Interval during Combined Oral Contraception. *Advances in Contraception*. 1990;6:33-40.
121. Kovacs G, Rusden J, Evans A. A Trimonthly Regimen for Oral Contraceptives. *The British Journal of Family Planning*. 1994;19:274-275.
122. Kwiecien M, Edelman A, Nichols M, Jensen J. Bleeding Patterns and Patient Acceptability of Standard or Continuous Dosing Regimens of a Low-dose Oral Contraceptive: A Randomized Trial. *Contraception*. 2003;67:9-13.
123. Loudon N, Foxwell M, Potts D, Guild A, Short R. Acceptability of an Oral Contraceptive that Reduces the Frequency of Menstruation: the Tri-Cyclic Pill Regimen. *British Medical Journal*. 1977;2:487-490.
124. Miller L, Hughes H. Continuous Combination Oral Contraceptive Pills to Eliminate Withdrawal Bleeding: A Randomized Trial. *Obstetrics and Gynecology*. 2003;101:653-661.
125. Rutter W, Knight C, Vizzard J, Mira M, Abraham S. Women's Attitudes to Withdrawal Bleeding and their Knowledge and Beliefs about the Oral Contraceptive Pill. *Medical Journal of Australia*. 1988;149:417-419.
126. Schlaff W, Lynch A, Hughes H, Cedars M, Smith D. Manipulation of the Pill-free Interval in Oral Contraceptive Pill Users: The Effect on Follicular Suppression. *American Journal of Obstetrics and Gynecology*. 2004;190(4):943-951.
127. Sillem M, Schneidereit R, Heithecker R, Mueck A. Use of an Oral Contraceptive Containing drospirenon in an Extended Regimen. *The European Journal of Contraception and Reproductive Health Care*. 2003;8:162-169.
128. Sulak P, Carl J, Gopalakrishnan I, Coffee A, Kuehl T. Outcomes of Extended Oral Contraceptive Regimens with a Shortened Hormone-free Interval to Manage Breakthrough Bleeding. *Contraception*. 2004;70:281-287.
129. Sulak P, Cressman B, Waldrop E, Holleman S, Kuehl T. Extending the Duration of Active Oral Contraceptive Pills to Manage Hormone Withdrawal Symptoms. *Obstetrics and Gynecology*. 1997;89:179-183.
130. Sulak P, Kuehl T, Oritz M, Shull B. Acceptance of Altering the Standard 21-day/7-day Oral Contraceptive Regimen to Delay Menses and Reduce Hormone Withdrawal Symptoms. *American Journal of Obstetrics and Gynecology*. 2002;186:1142-1149.
131. Sulak P, Scow R, Preece C, Riggs M, Kuehl T. Hormone Withdrawal Symptoms in Oral Contraceptive Users. *Obstetrics and Gynecology*. 2000;95:261-266.

132. Thomas S, Ellertson C. Nuisance or Natural and Healthy: Should Monthly Menstruation be Optional for Women? *Lancet*. 2000;355:922-924.
133. Baerwald A, Olatunbosun O, Pierson R. Ovarian Follicular Development is Initiated during the Hormone-Free Interval of Oral Contraceptive Use. *Contraception*. 2004;70:371-377.
134. Broome M, Clayton J, Fotherby K. Enlarged Follicles in Women Using Oral Contraceptives. *Contraception*. 1995;52:13-16.
135. Coney P, Del Conte A. The Effects of Ovarian Activity of a Monophasic Oral Contraceptive with 100 microgram levonorgestrel and 20 microgram ethinyl estradiol. *American Journal of Obstetrics and Gynecology*. 1999;181:53-58.
136. Crosignani P, Testa G, Vegetti W, Parazzini F. Ovarian Activity during Regular Oral Contraceptive Use. *Contraception*. 1996;54:271-273.
137. Egarter C, Putz M, Strohmmer H, Speiser P, Wenzl R, Huber J. Ovarian Function during Low-Dose Oral Contraceptive Use. *Contraception*. 1995;51:329-333.
138. Fitzgerald C, Feichtinger W, Spona J, Elstien M, Ludicke F, Muller U, Williams C. A Comparison of the Effects of Two Monophasic Low Dose Oral Contraceptives on the Inhibition of Ovulation. *Advances in Contraception*. 1994;10:5-18.
139. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M. Ovulation and Follicular Development Associated with Three Low-Dose Oral Contraceptives: A Randomized Controlled Trial. *Obstetrics and Gynecology*. 1994;83:29-34.
140. Hoogland J, Skouby S. Ultrasound Evaluation of Ovarian Activity under Oral Contraceptives. *Contraception*. 1993;47:583-590.
141. Jain J, Ota F, Mishell Jr. D. Comparison of Ovarian Follicular Activity during Treatment with a Monthly Injectable Contraceptive and a Low-Dose Oral Contraceptive. *Contraception*. 2000;61:195-198.
142. Killick S, Fitzgerald C, Davis A. Ovarian Activity in Women Taking an Oral Contraceptive containing 20 micrograms Ethinyl Estradiol and 150 micrograms Desogestrel: Effects of Low Estrogen Doses during the Hormone-free Interval. *American Journal of Obstetrics and Gynecology*. 1998;179:S18-24.
143. Rabe T, Nitsche D, Runnebaum B. The Effects of Monophasic and Triphasics Oral Contraceptives on Ovarian Function and Endometrial Thickness. *The European Journal of Contraception and Reproductive Health Care*. 1997;2:39-51.
144. Schwartz J, Creinin M, Pymar H, Reid L. Predicting Risk of Ovulation in New Start Oral Contraceptive Users. *American College of Obstetrician and Gynecologists*. 2002;99:177-182.

145. Spona J, Elstein M, Feichtinger W, Sullivan H, Ludicke F, Muller U, Dusterberg B. Shorter Pill-free Interval in Combined Oral Contraceptives Decreases Follicular Development. *Contraception*. 1996;54:71-77.
146. van der Does J, Exalto N, Dieben T, Bennink H. Ovarian Activity Suppression by Two Different Low-Dose Triphasic Oral Contraceptives. *Contraception*. 1995;52:357-361.
147. Van Heusden A, Fauser B. Activity of the Pituitary-Ovarian Axis in the Pill-Free Interval during use of Low-Dose Combined Oral Contraceptives. *Contraception*. 1999;59:237-243.
148. Young R, Snabes M, Frank M, Reilly M. A Randomized, Double-Blind, Placebo-Controlled Comparison of the Impact of Low-Dose and Triphasic Oral Contraceptives on Follicular Development. *American Journal of Obstetrics and Gynecology*. 1992;167:678-682.
149. Baerwald A, Adams G, Pierson R. A New Model for Ovarian Follicular Development during the Human Menstrual Cycle. *Fertility and Sterility*. 2003;80:116-122.
150. Polanczky M, Slap G, Forke C, Rappaport A, Sondheimer S. The Use of levonorgestrel Implants (Norplant) for Contraception in Adolescent Mothers. *New England Journal of Medicine*. 1994;331:1201-1206.
151. Emans S. Adolescents' Compliance with the Use of Oral Contraceptives. *Journal of the American Medical Association*. 1987;257:3377-3381.
152. Jung-Hoffmann C, Heidt F, Kuhl H. Effect of Two Oral Contraceptives Containing 30 microgram Ethinyl Estradiol and 75 microgram Gestodene or 150 microgram Desogestrel upon Various Hormonal Parameters. *Contraception*. 1988;38:593-603.
153. Kuhl H, Gahn G, Romberg G, Marz W, Taubert H. A Randomized Cross-Over Comparison of Two Low-Dose Oral Contraceptives upon Hormonal and Metabolic Parameters: 1. Effects upon Sexual Hormone Levels. *Contraception*. 1985;31:583-593.
154. Van der Vange N. Ovarian Activity during Low Dose Oral Contraceptives. In: Chamberlain G, ed. *Contemporary Obstetrics and Gynecology*. London: Butterworths; 1988:315-326.
155. Birtch R, Olatunbosun O, Baerwald A, Pierson R. Ultrasound Image Attributes of Human Ovarian Dominant Follicles during Natural and Oral Contraceptive Cycles. *Reproductive biology and endocrinology*. 2005;3(12).
156. Killick S, Eyong E, Elstein M. Ovarian Follicular Development in Oral Contraceptive Cycles. *Fertility and Sterility*. 1987;48(3):409-413.

157. Elomaa K, Rollan R, Brosens I, Moorrees M, Deprest JTJ, Lahtenmaki P. Omitting the First Oral Contraceptive Pills of the Cycle Does Not Automatically Lead to Ovulation. *American Journal of Obstetrics and Gynecology*. 1998;179:41-46.
158. Pierson R, Archer D, Moreau M, Shangold G, Fisher A, Creasy G. Ortho Evra/ Evra versus Oral Contraceptives: Follicular Development and Ovulation in Normal Cycles and After and Intentional Dosing Error. *Fertility and Sterility*. 2003;80:34-42.
159. Cohen B, Katz M. Pituitary and Ovarian Function in Women Receiving Hormonal Contraception. *Contraception*. 1979;20:475-484.
160. Fauser B, Van Heusden A. Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences. *Endocrine Reviews*. 1997;18:71-106.
161. Guillebaud J. The Forgotten Pill- and the Paramount Importance of the Pill-free Week. *British Journal of Family Planning*. 1987;12 (Supplement):S35-43.
162. Hedon B, Cristol P, Plauchut A, Vallon AM, Deschamps F, Taillant ML, Mares P, Pizelle AM, Laffargue F, Viala JL. Ovarian Consequences of the Transient Interruption of Combined Oral Contraceptives. *International Journal of Fertility*. 1992;37(5):270-276.
163. Landgren B, Csemiczky G. The Effect on Follicular Growth and Luteal Function of "Missing the Pill". *Contraception*. 1991;43(2):149-159.
164. Macklon N, Fauser B. Regulation of Follicle Development and Novel Approaches to Ovarian Stimulation for IVF. *Human Reproduction Update*. 2000;6:307-312.
165. Endrikat J, Cronin M, Gerlinger C, Ruebig A, Schmidt W, Dusterberg B. Double-blind, Multicenter Comparison of Efficacy, Cycle Control, and Tolerability of a 23-day versus a 21-day Low-dose Oral Contraceptive Regimen Containing 20 micrograms Ethinyl Estradiol and 75 micrograms Gestodene. *Contraception*. 2001;64:99-105.
166. Molloy B, Coulson K, Lee J, Watters J. "Missed Pill" Conception: Fact or Fiction? *British Medical Journal (Clinical Residents Addition)*. 1987;294:1645-1647.
167. Letterie G, Chow G. Effect of "Missed" Pills on Oral Contraceptive Effectiveness. *Obstetrics and Gynecology*. 1992;79(6):979-982.
168. Smith S, Kirkman R, Arce B, McNeilly A, Loudon N, Baird D. The Effect of Deliberate Omission of Trinordiol or Microgynon on The Hypothalamo-Pituitary-Ovarian Axis. *Contraception*. 1986;34(5):513-522.
169. Chowdbury V, Joshi U, Gopalkrishna K, Betrabet S, Mehta S, Saxena B. "Escape" Ovulation in Women due to the Missing of Low Dose Combination Oral Contraceptive Pills. *Contraception*. 1980;22(3):241-247.

170. Killick S. Ovarian Follicles during Oral Contraceptive Cycles: Their Potential for Ovulation. *Fertility and Sterility*. 1989;52:580-582.
171. Morris S, Groom G, Cameron E, Buckingham M, Everitt J, Elstein M. Studies on Low Dose Oral Contraceptives: Plasma Hormone Changes in Relation to Deliberate Pill ("Microgynon 30") Omission. *Contraception*. 1979;20(1):61-69.
172. Talwar P, Dingfelder J, Rewenholt R. Increased Risk of Breakthrough Bleeding When One Oral-Contraceptive Tablet is Missed. *New England Journal of Medicine*. 1977;296(21):1236-1237.
173. Vinnika L, Ylikala O, Vihko R, Hasenech H, Nieuwenhuysse H. Metabolism of a New Synthetic Progestagen ORG 2969 in Female Volunteers. The Distribution and Excretion of Radioactivity after and Oral Dose of the Labeled Drug. *Acta Univ Oulensis[Med]*. 1978;38:1-9.
174. Wang E, Shi S, Cekan S, Landgren B, Diczfalusy E. Hormonal Consequences of "Missing the Pill". *Contraception*. 1982;26(6):545-566.
175. Oakley D, Sereika S, Bogue E. Oral Contraceptive Pill use after an Initial Visit to a Family Planning Clinic. *Family Planning Perspectives*. 1991;23:150-154.
176. Potter L, Oakly D, de Leon-Wong E, Canamar R. Measuring Compliance among Oral Contraceptive Users. *Family Planning Perspective*. 1996;28:154-158.
177. Pratt W, Bachrach C. What do Women Use When they Stop Using the Pill? *Family Planning Perspectives*. 1987;19:257-266.
178. Rosenberg M, Waugh M, Te M. Use and Misuse of Oral Contraceptives: Risk Indicators for Poor Pill Taking and Discontinuation. *Contraception*. 1995;51:283-288.
179. Andrist L, Hoyt A, Weinstein D, McGibbon C. The Need to Bleed: Women's Attitudes and Beliefs about Menstrual Suppression. *Journal of the American Academy of Nurse Practitioners*. 2004;16:31-37.
180. Eaton S, Pike M, Short R, Lee NC, Trussell J, Hatcher RA, Wood JW, Worthman CM, Jone NG, Konner MJ. Women's Reproductive Cancers in Evolutionary Context. *The Quarterly Review of Biology*. 1994;69:353-367.
181. Kjerulff K, Erickson B, Langenberg P. Chronic Gynecological Conditions Reported by US Women: Findings from the National Health Interview Survey, 1984 to 1992. *American Journal of Public Health*. 1996;86:195-199.
182. Wiegatz I, Hommel H, Zimmermann T, Kuhl H. Attitude of German Women and Gynecologists Towards Long-cycle Treatment with Oral Contraceptives. *Contraception*. 2004;69:37-42.

183. Glasier A, Smith K, van der Spuy Z, Ho PC, Cheng L, Dada K, Wellings K, Baird DT. Amenorrhea Associated with Contraception- An International Study on Acceptability. *Contraception*. 2003;67:1-8.
184. Wiegratz I, Kuhl H. Long-cycle Treatment with Oral Contraceptives. *Drugs*. 2004;64:2447-2462.
185. Kaunitz A. Oral Contraceptive Health Benefits Perception versus Reality. *Contraception*. 1999;59:29S-33S.
186. Fraser I. Benefits and Risks of Steroidal Contraception. In: Salamonsen L, ed. *Hormones and Women's Health: The Reproductive Years*. Amsterdam: Harwood Academic Publishers; 2000:161-172.
187. Drife J. *The Benefits and Risks of Oral Contraceptives Today*. 2 ed. London: Parthenon Press; 1996.
188. Victory R, D'Souza C, Diamond P, McNeeley G, Vista-Deck D, Hendrix S. Reduced Cancer Risks in Oral Contraceptive Users: Results from the Women's Health Initiative. Paper presented at: American Society of Reproductive Medicine Annual Conference, 2004; Philadelphia.
189. Schlesselman J, Collins J. The Influence of Steroids on Gynecologic Cancers. In: Fraser I, Jansen R, Lobo R, Whitehead M, eds. *Estrogens and progestogens in clinical practice*. London: Livingstone; 1998:831-864.
190. Narod S, Feunteun J, Lynch H, Watson P, Conway T, Lynch J, Lenoir GM. Familial Breast-Ovarian Cancer Locus on Chromosome 17q12-q12. *Lancet*. 1991;228:82-83.
191. Rosenberg L, Palmer JR, Zauber AB, Warshauer ME, Lewis JL Jr, Strom BL, Harlap S, Shaprio SI. A Case-Control Study of Oral Contraceptive Use and Invasive Epithelial Ovarian Cancer. *American Journal of Epidemiology*. 1994;149:654-661.
192. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The Reduction in Risk of Ovarian Cancer Associated with Oral-Contraceptive Use. *New England Journal of Medicine*. 1987;316:650-655.
193. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination Oral Contraceptive Use and the Risk of Endometrial Cancer. *Journal of the American Medical Association*. 1987;257:796-800.
194. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Endometrial Cancer and Combined Oral Contraceptives. *International Journal of Epidemiology*. 1988;17:263-269.

195. Bracken M, Hellenbrand K, Holford T. Conception Delay after Oral Contraceptive Use: The Effect of Estrogen Dose. *Fertility and Sterility*. 1990;53(1):21-27.
196. Chasan-Taber L, Willett W, Stampfer M, Spiegelman D, Rosner BA, Hunter DJ, Colditz GA, Manson JE. Oral Contraceptives and Ovulatory Causes of Delayed Fertility. *American Journal of Epidemiology*. 1997;146(3):258-265.
197. Fraser I, Weisberg E. Fertility Following Discontinuation of Different Methods of Fertility Control. *Contraception*. 1982;26(4):389-415.
198. Vessey M, Wright N, McPherson K, Wiggins P. Fertility After Stopping Different Methods of Contraception. *British Medical Journal*. 1978;1:265-267.
199. Wolfers D. The Probability of Conception after Discontinuance of Oral Contraception: A Note on "Oral Contraception, Coital Frequency, and the Time Required to Conceive," by Westoff, Bumpass, and Ryder. *Social Biology*. 1970;17(1):57-59.
200. Pardthaisong T, Gray R. The Return of Fertility Following Discontinuation of Oral Contraceptive in Thailand. *Fertility and Sterility*. 1981;35(5):532-534.
201. Linn S, Schoenbaum S, Monson R, Rosner B, Ryan K. Delay in Conception for Former 'Pill' Users. *Journal of the American Medical Association*. 1982;247(5):629-632.
202. Janerich D, Lawrence C, Jacobson H. Fertility Patterns after Discontinuation of Use of Oral Contraceptives. *The Lancet*. 1976;1(7968):1051-1053.
203. Harlap S, Baras M. Conception-Waits in Fertile Women after Stopping Oral Contraceptives. *International Journal of Fertility*. 1984;29(2):73-80.
204. Spira A. [Fertility Following Hormonal Contraception (author's translation)]. *Contraception Fertility and Sex (Paris)*. 1983;11(7-8):903-907.
205. Hassan J, Kulenthiran A, Thum Y. The Return of Fertility after Discontinuation of Oral Contraception in Malaysian Women. *Medical Journal of Malaysia*. 1994;49(4):364-368.
206. Weisberg E. Fertility after Discontinuation of Oral Contraceptives. *Clinical Reproduction and Fertility*. 1982;1:261-272.
207. Speroff L, Glass R, Kase N. Female Infertility. *Clinical Gynecologic Endocrinology and Fertility*. 6th ed. Baltimore: Lippincott Williams & Wilkins; 1999:1013-1042.
208. Farrow A, Hull M, Northstone K, Taylor H, Ford W, Golding J. Prolonged Use of Oral Contraception before a Planned Pregnancy is Associated with a Decreased Risk of Delayed Conception. *Human Reproduction*. 2002;17(10):2754-2761.

209. Kay C. The Outcome of Pregnancy in Former Oral Contraceptive Users. *British Journal of Obstetrics and Gynecology*. 1976;83:608-616.
210. McMahon S, Hanse L, Mann J, Sevigny C, Wong T, Roache M. Contraception. *BMC Women's Health*. 2004;4 (Suppl 1):S25-S31.
211. Fisher W, Boroditsky R, Morris B. The 2002 Canadian Contraception Study: Part 1. *Journal of Obstetrics and Gynecology Canada*. 2004;26:580-590.
212. Bongaarts J. The Paradox of Transition. *Organon's magazine on women & health*. Vol 3; 1999:14-17.
213. Inhorn M. Global Infertility and the Globalization of New Reproductive Technologies: Illustrations from Egypt. *Social Science & Medicine*. 2003;56:1837-1851.
214. Jones E, Forrest J. Contraceptive Failure Rates Based on the 1988 NSFG. *Family Planning Perspectives*. 1990;24:12-19.
215. Trussell J, Hatcher R, Cates WJ, Stewart F, Kost K. Contraceptive Failure in the United States: An Update. *Studies in Family Planning*. 1990;21:51-54.
216. Trussell J, Vaughan B. Contraceptive Failure, Method-related Discontinuation and Resumption of Use: Results from the 1995 National Survey of Family Growth. *Family Planning Perspectives*. 1999;31:64-72, 93.
217. Rosenberg M, Waugh M. Causes and Consequences of Oral Contraceptive Noncompliance. *American Journal of Obstetrics and Gynecology*. 1999;180:S276-S279.
218. Adams H. Oral Contraception Noncompliance: the Extent of the Problem. *Advances in Contraception: the official journal of the Society for the Advancement of Contraception*. 1992;8 (Suppl 1):13-20.
219. Zeleznik A. Follicle Selection in Primates: "Many are Called but Few are Chosen". *Biology of Reproduction*. 2001;65:655-659.
220. Jaiswal R, Singh J, Adams G. Developmental Patterns of Small Antral Follicles in the Bovine Ovary. *Biology of Reproduction*. 2004;71:1244-1251.
221. Tom J, Pierson R, Adams G. Quantitative Echotexture Analysis of Bovine Ovarian Follicles. *Theriogenology*. 1998;50:339-346.
222. Vassena R, Adams G, Mapletoft R, Pierson R, Singh J. Ultrasound Image Characteristics of Ovarian Follicles in Relation to Oocyte Competence and Folicular Status in Cattle. *Animal Reproduction Science*. 2003;76:25-41.

223. Fisher W, Singh S, Shuper P, Carey M, Otchet F, MacLean-Brine D, Dal Bello B, Gunter J. Characteristics of Women Undergoing Repeat Induce Abortion. *Canadian Medical Association Journal*. 2005;172:637-641.
224. Holt V, Scholes D, Wicklund K, Cushing-Haugen K, Daling J. Body mass Index, Weight and Oral Contraceptive Failure Risk. *Obstetrics and Gynecology*. 2005;105:46-52.
225. Roumen F, Apter D, Mulders T, Dieben T. Efficacy, Tolerability and Acceptability of a Novel Contraceptive Vaginal Ring Releasing etonogestrel and ethinyl oestradiol. *Human Reproduction*. 2001;16:469-475.
226. Hillard P. The Patient's Reaction to Side Effects of Oral Contraceptives. *American Journal of Obstetrics and Gynecology*. 1989;161:1412-1415.
227. Kornaat H, Geerdink M, Klitsle J. The Acceptance of a 7-week Cycle with a Modern Low-dose Oral Contraceptive (Minulet). *Contraception*. 1992;45:119-127.
228. Benagiano G, Primiero F, Farris M. Clinical Profile of Contraceptive Progestins. *The European Journal of Contraception and Reproductive Health Care*. 2004;9:182-193.
229. Bjarnadottir R, Tuppurainen M, Killick S. Comparison of Cycle Control with a Combined Contraceptive Vaginal Ring and Oral levonorgestrel/ ethinyl estradiol. *American Journal of Obstetrics and Gynecology*. 2002;186:389-395.
230. Forinash A, Evans S. New Hormonal Contraceptives: A Comprehensive Review of the Literature. *Pharmacotherapy*. 2003;23:1573-1591.
231. Ortho-McNeil Pharmaceutical I. Ortho Evra (norelgestromin/ethinyl estradiol transdermal system) Package Insert. Raritan, NJ; 2001.
232. Dittrich R, Parker L, JB R, Shangold G, Creasy G, Fisher W. Transdermal Contraception: Evaluation of Three Transdermal norelgestromin/ethinyl estradiol Doses in a Randomized Multi Center Dose-response Study. *American Journal of Obstetrics and Gynecology*. 2002;186:15-20.
233. Smallwood G, Meador M, Lenihan J, Shangold G, Fisher A, Creasy G. Efficacy and Safety of a Transdermal Contraceptive System. *Obstetrics and Gynecology*. 2001;98:799-805.
234. Mulders T, Dieben T. Use of the Novel Combined Contraceptive Vaginal Ring NuvaRing for Ovulation Inhibition. *Fertility and Sterility*. 2001;75:865-870.
235. Mulders T, Dieben T, Bennick H. Ovarian Function with a Novel Combined Contraceptive Ring. *Human Reproduction*. 2002;17:2594-2599.